CEACAM5 ADC-anti-PD1 / PD-L1 combination therapy
The combination of ADCs targeting CEACAM5 with anti-PD-1/PD-L1 antibodies provides a potent therapeutic approach for lung, gastric, and esophageal cancers, addressing treatment resistance and enhancing efficacy in CEACAM5-expressing tumors.
Patent Information
- Application Number
- JP2024532762
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-11
- Filing Date
- 2022-12-01
- Publication Date
- 2024-12-06
AI Technical Summary
Current treatments for lung cancer, including immune checkpoint inhibitors and platinum-based chemotherapy, are not sufficient for effectively targeting and overcoming resistance in CEACAM5-expressing cancers, necessitating a more potent therapeutic approach.
A combination therapy using antibody-drug conjugates (ADCs) that specifically bind to CEACAM5, combined with anti-PD-1 or anti-PD-L1 antibodies, optionally with platinum-based agents, to enhance treatment efficacy.
The combination therapy demonstrates improved treatment outcomes for CEACAM5-expressing cancers by enhancing cytotoxicity and overcoming treatment resistance, with potential applications in lung, gastric, and esophageal cancers.
Smart Images

Figure 2024545427000024 
Figure 2024545427000025 
Figure 2024545427000026
Abstract
Description
[Technical field]
[0001] [Reference to sequence listing] This application contains a Sequence Listing that has been submitted electronically in .xml format, which is hereby incorporated by reference in its entirety. A copy of said .xml created on November 29, 2022 is named PR94313_S286_WO_SANOFI.xml.
[0002] The present disclosure relates to the field of therapeutic treatment of cancers that express CEACAM5. Certain aspects of the disclosure relate to combination therapy with immunoconjugates comprising anti-CEACAM5 antibodies with anti-PD-1 or anti-PD-L1 agents to treat cancers, including lung cancer, gastric cancer, gastroesophageal junction cancer, and esophageal cancer. [Background technology]
[0003] The mechanism of action of antibody drug conjugates (ADCs) begins with their binding to specific antigens that are well expressed on tumor cells to achieve selective and efficient internalization of the drug. Selective targeting of potent cytotoxicity to tumor cells using ADCs has now been shown to be an effective strategy for the treatment of cancer, as demonstrated by the recent approval of brentuximab vedotin for the treatment of Hodgkin's lymphoma and trastuzumab emtansine (T-DM1) for the treatment of relapsed metastatic HER2+ breast cancer (Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-9; Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;19:1783-91). Many other malignancies with unmet medical need, such as solid tumor cancers, could potentially benefit from such treatment options.
[0004] For example, lung cancer is an aggressive form of cancer that accounts for hundreds of thousands of deaths in the United States. Unfortunately, it tends to recur after initial treatment and becomes more resistant to subsequent treatments. Although multiple treatments are available for the treatment of individuals with lung cancer, more effective treatments are needed.
[0005] Various treatments are used to treat lung cancer. First-line therapy may include chemotherapy with platinum-containing drugs. More recently, immune checkpoint inhibitors have been approved for use in treating lung cancer. International Publication No. WO 2020 / 161214, the entire contents of which are incorporated herein by reference, discloses the use of anti-CEACAM5 immunoconjugates (ADCs) to treat lung cancer. Summary of the Invention [Means for solving the problem]
[0006] The present disclosure provides methods for treating cancer using a combination therapy comprising an ADC that specifically binds to CEACAM5. The combination therapy comprises an ADC and an anti-PD-1 antibody or an anti-PD-L1 antibody, optionally with a platinum-based agent with or without pemetrexed. In certain embodiments, the ADC is tusamitamaravtansine.
[0007] An aspect of the disclosure is a method of treating cancer, comprising administering to a subject in need thereof effective amounts of (i) an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody and (ii) an anti-PD-1 antibody or an anti-PD-L1 antibody, wherein the cancer expresses CEACAM5, thereby treating the cancer. In another aspect, the disclosure provides an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody for use in treating cancer, wherein the ADC is suitable for use in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody, wherein the cancer expresses CEACAM5, thereby treating the cancer.
[0008] One aspect of the disclosure is a combination of (i) an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody and (ii) an anti-PD-1 antibody or an anti-PD-L1 antibody in effective amounts, for use in treating cancer in a subject in need thereof, where the cancer expresses CEACAM5.
[0009] In certain embodiments, the anti-CEACAM5 antibody comprises an HCDR1 having the amino acid sequence of SEQ ID NO: 1, an HCDR2 having the amino acid sequence of SEQ ID NO: 2, an HCDR3 having the amino acid sequence of SEQ ID NO: 3, an LCDR1 having the amino acid sequence of SEQ ID NO: 4, an LCDR2 having the amino acid sequence NTR, and an LCDR3 having the amino acid sequence of SEQ ID NO: 5.
[0010] In certain embodiments, the anti-CEACAM5 antibody comprises a heavy chain variable domain (VH) consisting of SEQ ID NO:6 and a light chain variable domain (VL) consisting of SEQ ID NO:7.
[0011] In a particular embodiment, the anti-CEACAM5 antibody is tusamitamab.
[0012] In certain embodiments, the ADC comprises at least one cytotoxic agent.
[0013] In certain embodiments, the cytotoxic agent is selected from the group consisting of a radioisotope, a protein toxin, a small molecule toxin, and any combination thereof.
[0014] In certain embodiments, the small molecule toxin is selected from the group consisting of antimetabolites, DNA alkylating agents, DNA cross-linking agents, DNA intercalating agents, anti-microtubule agents, topoisomerase inhibitors, and any combination thereof.
[0015] In certain embodiments, the anti-microtubule agent is selected from the group consisting of taxanes, vinca alkaloids, maytansinoids, colchicine, podophyllotoxin, griseofulvin, and any combination thereof.
[0016] In certain embodiments, the maytansinoid is selected from the group consisting of N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine (DM1), N2'-deacetyl-N-2'(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4), and any combination thereof.
[0017] In certain embodiments, the anti-CEACAM5 antibody is covalently attached to at least one cytotoxic agent via a cleavable or non-cleavable linker.
[0018] In certain embodiments, the linker is selected from the group consisting of N-succinimidyl pyridyldithiobutyrate (SPDB), 4-(pyridin-2-yldisulfanyl)-2-sulfo-butyric acid (sulfo-SPDB), and succinimidyl (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC).
[0019] In certain embodiments, the ADC is characterized by a drug-to-antibody ratio (DAR) in the range of 1-10.
[0020] In certain embodiments, the ADC is tusamitamaravtansine.
[0021] In certain embodiments, the cancer expresses CEACAM5 at moderate or high intensity as defined by immunohistochemistry.
[0022] In certain embodiments, the cancer expresses CEACAM5 with moderate intensity (immunohistochemical intensity ≧2+ in ≧1% to <50% of tumor cells).
[0023] In certain embodiments, the cancer expresses CEACAM5 with high intensity (immunohistochemical intensity ≧2+ in ≧50% of tumor cells).
[0024] In certain embodiments, the cancer is selected from the group consisting of colorectal cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, lung cancer, cervical cancer, pancreatic cancer, ovarian cancer, thyroid cancer, bladder cancer, endometrial cancer, breast cancer, liver cancer, biliary tract cancer (e.g., cholangiocarcinoma), prostate cancer, and skin cancer.
[0025] In certain embodiments, the cancer is gastric cancer, gastroesophageal junction cancer, or esophageal cancer.
[0026] In certain embodiments, the cancer is lung cancer.
[0027] In certain embodiments, the lung cancer is non-squamous non-small cell lung cancer (NSQ NSCLC).
[0028] In certain embodiments, the subject has advanced or metastatic NSQ NSCLC.
[0029] In certain embodiments, the subject has NSQ NSCLC without epidermal growth factor receptor (EGFR) sensitizing mutations or v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations or anaplastic lymphoma kinase / c-ros oncogene 1 (ALK / ROS) alterations.
[0030] In certain embodiments, the subject has not previously undergone systemic chemotherapy for the treatment of cancer.
[0031] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is an anti-PD-1 antibody.
[0032] In certain embodiments, the anti-PD-1 antibody is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, sintilimab, dostallimab, and tislelizumab.
[0033] In a particular embodiment, the anti-PD-1 antibody is pembrolizumab.
[0034] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is an anti-PD-L1 antibody.
[0035] In certain embodiments, the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, avelumab, and durvalumab.
[0036] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered sequentially.
[0037] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered prior to the ADC.
[0038] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered simultaneously.
[0039] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered to the subject for at least four cycles.
[0040] In certain embodiments, each cycle is about 2-6 weeks.
[0041] In certain embodiments, each cycle is about 2 weeks.
[0042] In certain embodiments, each cycle is about 3 weeks.
[0043] In certain embodiments, each cycle is about 6 weeks.
[0044] In certain embodiments, each tusamitamab ravtansine cycle is selected from the group consisting of 2 weeks, 3 weeks, and 4 weeks.
[0045] In certain embodiments, the cycle of each anti-PD-1 antibody or anti-PD-L1 antibody is selected from the group consisting of 2 weeks, 3 weeks, and 6 weeks.
[0046] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 200 mg to about 400 mg.
[0047] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose selected from 200 mg, 350 mg, 360 mg, and 400 mg.
[0048] In certain embodiments, tusamitamavutansine is administered at a dose of about 60 mg / m 2 ~about 190mg / m 2 is administered intravenously to the subject at a dose of
[0049] In certain embodiments, tusamitamavutansine is administered at a dose of about 120 mg / m 2~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0050] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 200 mg and the tusamitamaravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0051] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamaravtansine are administered once every three weeks.
[0052] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 400 mg and the tusamitamaravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0053] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered once every six weeks, and the tusamitamaravtansine is administered once every three weeks.
[0054] In certain embodiments, the ADC is tusamitamaravtansine and the anti-PD-1 antibody or anti-PD-L1 antibody is pembrolizumab.
[0055] In a particular embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered about once every three weeks, and the ADC is tusamitamaravtansine and is about 120 mg / m 2 is administered intravenously to the subject at a dose of
[0056] In a particular embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered about once every three weeks, and the ADC is tusamitamaravtansine and is about 150 mg / m 2 is administered intravenously to the subject at a dose of
[0057] In certain embodiments, the anti-PD-1 antibody is administered intravenously to a subject at a dose of about 200 mg.
[0058] In some embodiments, the methods or uses of the present disclosure further comprise administering to the subject platinum-based chemotherapy.
[0059] An aspect of the disclosure is a method of treating cancer comprising administering to a subject in need thereof an effective amount of (i) an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody, (ii) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (iii) a platinum-based chemotherapy, wherein the cancer expresses CEACAM5, thereby treating the cancer. In another aspect, the disclosure provides an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody for use in treating cancer, wherein the ADC is suitable for use in combination with (i) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (ii) a platinum-based chemotherapy, wherein the cancer expresses CEACAM5, thereby treating the cancer.
[0060] One aspect of the disclosure is a combination of (i) an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody, (ii) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (iii) platinum-based chemotherapy in effective amounts, for use in treating cancer in a subject in need thereof, where the cancer expresses CEACAM5.
[0061] In certain embodiments, the anti-CEACAM5 antibody comprises an HCDR1 having the amino acid sequence of SEQ ID NO: 1, an HCDR2 having the amino acid sequence of SEQ ID NO: 2, an HCDR3 having the amino acid sequence of SEQ ID NO: 3, an LCDR1 having the amino acid sequence of SEQ ID NO: 4, an LCDR2 having the amino acid sequence NTR, and an LCDR3 having the amino acid sequence of SEQ ID NO: 5.
[0062] In certain embodiments, the anti-CEACAM5 antibody comprises a heavy chain variable domain (VH) consisting of SEQ ID NO:6 and a light chain variable domain (VL) consisting of SEQ ID NO:7.
[0063] In a particular embodiment, the anti-CEACAM5 antibody is tusamitamab.
[0064] In certain embodiments, the ADC comprises at least one cytotoxic agent.
[0065] In certain embodiments, the cytotoxic agent is selected from the group consisting of a radioisotope, a protein toxin, a small molecule toxin, and any combination thereof.
[0066] In certain embodiments, the small molecule toxin is selected from the group consisting of antimetabolites, DNA alkylating agents, DNA cross-linking agents, DNA intercalating agents, anti-microtubule agents, topoisomerase inhibitors, and any combination thereof.
[0067] In certain embodiments, the anti-microtubule agent is selected from the group consisting of taxanes, vinca alkaloids, maytansinoids, colchicine, podophyllotoxin, griseofulvin, and any combination thereof.
[0068] In certain embodiments, the maytansinoid is selected from the group consisting of N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine (DM1), N2'-deacetyl-N-2'(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4), and any combination thereof.
[0069] In certain embodiments, the anti-CEACAM5 antibody is covalently attached to at least one cytotoxic agent via a cleavable or non-cleavable linker.
[0070] In certain embodiments, the linker is selected from the group consisting of N-succinimidyl pyridyldithiobutyrate (SPDB), 4-(pyridin-2-yldisulfanyl)-2-sulfo-butyric acid (sulfo-SPDB), and succinimidyl (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC).
[0071] In certain embodiments, the ADC is characterized by a drug-to-antibody ratio (DAR) in the range of 1-10.
[0072] In certain embodiments, the ADC is tusamitamaravtansine.
[0073] In certain embodiments, the cancer expresses CEACAM5 at moderate or high intensity as defined by immunohistochemistry.
[0074] In certain embodiments, the cancer expresses CEACAM5 with moderate intensity (eg, immunohistochemical intensity ≧2+ in ≧1% to <50% of tumor cells).
[0075] In certain embodiments, the cancer expresses CEACAM5 with high intensity (eg, immunohistochemical intensity ≧2+ in ≧50% of tumor cells).
[0076] In certain embodiments, the cancer is selected from the group consisting of colorectal cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, lung cancer, cervical cancer, pancreatic cancer, ovarian cancer, thyroid cancer, bladder cancer, endometrial cancer, breast cancer, liver cancer, biliary tract cancer (e.g., cholangiocarcinoma), prostate cancer, and skin cancer.
[0077] In certain embodiments, the cancer is gastric cancer, gastroesophageal junction cancer, or esophageal cancer.
[0078] In certain embodiments, the cancer is lung cancer.
[0079] In certain embodiments, the lung cancer is non-squamous non-small cell lung cancer (NSQ NSCLC).
[0080] In certain embodiments, the subject has advanced or metastatic NSQ NSCLC.
[0081] In certain embodiments, the subject has NSQ NSCLC without epidermal growth factor receptor (EGFR) sensitizing mutations or v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations or anaplastic lymphoma kinase / c-ros oncogene 1 (ALK / ROS) alterations.
[0082] In certain embodiments, the subject has not previously undergone systemic chemotherapy for the treatment of cancer.
[0083] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is an anti-PD-1 antibody.
[0084] In certain embodiments, the anti-PD-1 antibody is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, sintilimab, dostallimab, and tislelizumab.
[0085] In a particular embodiment, the anti-PD-1 antibody is pembrolizumab.
[0086] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is an anti-PD-L1 antibody.
[0087] In certain embodiments, the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, avelumab, and durvalumab.
[0088] In certain embodiments, the platinum-based chemotherapy is selected from the group consisting of cisplatin and carboplatin.
[0089] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered sequentially.
[0090] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered prior to the ADC.
[0091] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered prior to the ADC and platinum-based chemotherapy.
[0092] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered simultaneously.
[0093] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody, the ADC, and the platinum-based chemotherapy are administered to the subject for at least four cycles.
[0094] In certain embodiments, each cycle is about 2-6 weeks.
[0095] In certain embodiments, each cycle is about 2 weeks.
[0096] In certain embodiments, each cycle is about 3 weeks.
[0097] In certain embodiments, each cycle is about 6 weeks.
[0098] In certain embodiments, each tusamitamab ravtansine cycle is selected from the group consisting of 2 weeks, 3 weeks, and 4 weeks.
[0099] In certain embodiments, the cycle of each anti-PD-1 antibody or anti-PD-L1 antibody is selected from the group consisting of 2 weeks, 3 weeks, and 6 weeks.
[0100] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 200 mg to about 400 mg.
[0101] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose selected from 200 mg, 350 mg, 360 mg, and 400 mg.
[0102] In certain embodiments, tusamitamavutansine is administered at a dose of about 60 mg / m 2 ~about 190mg / m 2 is administered intravenously to the subject at a dose of
[0103] In certain embodiments, tusamitamavutansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0104] In certain embodiments, tusamitamavutansine is administered at a dose of about 120 mg / m 2 is administered intravenously to the subject at a dose of
[0105] In certain embodiments, tusamitamavutansine is administered at a dose of about 150 mg / m 2 is administered intravenously to the subject at a dose of
[0106] In certain embodiments, tusamitamavutansine is administered at a dose of about 170 mg / m 2 is administered intravenously to the subject at a dose of
[0107] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 200 mg and the tusamitamaravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0108] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamaravtansine are administered once every three weeks.
[0109] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 400 mg and the tusamitamaravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0110] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered once every six weeks, and the tusamitamaravtansine is administered once every three weeks.
[0111] In certain embodiments, the methods include administering cisplatin to the subject.
[0112] In certain embodiments, cisplatin is administered at 38 mg / m 2 ~75mg / m 2 is administered intravenously to the subject at a dose of
[0113] In certain embodiments, cisplatin is administered at about 75 mg / m 2 is administered intravenously to the subject at a dose of
[0114] In certain embodiments, the methods include administering carboplatin to the subject.
[0115] In certain embodiments, carboplatin is administered intravenously to a subject at a dose of about (target AUC) x [(140 - age) x (weight (kg)) / serum creatinine (mg / dL) x 72 (x 0.85 for women) + 25], where the target AUC is between AUC 2.5 and AUC 5.
[0116] In certain embodiments, the target AUC is AUC 5.
[0117] In a particular embodiment, the ADC is tusamitamab and the anti-PD-1 antibody is pembrolizumab.
[0118] In some embodiments, the methods or uses of the disclosure further comprise administering pemetrexed to the subject.
[0119] An aspect of the disclosure is a method of treating cancer comprising administering to a subject in need thereof an effective amount of (i) an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody, (ii) an anti-PD-1 antibody or an anti-PD-L1 antibody, (iii) a platinum-based chemotherapy, and (iv) pemetrexed, wherein the cancer expresses CEACAM5, thereby treating the cancer. In another aspect, the disclosure provides an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody for use in treating cancer, wherein the ADC is suitable for use in combination with (i) an anti-PD-1 antibody or an anti-PD-L1 antibody, (ii) a platinum-based chemotherapy, and (iii) pemetrexed, wherein the cancer expresses CEACAM5, thereby treating the cancer.
[0120] One aspect of the disclosure is a combination of (i) an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody, (ii) an anti-PD-1 antibody or an anti-PD-L1 antibody, (iii) platinum-based chemotherapy, and (iv) pemetrexed in effective amounts, for use in treating cancer in a subject in need thereof, wherein the cancer expresses CEACAM5.
[0121] In certain embodiments, the anti-CEACAM5 antibody comprises an HCDR1 having the amino acid sequence of SEQ ID NO: 1, an HCDR2 having the amino acid sequence of SEQ ID NO: 2, an HCDR3 having the amino acid sequence of SEQ ID NO: 3, an LCDR1 having the amino acid sequence of SEQ ID NO: 4, an LCDR2 having the amino acid sequence NTR, and an LCDR3 having the amino acid sequence of SEQ ID NO: 5.
[0122] In certain embodiments, the anti-CEACAM5 antibody comprises a heavy chain variable domain (VH) consisting of SEQ ID NO:6 and a light chain variable domain (VL) consisting of SEQ ID NO:7.
[0123] In a particular embodiment, the anti-CEACAM5 antibody is tusamitamab.
[0124] In certain embodiments, the ADC comprises at least one cytotoxic agent.
[0125] In certain embodiments, the cytotoxic agent is selected from the group consisting of a radioisotope, a protein toxin, a small molecule toxin, and any combination thereof.
[0126] In certain embodiments, the small molecule toxin is selected from the group consisting of antimetabolites, DNA alkylating agents, DNA cross-linking agents, DNA intercalating agents, anti-microtubule agents, topoisomerase inhibitors, and any combination thereof.
[0127] In certain embodiments, the anti-microtubule agent is selected from the group consisting of taxanes, vinca alkaloids, maytansinoids, colchicine, podophyllotoxin, griseofulvin, and any combination thereof.
[0128] In certain embodiments, the maytansinoid is selected from the group consisting of N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine (DM1), N2'-deacetyl-N-2'(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4), and any combination thereof.
[0129] In certain embodiments, the anti-CEACAM5 antibody is covalently attached to at least one cytotoxic agent via a cleavable or non-cleavable linker.
[0130] In certain embodiments, the linker is selected from the group consisting of N-succinimidyl pyridyldithiobutyrate (SPDB), 4-(pyridin-2-yldisulfanyl)-2-sulfo-butyric acid (sulfo-SPDB), and succinimidyl (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC).
[0131] In certain embodiments, the ADC is characterized by a drug-to-antibody ratio (DAR) in the range of 1-10.
[0132] In certain embodiments, the ADC is tusamitamaravtansine.
[0133] In certain embodiments, the cancer expresses CEACAM5 at moderate or high intensity as defined by immunohistochemistry.
[0134] In certain embodiments, the cancer expresses CEACAM5 with moderate intensity (immunohistochemical intensity ≧2+ in ≧1% to <50% of tumor cells).
[0135] In certain embodiments, the cancer expresses CEACAM5 with high intensity (immunohistochemical intensity ≧2+ in ≧50% of tumor cells).
[0136] In certain embodiments, the cancer is selected from the group consisting of colorectal cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, lung cancer, cervical cancer, pancreatic cancer, ovarian cancer, thyroid cancer, bladder cancer, endometrial cancer, breast cancer, liver cancer, biliary tract cancer (e.g., cholangiocarcinoma), prostate cancer, and skin cancer.
[0137] In certain embodiments, the cancer is gastric cancer, gastroesophageal junction cancer, or esophageal cancer.
[0138] In certain embodiments, the cancer is lung cancer.
[0139] In certain embodiments, the lung cancer is non-squamous non-small cell lung cancer (NSQ NSCLC).
[0140] In certain embodiments, the subject has advanced or metastatic NSQ NSCLC.
[0141] In certain embodiments, the subject has NSQ NSCLC without epidermal growth factor receptor (EGFR) sensitizing mutations or v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations or anaplastic lymphoma kinase / c-ros oncogene 1 (ALK / ROS) alterations.
[0142] In certain embodiments, the subject has not previously undergone systemic chemotherapy for the treatment of cancer.
[0143] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is an anti-PD-1 antibody.
[0144] In certain embodiments, the anti-PD-1 antibody is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, sintilimab, dostallimab, and tislelizumab.
[0145] In a particular embodiment, the anti-PD-1 antibody is pembrolizumab.
[0146] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is an anti-PD-L1 antibody.
[0147] In certain embodiments, the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, avelumab, and durvalumab.
[0148] In certain embodiments, the platinum-based chemotherapy is selected from the group consisting of cisplatin and carboplatin.
[0149] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered sequentially.
[0150] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered prior to the ADC.
[0151] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered prior to the ADC, platinum-based chemotherapy, and pemetrexed.
[0152] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered simultaneously.
[0153] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody, the ADC, and the platinum-based chemotherapy are administered to the subject for at least four cycles.
[0154] In certain embodiments, each cycle is about 2-6 weeks.
[0155] In certain embodiments, each cycle is about 2 weeks.
[0156] In certain embodiments, each cycle is about 3 weeks.
[0157] In certain embodiments, each cycle is about 6 weeks.
[0158] In certain embodiments, each tusamitamab ravtansine cycle is selected from the group consisting of 2 weeks, 3 weeks, and 4 weeks.
[0159] In certain embodiments, the cycle of each anti-PD-1 antibody or anti-PD-L1 antibody is selected from the group consisting of 2 weeks, 3 weeks, and 6 weeks.
[0160] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 200 mg to about 400 mg.
[0161] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose selected from 200 mg, 350 mg, 360 mg, and 400 mg.
[0162] In certain embodiments, tusamitamavutansine is administered at a dose of about 60 mg / m 2 ~about 190mg / m 2 is administered intravenously to the subject at a dose of
[0163] In certain embodiments, tusamitamavutansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0164] In certain embodiments, tusamitamavutansine is administered at a dose of about 120 mg / m 2 is administered intravenously to the subject at a dose of
[0165] In certain embodiments, tusamitamavutansine is administered at a dose of about 150 mg / m 2 is administered intravenously to the subject at a dose of
[0166] In certain embodiments, tusamitamavutansine is administered at a dose of about 170 mg / m 2 is administered intravenously to the subject at a dose of
[0167] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 200 mg and the tusamitamaravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0168] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamaravtansine are administered once every three weeks.
[0169] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 400 mg and the tusamitamaravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0170] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered once every six weeks, and the tusamitamaravtansine is administered once every three weeks.
[0171] In certain embodiments, the methods include administering cisplatin to the subject.
[0172] In certain embodiments, cisplatin is administered at 38 mg / m 2 ~75mg / m 2 is administered intravenously to the subject at a dose of
[0173] In certain embodiments, cisplatin is administered at about 75 mg / m 2 is administered intravenously to the subject at a dose of
[0174] In certain embodiments, the methods include administering carboplatin to the subject.
[0175] In certain embodiments, carboplatin is administered intravenously to a subject at a dose of about (target AUC) x [(140 - age) x (weight (kg)) / serum creatinine (mg / dL) x 72 (x 0.85 for women) + 25], where the target AUC is between AUC 2.5 and AUC 5.
[0176] In certain embodiments, the target AUC is AUC 5.
[0177] In certain embodiments, pemetrexed is administered at 250 mg / m 2~500mg / m 2 It is administered intravenously at a dose of
[0178] In certain embodiments, pemetrexed is administered at 500 mg / m 2 It is administered intravenously at a dose of
[0179] In certain embodiments, pemetrexed is administered intravenously following vitamin supplementation.
[0180] In a particular embodiment, the ADC is tusamitamab and the anti-PD-1 antibody is pembrolizumab.
[0181] In a particular embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered about once every three weeks, and the ADC is tusamitamaravtansine and is about 120 mg / m 2 is administered intravenously to the subject at a dose of
[0182] In a particular embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered about once every three weeks, and the ADC is tusamitamaravtansine and is about 150 mg / m 2 is administered intravenously to the subject at a dose of
[0183] In a particular embodiment, the anti-PD-1 antibody is pembrolizumab.
[0184] In certain embodiments, the anti-PD-1 antibody is administered intravenously to a subject at a dose of about 200 mg.
[0185] In some embodiments, item 1 of the present disclosure relates to a combination of (i) an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody and (ii) an anti-PD-1 antibody or an anti-PD-L1 antibody in effective amounts, for use in treating cancer in a subject in need thereof, where the cancer expresses CEACAM5.
[0186] In some embodiments, item 2 of the present disclosure relates to the combination described in item 1, wherein the anti-CEACAM5 antibody comprises an HCDR1 having the amino acid sequence of SEQ ID NO: 1, an HCDR2 having the amino acid sequence of SEQ ID NO: 2, an HCDR3 having the amino acid sequence of SEQ ID NO: 3, an LCDR1 having the amino acid sequence of SEQ ID NO: 4, an LCDR2 having the amino acid sequence NTR, and an LCDR3 having the amino acid sequence of SEQ ID NO: 5.
[0187] In some embodiments, item 3 of the present disclosure relates to a combination described in item 1 or 2, wherein the anti-CEACAM5 antibody comprises a heavy chain variable domain (VH) consisting of SEQ ID NO: 6 and a light chain variable domain (VL) consisting of SEQ ID NO: 7.
[0188] In some embodiments, item 4 of the present disclosure relates to a combination according to any one of items 1 to 3, wherein the anti-CEACAM5 antibody is tusamitamab.
[0189] In some embodiments, item 5 of the present disclosure relates to a combination according to any one of items 1 to 4, wherein the ADC comprises at least one cytotoxic agent.
[0190] In some embodiments, item 6 of the present disclosure relates to the combination according to item 5, wherein the cytotoxic agent is selected from the group consisting of a radioisotope, a protein toxin, a small molecule toxin, and any combination thereof.
[0191] In some embodiments, item 7 of the present disclosure relates to the combination according to item 6, wherein the small molecule toxin is selected from the group consisting of antimetabolites, DNA alkylating agents, DNA crosslinking agents, DNA intercalating agents, anti-microtubule agents, topoisomerase inhibitors, and any combination thereof.
[0192] In some embodiments, item 8 of the present disclosure relates to the combination described in item 7, wherein the anti-microtubule agent is selected from the group consisting of taxanes, vinca alkaloids, maytansinoids, colchicine, podophyllotoxin, griseofulvin, and any combination thereof.
[0193] In some embodiments, item 9 of the present disclosure relates to the combination according to item 8, wherein the maytansinoid is selected from the group consisting of N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine (DM1), N2'-deacetyl-N2'(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4), and any combination thereof.
[0194] In some embodiments, item 10 of the present disclosure relates to a combination described in any one of items 5 to 9, wherein the anti-CEACAM5 antibody is covalently linked to at least one cytotoxic agent via a cleavable or non-cleavable linker.
[0195] In some embodiments, item 11 of the present disclosure relates to the combination according to item 10, wherein the linker is selected from the group consisting of N-succinimidyl pyridyldithiobutyrate (SPDB), 4-(pyridin-2-yldisulfanyl)-2-sulfo-butyric acid (sulfo-SPDB), and succinimidyl (N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC).
[0196] In some embodiments, item 12 of the present disclosure relates to a combination according to any one of items 1 to 11, wherein the ADC is characterized by a drug-to-antibody ratio (DAR) in the range of 1 to 10.
[0197] In some embodiments, item 13 of the present disclosure relates to a combination according to any one of items 1 to 12, wherein the ADC is tusamitamaravtansine.
[0198] In some embodiments, item 14 of the present disclosure relates to the combination according to any one of items 1 to 13, wherein the cancer expresses CEACAM5 at moderate or high intensity as defined by immunohistochemistry.
[0199] In some embodiments, item 15 of the present disclosure relates to a combination described in any one of items 1 to 14, wherein the cancer expresses CEACAM5 with moderate intensity (immunohistochemical intensity ≧2+ in ≧1% to <50% of tumor cells).
[0200] In some embodiments, item 16 of the present disclosure relates to a combination according to any one of items 1 to 14, wherein the cancer expresses CEACAM5 with high intensity (immunohistochemical intensity ≧2+ in ≧50% of tumor cells).
[0201] In some embodiments, item 17 of the present disclosure relates to a combination according to any one of items 1 to 16, wherein the cancer is selected from the group consisting of colorectal cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, lung cancer, cervical cancer, pancreatic cancer, ovarian cancer, thyroid cancer, bladder cancer, endometrial cancer, breast cancer, liver cancer, biliary tract cancer (e.g., cholangiocarcinoma), prostate cancer, and skin cancer.
[0202] In some embodiments, item 18 of the present disclosure relates to the combination according to item 17, wherein the cancer is gastric cancer, gastroesophageal junction cancer, or esophageal cancer.
[0203] In some embodiments, item 19 of the present disclosure relates to the combination according to item 17, wherein the cancer is lung cancer.
[0204] In some embodiments, item 20 of the present disclosure relates to the combination according to item 19, wherein the lung cancer is non-squamous non-small cell lung cancer (NSQ NSCLC).
[0205] In some embodiments, item 21 of the present disclosure relates to the combination according to item 20, wherein the subject has advanced or metastatic NSQ NSCLC.
[0206] In some embodiments, item 22 of the present disclosure relates to the combination according to item 20, wherein the subject has NSQ NSCLC without epidermal growth factor receptor (EGFR) sensitizing mutation or v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation or anaplastic lymphoma kinase / c-ros oncogene 1 (ALK / ROS) alteration.
[0207] In some embodiments, item 23 of the present disclosure relates to a combination according to any one of items 1 to 22, wherein the subject has not previously received systemic chemotherapy for the treatment of cancer.
[0208] In some embodiments, item 24 of the present disclosure relates to the combination of any one of items 1 to 23, wherein the anti-PD-1 antibody is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, sintilimab, dostallimab, and tislelizumab.
[0209] In some embodiments, item 25 of the present disclosure relates to the combination according to item 24, wherein the anti-PD-1 antibody is pembrolizumab.
[0210] In some embodiments, item 26 of the present disclosure relates to the combination of any one of items 1 to 23, wherein the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, avelumab, and durvalumab.
[0211] In some embodiments, item 27 of the present disclosure relates to a combination according to any one of items 1 to 26, wherein the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered sequentially.
[0212] In some embodiments, item 28 of the present disclosure relates to a combination according to any one of items 1 to 26, wherein the anti-PD-1 antibody or anti-PD-L1 antibody is administered prior to the ADC.
[0213] In some embodiments, item 29 of the present disclosure relates to a combination according to any one of items 1 to 26, wherein the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered simultaneously.
[0214] In some embodiments, item 30 of the present disclosure relates to the combination of any one of items 1 to 29, wherein the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to the subject at a dose of about 200 mg to about 400 mg.
[0215] In some embodiments, item 31 of the present disclosure relates to the combination of item 30, wherein the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to the subject at a dose selected from 200 mg, 350 mg, 360 mg, and 400 mg.
[0216] In some embodiments, item 32 of the present disclosure provides that tusamitamab ravtansine is administered at a concentration of about 60 mg / m 2 ~about 190mg / m 2 32. The combination according to any one of items 13 to 31, wherein the combination is administered intravenously to the subject at a dose of
[0217] In some embodiments, item 33 of the present disclosure provides that tusamitamab ravtansine is administered at a concentration of about 120 mg / m 2 ~about 170mg / m 2 33. The combination according to item 32, wherein the combination is administered intravenously to a subject at a dose of
[0218] In some embodiments, item 34 of the present disclosure provides a method for administering an anti-PD-1 antibody or an anti-PD-L1 antibody intravenously to a subject at a dose of about 200 mg and a tusamitamab ravtansine at a dose of about 120 mg / m 2 ~about 170mg / m 2 34. The combination according to any one of items 30 to 33, wherein the combination is administered intravenously to a subject at a dose of
[0219] In some embodiments, item 35 of the present disclosure relates to the combination of item 34, wherein the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamaravtansine are administered once every three weeks.
[0220] In some embodiments, item 36 of the present disclosure provides a method for treating rheumatoid arthritis in a subject, comprising administering to the subject an anti-PD-1 antibody or an anti-PD-L1 antibody at a dose of about 400 mg intravenously to the subject and administering to the subject a tumour stimulatory system at a dose of about 120 mg / m 2 ~about 170mg / m 2 34. The combination according to any one of items 30 to 33, wherein the combination is administered intravenously to a subject at a dose of
[0221] In some embodiments, item 37 of the present disclosure relates to the combination of item 36, wherein the anti-PD-1 antibody or anti-PD-L1 antibody is administered once every 6 weeks, and the tusamitamaravtansine is administered once every 3 weeks.
[0222] In some embodiments, item 38 of the present disclosure relates to a combination according to any one of items 1 to 37, wherein the ADC is tusamitamaravtansine and the anti-PD-1 antibody is pembrolizumab.
[0223] In some embodiments, item 39 of the present disclosure is a method for treating rheumatoid arthritis in which the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered about once every three weeks, and the ADC is tusamitamaravtansine and is administered at about 120 mg / m 2 37. The combination according to any one of items 1 to 36, wherein the combination is administered intravenously to a subject at a dose of
[0224] In some embodiments, item 40 of the present disclosure is a method for treating rheumatoid arthritis in which the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered about once every three weeks, and the ADC is tusamitamaravtansine and is administered at about 150 mg / m 2 37. The combination according to any one of items 1 to 36, wherein the combination is administered intravenously to a subject at a dose of
[0225] In some embodiments, item 41 of the present disclosure relates to the combination according to items 39 or 40, wherein the anti-PD-1 antibody is pembrolizumab.
[0226] In some embodiments, item 42 of the present disclosure relates to the combination according to any one of items 39 to 41, wherein the anti-PD-1 antibody is administered intravenously to the subject at a dose of about 200 mg.
[0227] In some embodiments, item 43 of the present disclosure relates to the combination of any one of items 1 to 38, further comprising (iii) administering platinum-based chemotherapy to the subject.
[0228] In some embodiments, item 44 of the present disclosure relates to the combination according to item 43, wherein the platinum-based chemotherapy is selected from the group consisting of cisplatin and carboplatin.
[0229] In some embodiments, item 45 of the present disclosure relates to the combination according to items 43 or 44, wherein the anti-PD-1 antibody or anti-PD-L1 antibody is administered prior to the ADC and platinum-based chemotherapy.
[0230] In some embodiments, item 46 of the present disclosure relates to the combination of any one of items 43 to 45, wherein the anti-PD-1 antibody or anti-PD-L1 antibody, the ADC, and the platinum-based chemotherapy are administered to the subject for at least 4 cycles.
[0231] In some embodiments, item 47 of the present disclosure relates to the combination according to any one of items 39 to 42, wherein the platinum-based chemotherapy is cisplatin.
[0232] In some embodiments, item 48 of the present disclosure relates to a method for treating cisplatin in a dose of 38 mg / m 2 ~75mg / m 2 48. The combination according to item 47, wherein the combination is administered intravenously to a subject at a dose of
[0233] In some embodiments, item 49 of the present disclosure provides a method for administering cisplatin at a concentration of about 75 mg / m 2 The combination according to item 48, wherein the compound is administered intravenously to the subject at a dose of
[0234] In some embodiments, item 50 of the present disclosure relates to the combination according to any one of items 43 to 46, wherein the platinum-based chemotherapy is carboplatin.
[0235] In some embodiments, item 51 of the present disclosure relates to the combination of item 50, wherein carboplatin is administered intravenously to a subject at a dose of about (target AUC)×[(140−age)×(body weight (kg)) / serum creatinine (mg / dL)×72 (×0.85 for women)+25], and the target AUC is between AUC 2.5 and AUC 5.
[0236] In some embodiments, item 52 of the present disclosure relates to the combination described in item 51, wherein the target AUC is AUC 5.
[0237] In some embodiments, item 53 of the present disclosure relates to a combination according to any one of items 1 to 52, further comprising administering pemetrexed to the subject.
[0238] In some embodiments, item 54 of the present disclosure relates to a method for treating pemetrexed at a dose of 250 mg / m 2 ~500mg / m 2 54. The combination according to item 53, wherein the compound is administered intravenously at a dose of
[0239] In some embodiments, item 55 of the present disclosure relates to a method for treating pemetrexed at about 500 mg / m 2 55. The combination according to item 54, wherein the compound is administered intravenously at a dose of
[0240] In some embodiments, item 56 of the present disclosure relates to the combination according to any one of items 53-54, wherein pemetrexed is administered intravenously after vitamin supplementation.
[0241] In some embodiments, item 57 of the present disclosure is a method for treating rheumatoid arthritis in which the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered about once every three weeks, and the ADC is tusamitamaravtansine and is administered at about 120 mg / m 2 57. The combination according to any one of items 53 to 56, wherein the combination is administered intravenously to a subject at a dose of
[0242] In some embodiments, item 58 of the present disclosure is a method for treating rheumatoid arthritis in which the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered about once every three weeks, and the ADC is tusamitamaravtansine and is administered at about 150 mg / m 2 57. The combination according to any one of items 53 to 56, wherein the combination is administered intravenously to a subject at a dose of
[0243] In some embodiments, item 59 of the present disclosure relates to the combination of items 57 or 58, wherein the anti-PD-1 antibody is pembrolizumab.
[0244] In some embodiments, item 60 of the present disclosure relates to the combination of any one of items 57-59, wherein the anti-PD-1 antibody is administered intravenously to the subject at a dose of about 200 mg. [Brief description of the drawings]
[0245] [Figure 1] FIG. 1 is a schematic diagram showing the process of determining tusamitamaravtansine doses in Part A, Part B, and Part C of a Phase 2 clinical trial according to an embodiment of the present disclosure. [Diagram 2] FIG. 1 is a schematic diagram showing the study design for Part A of a Phase 2 clinical trial according to an embodiment of the present disclosure. [Diagram 3] FIG. 1 is a schematic diagram showing the study design for Part B of a Phase 2 clinical trial according to an embodiment of the present disclosure. [Figure 4] FIG. 1 is a schematic diagram showing the study design for Part C of a Phase 2 clinical trial according to an embodiment of the present disclosure. [Diagram 5]Shown is the activity of immunoconjugate huMAb2-3-SPDB-DM4 and anti-muPD-1 antibodies as single agents or in combination against a subcutaneous colon MC38 syngeneic tumor model in C57Bl / 6 mice. Tumor volume evolution by treatment group. Curves represent the median + or - maximum administered dose (MAD) for each day in each group. [Figure 6] Shows the activity of immunoconjugate huMAb2-3-SPDB-DM4 and anti-mu / huPD-L1 antibodies as single agents or in combination against a subcutaneous colon MC38 syngeneic tumor model in C57Bl / 6 mice. Tumor volume evolution by treatment group. Curves represent the median + or - MAD for each day in each group. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0246] The present disclosure provides pharmaceutical compositions and methods of using these compositions for the treatment of cancer (e.g., lung cancer, including NSQ NSCLC) and amelioration of at least one symptom of the disease. These compositions comprise at least one antibody that specifically binds to (CEACAM5).
[0247] Tusamitamab ravtansine is an immunoconjugate ADC that combines a humanized anti-CEACAM5 antibody (tusamitamab) and maytansinoid derivative 4 (DM4) [N2'-deacetyl-N2'-(4-methyl-4-mercapto-1-oxopentyl)-matansine], a potent mitotic inhibitor that inhibits microtubule assembly. DM4 is covalently attached to the antibody via an optimized linker SPDB [N-succinimidyl 4-(2-pyridyldithio)-butyrate], which is stable in plasma and cleavable inside cells. After binding and internalization into the targeted cancer cells, the ADC is degraded, releasing the cytotoxic DM4 metabolites.
[0248] Tusamitama ravtansine specifically binds to the A3B3 domain of human CEACAM5 and does not recognize other CEACAMs (CEACAM1, CEACAM6, CEACAM7, and CEACAM8) that display A or / and B domains in their structures. The naked antibody and ADC bind recombinant human CEACAM5 with an affinity of approximately 0.02 nM (ELISA) and show high affinity for CEACAM5-expressing tumor cells (K D APP 0.24~0.68nM).
[0249] After binding to the CEACAM5 antigen, tusamitamaravtansine is internalized by cancer cells via antigen-mediated endocytosis, delivered to lysosomes, and degraded to the lysine-linked derivative lysine-SPDB-DM4, which is further degraded in DM4 and then S-methylated to form methyl-DM4 [Me-DM4]; all three metabolites have potent cytotoxic activity through binding to tubulin and inhibition of microtubule polymerization.
[0250] As used herein, CEACAM5 expressing cancer refers to several types of cancer, including colorectal cancer, gastric cancer, esophagogastric junction cancer, esophageal cancer, lung cancer, cervical cancer, pancreatic cancer, ovarian cancer, thyroid cancer, bladder cancer, endometrial cancer, breast cancer, liver cancer, biliary tract cancer (e.g., cholangiocarcinoma), prostate cancer, and skin cancer.In some embodiments, the cancer is lung cancer.In some embodiments, the lung cancer is non-squamous non-small cell lung cancer.
[0251] In certain embodiments, the cancer is a moderate CEACAM5 expressor, with an intensity of ≧2+ in ≧1% to <50% of the expressing tumor cell population, as measured using immunohistochemistry.
[0252] In certain embodiments, the cancer is a high CEACAM5 expressor.A high CEACAM5 expressor has an intensity of ≧2+ in ≧50% of expressing tumor cell population as measured by immunohistochemistry.A high CEACAM5 expressor accounts for about 20% of lung cancers.
[0253] The ADC in monotherapy was analyzed in a Phase 1 / 2 study in heavily pretreated high CEACAM5 expressers. The ADC demonstrated competitive overall response rates (OR) and duration of response (DoR). The most common adverse drug reactions (ADRs) were ocular toxicity (reversible without discontinuing treatment), with minimal hematologic / neurologic toxicity.
[0254] non-small cell lung cancer Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Smoking is the main cause of the disease. It is a type of epithelial lung cancer other than small cell lung cancer. There are several types of non-small cell lung cancer. Each type of non-small cell lung cancer has a different kind of cancer cells. The cancer cells of each type grow and spread in different ways. The types of non-small cell lung cancer are named for the type of cells found in the cancer and the appearance of the cells under a microscope: (1) Squamous cell carcinoma: A cancer that begins in squamous cells, which are thin, flat cells that look like fish scales. It is also called epidermoid carcinoma. (2) Large cell carcinoma: A cancer that can begin in several types of large cells. (3) Adenocarcinoma: A cancer that begins in the cells that line the alveoli and make substances such as mucus.
[0255] Selective targeting of potent cytotoxicity to tumor cells using antibody drug conjugates (ADCs) has now been shown to be an effective strategy for the treatment of cancer, as demonstrated by the recent approval of brentuximab vedotin for the treatment of Hodgkin's lymphoma and trastuzumab emtansine (T-DM1) for the treatment of relapsed metastatic HER2+ breast cancer (Young A. et al., 2012 J Clin Oncol. 30(18):2183-9; Verma, S. et al., 2012 N Engl J Med. 19:1783-91). Many other malignant diseases with unmet medical needs could benefit from such treatment options. The mechanism of action of ADCs begins with their binding to specific antigens that are well expressed on tumor cells to achieve selective and efficient internalization of the drug.
[0256] Definitive surgery (e.g., pulmonary resection, lobectomy, segmentectomy or wedge resection, sleeve resection) is the standard treatment for patients with appropriate stage I NSCLC. Adjuvant treatment should only be offered as part of a clinical trial. Stage II and IIIA adjuvant cisplatin-based chemotherapy remains the gold standard for completely resected NSCLC tumors. Other chemotherapeutic agents used in combination with cisplatin or in combination with each other may include carboplatin, paclitaxel (Taxol), albumin-bound paclitaxel (nab-paclitaxel, Abraxane), docetaxel (Taxotere), gemcitabine (Gemzar), vinorelbine (Navelbine), irinotecan (Camptosar), etoposide (VP-16), vinblastine, and pemetrexed (Alimta). In addition, radiation therapy may be used in patients with N2 lymph nodes. In patients with advanced stage IIIB / IV or inoperable NSCLC, treatment may include multiple cycles of cisplatin-based chemotherapy and third generation cytotoxic or cytostatic agents (anti-EGFR, anti-VEGFR) (see Zarogoulidis et al., J Thorac Dis. 2013 Sep;5(Suppl 4):S389-S396).
[0257] Treatment of cancer, including lung cancer, may include angiogenesis inhibitors, epidermal growth factor receptor (EGFR) inhibitors, and immune checkpoint inhibitors.
[0258] Angiogenesis inhibitors may include, but are not limited to, axitinib (Inlyta), bevacizumab (Avastin), cabozantinib (Cometrik), everolimus (Afinitor, Zotres), lenalidomide (Revlimid), pazopanib (Votrient), ramucirumab (Cyramza), regorafenib (Stivarga), sorafenib (Nexavar), sunitinib (Sutent), thalidomide (Sinovir, Talomid), vandetanib (Caprelsa), and Ziv-aflibercept (Zaltrap).
[0259] EGFR inhibitors may include, but are not limited to, gefitinib (Iressa), erlotinib (Tarceva), lapatinib (Tykerb), cetuximab (Erbitux), neratinib (Nerlynx), osimertinib (Tagrisso), panitumumab (Vectibix), vandetanib (Caprelsa), necitumumab (Portrazza), and dacomitinib (Vizinpro).
[0260] Immune checkpoint inhibitors include programmed death receptor 1 (PD-1) binders (e.g., pembrolizumab, nivolumab, cemiplimab, sintilimab, dostallimab, and tislelizumab), programmed death-ligand 1 (PD-L1) binders (e.g., atezolizumab, avelumab, durvalumab), CTLA-4 binders (e.g., ipilimumab), OX40 or OX40L binders, adenosine A2A receptor binders, B7-H3 binders, B7-H4 binders, BTLA binders, indoleamine-2,3-dioxygenase binders, killer cell These may include, but are not limited to, cytoplasmic immunoglobulin-like receptor (KIR) binders, lymphocyte-activation gene-3 (LAG-3) binders, nicotinamide adenine dinucleotide phosphate NADPH oxidase isoform (NOX2) binders, T cell immunoglobulin domain and mucin domain 3 (TIM-3) binders, V domain Ig inhibitor of T cell activation (VISTA) binders, glucocorticoid-inducible TNFR family related gene (GITR) binders, and sialic acid-binding immunoglobulin-type lectin 7 (SIGLEC7) binders.
[0261] CEACAM5 and its indications: Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion. CEA was first identified in 1965 (Gold and Freedman, J Exp Med, 121, 439, 1965) as a protein normally expressed by fetal intestine during the first 6 months of pregnancy and has been found in cancers of the pancreas, liver and colon. The CEA family belongs to the immunoglobulin superfamily. The CEA family, consisting of 18 genes, is subdivided into two subgroups of proteins: the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) subgroup and the pregnancy-specific glycoprotein subgroup (Kammerer & Zimmermann, BMC Biology 2010, 8:12).
[0262] In humans, the CEACAM subgroup consists of seven members: CEACAM1, CEACAM3, CEACAM4, CEACAM5, CEACAM6, CEACAM7, CEACAM8. Numerous studies have shown that CEACAM5, identical to the first identified CEA, is highly expressed on the surface of colorectal, gastric, esophagogastric junction, esophageal, lung, breast, prostate, ovarian, cervical and bladder tumor cells, and weakly expressed in a few normal epithelial tissues, such as columnar and goblet cells of the colon, mucous cervical cells of the stomach, and squamous cells of the esophagus and cervix (Hammarstroem et al, 2002, in "Tumor Markers, Physiology, Pathobiology, Technology and Clinical Applications" Eds. Diamandis EP et al., AACC Press, Washington pp 375). CEACAM5 may therefore constitute a suitable therapeutic target for tumor-specific targeting approaches, such as immunoconjugates.
[0263] The extracellular domain of CEACAM family members is composed of repeated immunoglobulin-like (Ig-like) domains classified by sequence homology into three types: A, B and N. CEACAM5 contains seven such domains, namely N, A1, B1, A2, B2, A3 and B3.
[0264] The CEACAM5 A1, A2 and A3 domains on the one hand, and the B1, B2 and B3 domains on the other hand, show high sequence homology, with the A domain of human CEACAM5 showing 84-87% pairwise sequence similarity and the B domain showing 69-80%. Furthermore, other human CEACAM members presenting A and / or B domains in their structures, namely CEACAM1, CEACAM6, CEACAM7 and CEACAM8, show homology with human CEACAM5. In particular, the A and B domains of the human CEACAM6 protein show sequence homology with either the A1 and A3 domains, and the B1-B3 domains, respectively, of human CEACAM5, which is even higher than that observed between the A and B domains of human CEACAM5.
[0265] One embodiment of the present disclosure is a method of treating cancer, wherein the cancer expresses CEACAM5.
[0266] In certain embodiments, the cancer is selected from the group consisting of colorectal cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, lung cancer, cervical cancer, pancreatic cancer, ovarian cancer, thyroid cancer, bladder cancer, endometrial cancer, breast cancer, liver cancer, biliary tract cancer (e.g., cholangiocarcinoma), prostate cancer, and skin cancer.
[0267] In certain embodiments, the cancer is gastric cancer, gastroesophageal junction cancer, or esophageal cancer.
[0268] In certain embodiments, the cancer is lung cancer.
[0269] In certain embodiments, the cancer is non-squamous non-small cell lung cancer (NSQ-NSCLC).
[0270] Anti-CEACAM5 antibody Considering the diagnostic or therapeutic purpose of targeting CEA, a number of anti-CEA antibodies have been generated. Specificity to related antigens has always been mentioned as a concern in the field, for example by Sharkey et al (1990, Cancer Research 50, 2823). Due to the above-mentioned homology, some of the previously described antibodies may show binding to repeated epitopes of CEACAM5 present in different immunoglobulin domains, show cross-reactivity to other CEACAM members such as CEACAM1, CEACAM6, CEACAM7, or CEACAM8, and lack specificity for CEACAM5. The specificity of the anti-CEACAM5 antibody is desirable in terms of CEA targeting therapy, such that it binds to human CEACAM5-expressing tumor cells but not to some normal tissues expressing other CEACAM members. Of note, CEACAM1, CEACAM6, and CEACAM8 have been described to be expressed by human and non-human primate neutrophils (Ebrahimmnejad et al, 2000, Exp Cell Res, 260, 365; Zhao et al, 2004, J Immunol Methods 293, 207; Strickland et al, 2009 J Pathol, 218, 380), where they have been shown to regulate granulopoiesis and play a role in the immune response.
[0271] The ADC tusamitamab ravtansine can be internalized into cells expressing CEACAM5 after binding and has been shown to induce cytotoxic activity on tumor cells in vitro. tusamitamab ravtansine can also significantly inhibit tumor growth in vivo in mice bearing human primary colon and gastric tumors. See WO 2014 / 079886, which is incorporated herein by reference in its entirety.
[0272] As used herein, the term "about" in a quantitative term refers to plus or minus 10% of the value it modifies (when the value is not divisible, such as the number of molecules or nucleotides, it is rounded up to the nearest whole number). For example, the phrase "about 100 mg" would encompass 90 mg to 110 mg, inclusive; the phrase "about 2500 mg" would encompass 2250 mg to 2750 mg. When applied to a percentage, the term "about" refers to plus or minus 10% relative to that percentage. For example, the phrase "about 20%" would encompass 18% to 22%, and "about 80%" would encompass 72% to 88%, inclusive. Furthermore, when "about" is used in conjunction with a quantitative term herein, it is understood that in addition to the value plus or minus 10%, the exact value of the quantitative term is also contemplated and described. For example, the term "about 23%" specifically contemplates, describes, and exactly includes 23%.
[0273] It should be noted that the term "a" or "an" entity refers to one or more of that entity; for example, "a symptom" is understood to refer to one or more symptoms. Thus, the terms "a" (or "an"), "one or more," and "at least one" may be used interchangeably herein.
[0274] Furthermore, "and / or" as used herein should be considered as a specific disclosure of each of the two specified features or components with or without the other. Thus, the term "and / or" as used in phrases such as "A and / or B" is intended herein to include "A and B," "A or B," "A" (single), and "B" (single). Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (single); B (single); and C (single).
[0275] Whenever an embodiment is described herein with the term "comprising," it is understood that other similar embodiments described with the terms "consisting of" and / or "consisting essentially of" are also provided.
[0276] As used herein, "CEACAM5" designates "carcinoembryonic antigen-related cell adhesion molecule 5," also known as "CD66e" (cluster of differentiation 66e) or CEA. CEACAM5 is a glycoprotein involved in cell adhesion. CEACAM5 is highly expressed, particularly on the surface of colorectal, gastric, esophagogastric junction, esophageal, lung, and uterine tumor cells.
[0277] The reference sequence of full-length human CEACAM5, including the signal peptide (positions 1-34) and the propeptide (positions 686-702), is available from the GenBank database under the accession number AAA51967.1. Five nonsynonymous SNPs were identified with a frequency of more than 2% in the Caucasian population, four of which are located in the N domain of human CEACAM5 (positions 80, 83, 112, 113), the last one in the A2 domain (position 398).
[0278] Whenever an aspect or embodiment is described herein with the term "comprising," it is understood that other similar aspects described with the terms "consisting of" and / or "consisting essentially of" are also provided.
[0279] The term "antibody", as used herein, also includes antigen-binding fragments of an intact antibody molecule. The terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, and the like, as used herein, include any naturally occurring, enzymatically derived, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of antibodies can be derived from intact antibody molecules using any suitable standard technique, such as, for example, proteolytic digestion or recombinant genetic engineering techniques, including the manipulation and expression of DNA encoding antibody variable domains and, optionally, constant domains. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage antibody libraries), or can be synthesized. The DNA can be sequenced and manipulated, for example, chemically or using molecular biology techniques, to place one or more variable and / or constant domains in a suitable configuration, or to introduce codons, generate cysteine residues, modify, add or delete amino acids, and the like.
[0280] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of amino acid residues that mimic the hypervariable regions (e.g., isolated complementarity determining regions (CDRs) such as CDR3 peptides) of an antibody or the constraining FR3-CDR3-FR4 peptide. Domain-specific antibodies, single domain antibodies, domain deleted antibodies, chimeric antibodies, CDR grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, VHHs or NANOBODYs (e.g., monovalent VHHs and bivalent VHHs), small modular immunopharmaceuticals (SMIPs), and other engineered molecules such as shark variable IgNAR domains are also encompassed by the term "antigen-binding fragment" as used herein.
[0281] An antigen-binding fragment of an antibody will usually contain at least one variable domain. The variable domain may be of any size or amino acid composition and will generally contain at least one CDR adjacent to or in frame with one or more framework sequences. In an antigen-binding fragment having a VH domain bound to a VL domain, the VH and VL domains may be positioned relative to each other in any suitable configuration. For example, the variable region may be dimeric and contain VH-VH, VH-VL or VL-VL dimers. Alternatively, an antigen-binding fragment of an antibody may contain a monomeric VH or VL domain.
[0282] In certain embodiments, an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found in an antigen-binding fragment of an antibody include: (i) VH-CH1; (ii) VH-CH2; (iii) VH-CH3; (iv) VH-CH1-CH2; (v) VH-CH1-CH2-CH3; (vi) VH-CH2-CH3; (vii) VH-CL; (viii) VL-CH1; (ix) VL-CH2; (x) VL-CH3; (xi) VL-CH1-CH2; (xii) VL-CH1-CH2-CH3; (xiii) VL-CH2-CH3; and (xiv) VL-CL. In any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be directly linked to each other or may be linked by a complete or partial hinge or linker region. The hinge region may, in various embodiments, consist of at least two (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids that provide a flexible or semi-flexible linkage between adjacent variable and / or constant domains in a single polypeptide molecule. Furthermore, antigen-binding fragments of antibodies may, in various embodiments, comprise homodimers or heterodimers (or other multimers) of any of the variable and constant domain configurations listed above in non-covalent association (e.g., by disulfide bonds) with each other and / or with one or more monomeric VH or VL domains.
[0283] In certain embodiments, the antibody or antibody fragment for use in the methods of the present disclosure may be a multispecific antibody that may be specific for different epitopes of one target polypeptide, or may contain antigen binding domains specific for epitopes of two or more target polypeptides. An exemplary bispecific antibody format that may be used in the context of the present disclosure includes the use of a first immunoglobulin (Ig) CH3 domain and a second Ig CH3 domain, where the first Ig CH3 domain and the second Ig CH3 domain differ from each other by at least one amino acid, and the at least one amino acid difference reduces binding of the bispecific antibody to Protein A compared to a bispecific antibody lacking the amino acid difference. In one embodiment, the first Ig CH3 domain binds Protein A and the second Ig CH3 domain contains a mutation that reduces or eliminates Protein A binding, such as an H95R modification (according to IMGT exon numbering; H435R according to EU numbering). The second CH3 may further include a Y96F modification (according to IMGT; Y436F according to EU). Further modifications that may be found within the second CH3 include, for IgG1 antibodies, D16E, L18M, N44S, K52N, V57M, and V82I (by IMGT; D356E, L358M, N384S, K392N, V397M, and V422I by EU); for IgG2 antibodies, N44S, K52N, and V82I (by IMGT; N384S, K392N, and V422I by EU); and for IgG4 antibodies, Q15R, N44S, K52N, V57M, R69K, E79Q, and V82I (by IMGT; Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I by EU).
[0284] Variations on the bispecific antibody formats described above are contemplated within the scope of this disclosure. Any multispecific antibody format, including the exemplary bispecific antibody formats disclosed herein, can be adapted for use in the context of an antigen-binding fragment of an anti-CEACAM5 antibody, in various embodiments, using routine techniques available in the art.
[0285] The CEACAM5 antibodies disclosed herein may contain one or more amino acid substitutions, insertions and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains compared to the corresponding germline sequences. Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available, for example, from public antibody sequence databases. The present disclosure includes antibodies, and antigen-binding fragments thereof, derived from any of the amino acid sequences disclosed herein, in which one or more amino acids in one or more framework and / or CDR regions are backmutated to the corresponding germline residue or a conservative amino acid substitution (natural or non-natural) of the corresponding germline residue (such sequence changes are referred to herein as "germline backmutations"). Starting from the heavy and light chain variable region sequences disclosed herein, one skilled in the art can readily generate numerous antibodies and antigen-binding fragments containing one or more individual germline backmutations or combinations thereof. In certain embodiments, all framework and / or CDR residues in the VH and / or VL domains are backmutated to the germline sequence. In other embodiments, only certain residues are mutated back to the germline sequence, for example only those mutated residues found within the first 8 amino acids of FR1 or the last 8 amino acids of FR4, or only those mutated residues found within CDR1, CDR2, or CDR3. Furthermore, the antibodies of the present disclosure may contain any combination of two or more germline backmutations in the framework and / or CDR regions, i.e., certain individual residues are mutated back to the germline sequence while certain other residues that differ from the germline sequence are maintained. Once obtained, antibodies and antigen-binding fragments containing one or more germline backmutations can be readily tested for one or more desired properties, such as improved binding specificity, increased binding affinity, improved or enhanced biological properties of antagonists or agonists (as the case may be), reduced immunogenicity, etc. Antibodies and antigen-binding fragments obtained in this general manner are encompassed within the present disclosure.
[0286] The constant region of an antibody is important in the ability of the antibody to fix complement and mediate cell-dependent cytotoxicity. Thus, an antibody isotype can be selected based on whether it is desirable for the antibody to mediate cytotoxicity.
[0287] The term "human antibody" as used herein is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Nevertheless, human antibodies of interest in this disclosure may, in various embodiments, include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or somatic mutation in vivo), e.g., in the CDRs, and in some embodiments, in the CDR3. However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
[0288] The term "recombinant human antibody", as used herein, is intended to include all human antibodies prepared, expressed, generated or isolated by recombinant means, e.g., antibodies expressed using a recombinant expression vector (described further below) transfected into a host cell, antibodies isolated from a recombinant, combinatorial human antibody library (described further below), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (e.g., Taylor et al., (1992) Nucl. Acids Res. 20:6287-6295, incorporated herein by reference in its entirety), or antibodies prepared, expressed, generated or isolated by any other means, including splicing human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when animals transgenic for human Ig sequences are used, in vivo somatic mutagenesis) such that the amino acid sequences of the VH and VL regions of the recombinant antibodies, while derived from and related to human germline VH and VL sequences, are sequences that may not naturally occur within the human antibody germline repertoire in vivo.
[0289] Human antibodies can exist in two forms related to hinge heterogeneity. In one embodiment, the immunoglobulin molecule comprises a stable four-chain construct of approximately 150-160 kDa in which the dimers are held together by interchain heavy chain disulfide bonds. In another embodiment, the dimers are not linked via interchain disulfide bonds and the approximately 75-80 kDa molecule is composed of covalently linked light and heavy chains (half antibodies). These embodiments / forms have been extremely difficult to separate, even after affinity purification.
[0290] The term "humanised antibody" or "humanised antibody" refers to an antibody which is wholly or partially of non-human origin and which has been modified, for example by replacing certain amino acids in the framework regions of the VH and VL domains, to avoid or minimize an immune response in humans. The constant domains of a humanised antibody are most often human CH and CL domains.
[0291] Numerous methods for humanisation / humanisation of antibody sequences are known in the art; see for example the review by Almagro & Fransson (2008) Front Biosci. 13:1619-1633. One commonly used method is CDR grafting, or antibody reshaping, which involves the grafting of CDR sequences of a donor antibody, generally a murine antibody, onto the framework scaffold of a human antibody of different specificity. Since CDR grafting may reduce the binding specificity and affinity, and therefore the biological activity, of the CDR-grafted non-human antibody, back mutations may be introduced at selected positions of the CDR-grafted antibody to retain the binding specificity and affinity of the parent antibody. Identification of positions for possible back mutations may be performed using information available in the literature and antibody databases. Candidate amino acid residues for back mutations are usually those located on the surface of the antibody molecule, while buried or less surface-exposed residues will usually not be altered. An alternative humanization technique to CDR grafting and backmutation is resurfacing, in which surface residues are altered to human residues while non-surface exposed residues of non-human origin are retained. Another alternative technique, also known as "guided selection" (Jespers et al. (1994) Biotechnology 12, 899), can be used to derive fully human antibodies from murine antibodies that preserve the epitope and binding specificity of the parent antibody.
[0292] The frequency of occurrence of the second form in various intact IgG isotypes is due to, but not limited to, structural differences associated with the hinge region isotype of the antibody. A single amino acid substitution in the hinge region of a human IgG4 hinge can significantly reduce the occurrence of the second form to the level typically observed using a human IgG1 hinge (Angal et al., (1993) Molecular Immunology 30:105, incorporated by reference in its entirety). The present disclosure encompasses, in various embodiments, antibodies with one or more mutations in the hinge, CH2 or CH3 regions that may be desirable, for example, to improve the yield of the desired antibody form in production.
[0293] An "isolated antibody," as used herein, refers to an antibody that has been identified and separated and / or recovered from at least one component of its natural environment. For example, an antibody that has been separated or removed from at least one component of an organism, or from a tissue or cell in which it naturally occurs or is naturally produced, is an "isolated antibody." In various embodiments, an isolated antibody also includes an antibody in situ within a recombinant cell. In other embodiments, an isolated antibody is an antibody that has been subjected to at least one purification or isolation step. In various embodiments, an isolated antibody may be substantially free of other cellular material and / or chemicals.
[0294] The term "specifically binds" and the like means that an antibody or an antigen-binding fragment thereof forms a complex with an antigen that is relatively stable under physiological conditions. Methods for determining whether an antibody specifically binds to an antigen are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. For example, an antibody that "specifically binds" to CEACAM5, as used herein, includes an antibody that binds to CEACAM5 or a portion thereof with a KD of less than about 1000nM, less than about 500nM, less than about 300nM, less than about 200nM, less than about 100nM, less than about 90nM, less than about 80nM, less than about 70nM, less than about 60nM, less than about 50nM, less than about 40nM, less than about 30nM, less than about 20nM, less than about 10nM, less than about 5nM, less than about 4nM, less than about 3nM, less than about 2nM, less than about 1nM, or less than about 0.5nM as measured by surface plasmon resonance assay. Specific binding also indicates at least about 1×10 -6 In other embodiments, the dissociation constant is at least about 1×10 -7 M, 1×10 -8 M, or 1×10 -9 An isolated antibody that specifically binds human CEACAM5 may, however, have cross-reactivity to other antigens, such as CEACAM5 molecules from other (non-human) species.
[0295] The term "surface plasmon resonance," as used herein, refers to an optical phenomenon that allows analysis of real-time interactions by detecting changes in protein concentration within a biosensor matrix, for example, using a BIACORE™ system (Biacore Life Sciences division of GE Healthcare, Piscataway, NJ).
[0296] The term "KD," as used herein, is intended to refer to the equilibrium dissociation constant of an antibody-antigen interaction.
[0297] "Affinity" is theoretically defined by the equilibrium association between the whole antibody and the antigen. It can be experimentally evaluated by various known methods, such as measuring the association and dissociation rates by surface plasmon resonance or measuring the EC50 (or apparent KD) in immunochemical assays (ELISA, FACS). In these assays, the EC50 is the concentration of antibody that induces a response halfway between the baseline and maximum after a specified exposure time to a defined concentration of antigen by ELISA (enzyme-linked immunosorbent assay) or a defined concentration of cells expressing the antigen by FACS (fluorescence-activated cell sorting).
[0298] A monoclonal antibody that binds to antigen 1 (Ag1) is "cross-reactive" to antigen 2 (Ag2) when the EC50 is in the similar range for both antigens. In the present application, a monoclonal antibody that binds to Ag1 is cross-reactive to Ag2 when the ratio of the affinity of Ag2 to the affinity of Ag1 is less than or equal to 10 (e.g., 5, 2, 1, or 0.5), and affinity is measured in the same way for both antigens.
[0299] Affinity for human CEACAM5 or cynomolgus monkey (Macaca fascicularis) CEACAM5 can be determined as EC50 values in ELISA using soluble recombinant CEACAM5 as the capture antigen.
[0300] The antibodies of the disclosure may also have an apparent dissociation constant (apparent KD), as may be determined by FACS analysis on the tumor cell line MKN45 (DSMZ, ACC 409) or patient-derived xenograft tumor cells (CR-IGR-034P available from Oncodesign Biotechnology, tumor collection CReMEC), that is ≦25 nM, e.g., ≦20 nM, ≦10 nM, ≦5 nM, ≦3 nM, or ≦1 nM. The apparent KD may be in the range of 0.01-20 nM, or in the range of 0.1-20 nM, 0.1-10 nM, or 0.1-5 nM.
[0301] Furthermore, antibodies according to the present disclosure have been shown to be capable of detecting CEACAM5 expression by immunohistochemistry in frozen and formalin-fixed paraffin-embedded (FFPE) tissue sections.
[0302] The term "epitope" refers to an antigenic determinant that interacts with a specific antigen-binding site in the variable region of an antibody molecule known as the paratope. A single antigen may have more than one epitope. Thus, different antibodies may bind to different regions on an antigen and have different biological effects. Epitopes may be either conformational or linear. Conformational epitopes are generated by spatially juxtaposed amino acids from different segments of a linear polypeptide chain. Linear epitopes are those generated by adjacent amino acid residues in a polypeptide chain. In certain circumstances, epitopes may include portions of sugars, phosphoryl groups, or sulfonyl groups on an antigen.
[0303] Anti-CEACAM5 antibodies useful in the methods described herein may, in various embodiments, contain one or more amino acid substitutions, insertions and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains compared to the corresponding germline sequences from which the antibody is derived. Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available, for example, from public antibody sequence databases. The disclosure, in various embodiments, includes methods that include the use of antibodies derived from any of the amino acid sequences disclosed herein, and antigen-binding fragments thereof, in which one or more amino acids in one or more framework and / or CDR regions are mutated to the corresponding residue in the germline sequence from which the antibody is derived, or to the corresponding residue in another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue (such sequence changes are collectively referred to herein as "germline mutations"). Numerous antibodies and antigen-binding fragments can be constructed that contain one or more individual germline mutations or combinations thereof. In certain embodiments, all of the framework and / or CDR residues in the VH and / or VL domains are mutated back to the residue found in the original germline sequence from which the antibody is derived. In other embodiments, only certain residues are mutated back to the original germline sequence, e.g., only those mutated residues found within the first 8 amino acids of FR1 or the last 8 amino acids of FR4, or only those mutated residues found within CDR1, CDR2, or CDR3. In other embodiments, one or more of the framework and / or CDR residues are mutated to the corresponding residue in a different germline sequence (i.e., a germline sequence that differs from the germline sequence from which the antibody was originally derived). Furthermore, an antibody may contain any combination of two or more germline mutations in the framework and / or CDR regions, e.g., certain individual residues are mutated to the corresponding residue in a particular germline sequence, while certain other residues that differ from the original germline sequence are maintained or mutated to the corresponding residue in a different germline sequence.Once obtained, antibodies and antigen-binding fragments containing one or more germline mutations can be readily tested for one or more desired properties, e.g., improved binding specificity, increased binding affinity, improved or enhanced antagonist or agonist biological properties (as the case may be), reduced immunogenicity, etc. Uses of antibodies and antigen-binding fragments obtained in this general manner are encompassed by the present disclosure.
[0304] The present disclosure also includes methods that include the use of anti-CEACAM5 antibodies that include variants of any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein having one or more conservative substitutions. For example, the present disclosure includes the use of anti-CEACAM5 antibodies that have HCVR, LCVR, and / or CDR amino acid sequences that have, for example, 10 or less, 8 or less, 6 or less, 4 or less, etc., conservative amino acid substitutions compared to any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein.
[0305] According to the present disclosure, an anti-CEACAM5 antibody, or an antigen-binding fragment thereof, in various embodiments, comprises a heavy chain variable region (HCVR), a light chain variable region (LCVR), and / or a complementarity determining region (CDR) comprising any of the amino acid sequences of the anti-CEACAM5 antibodies described in International Publication No. WO 2014 / 079886 A1, the entirety of which is incorporated herein by reference.
[0306] Amino acid sequence modifications of the antibodies described herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. If a humanized antibody is generated by simply grafting only the CDRs in the VH and VL of an antibody derived from a non-human animal into the FRs of the VH and VL of a human antibody, the antigen binding activity may be reduced compared to that of the original antibody derived from a non-human animal. It is believed that some amino acid residues in the VH and VL of a non-human antibody may be directly or indirectly related to the antigen binding activity, not only in the CDRs but also in the FRs. Therefore, replacing these amino acid residues with different amino acid residues derived from the FRs of the VH and VL of a human antibody will reduce the binding activity. To solve this problem, in a human antibody grafted with non-human CDRs, an attempt must be made to identify amino acid residues from the amino acid sequences of the FRs of the VH and VL of the human antibody that are directly related to the binding of the antibody, or that interact with the amino acid residues of the CDRs, or that maintain the three-dimensional structure of the antibody and are directly related to the binding to the antigen, among the amino acid sequences of the FRs of the VH and VL of the human antibody. The reduced antigen binding activity could be increased by replacing the identified amino acids with amino acid residues of the original antibody derived from a non-human animal.
[0307] Modifications and changes may be made in the structure of the antibodies of this disclosure, and in the DNA sequences which encode them, while still obtaining a functional antibody or polypeptide possessing the desired characteristics.
[0308] Further objects of the present disclosure also include function-conserving variants of the polypeptides of the present disclosure. For example, certain amino acids can be substituted by other amino acids in the protein structure without a significant decrease in activity. Because the ability and nature of a protein's interactions define its biological functional activity, certain amino acid substitutions can be made in the protein sequence, and of course in the DNA coding sequence, while still obtaining a protein with similar properties. Thus, it is contemplated that various changes can be made in the antibody sequences of the present disclosure or the corresponding DNA sequence encoding said polypeptides without a significant decrease in their biological activity. It is known in the art that certain amino acids can be substituted by other amino acids with similar hydropathic index or score and still obtain a protein with similar biological activity, i.e., still obtain a biologically functional equivalent protein. It is also possible to use well-established techniques such as alanine scanning techniques to identify all amino acids that can be substituted in the antibodies or polypeptides of the present disclosure without a significant decrease in binding to the antigen. Such residues can be qualified as neutral because they are not involved in antigen binding or maintaining the structure of the antibody. One or more of these neutral positions can be substituted with alanine or another amino acid without altering the main characteristics of the antibodies or polypeptides of the disclosure.
[0309] Neutral positions can be considered as positions where any amino acid substitution can be incorporated into the antibody. In fact, in the principle of alanine scanning, alanine is selected because this residue does not have any particular structural or chemical characteristics. In general, if alanine can be substituted for a particular amino acid without changing the properties of a protein, it is recognized that many other amino acid substitutions are likely to be neutral as well, even if not all amino acid substitutions are neutral. In the opposite case where alanine is the wild-type amino acid, if a particular substitution can be shown as neutral, other substitutions are likely to be neutral as well. Thus, as outlined above, amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, such as their hydrophobicity, hydrophilicity, charge, size, etc. Exemplary substitutions that take into account any of the aforementioned characteristics are well known to those skilled in the art, and include arginine and lysine; glutamic acid and aspartic acid; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.
[0310] It may also be desirable to modify the antibodies of the present disclosure with respect to effector function, for example to enhance antigen-dependent cell-mediated cytotoxicity (ADCC) and / or complement-dependent cytotoxicity (CDC) of the antibody. This can be achieved by introducing one or more amino acid substitutions in the Fc region of the antibody. Alternatively or additionally, cysteine residues may be introduced into the Fc region to allow interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and / or increased complement-mediated cell killing and / or antibody-dependent cellular cytotoxicity (ADCC) (Caron PC. et al. 1992; and Shopes B. 1992).
[0311] Another type of amino acid modification of the antibodies of the disclosure may be useful for altering the original glycosylation pattern of the antibody (i.e., by deleting one or more carbohydrate moieties found in the antibody and / or by adding one or more glycosylation sites that are not present in the antibody). The presence of either of the tripeptide sequences asparagine-X-serine, and asparagine-X-threonine, where X is any amino acid except proline, creates a potential glycosylation site. Addition or deletion of glycosylation sites from the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above tripeptide sequences (in the case of N-linked glycosylation sites).
[0312] Another type of modification involves the removal of sequences identified in silico or experimentally as potentially resulting in degradation products or heterogeneity of antibody preparations. By way of example, deamidation of asparagine and glutamine residues can occur depending on factors such as pH and surface exposure. Asparagine residues are particularly susceptible to deamidation when present primarily in the sequence Asn-Gly, and to a lesser extent in other dipeptide sequences such as Asn-Ala. When such deamidation sites, particularly Asn-Gly, are present in the antibodies or polypeptides of the present disclosure, it may therefore be desirable to remove the site, typically by a conservative substitution that removes one of the relevant residues. Such substitutions in the sequence to remove one or more of the relevant residues are also intended to be encompassed by the present disclosure.
[0313] Another type of covalent modification involves chemically or enzymatically coupling glycosides to the antibody. These procedures are advantageous in that they do not require production of the antibody in a host cell that has glycosylation capabilities for N- or O-linked glycosylation. Depending on the coupling mode used, sugars can be attached to (a) arginine and histidine, (b) free carboxyl groups, (c) free sulfhydryl groups such as those of cysteine, (d) free hydroxyl groups such as those of serine, threonine, or hydroxyproline, (e) aromatic residues such as those of phenylalanine, tyrosine, or tryptophan, or (f) the amide group of glutamine. For example, such methods are described in WO 87 / 05330.
[0314] Removal of any carbohydrate moieties present on an antibody can be accomplished chemically or enzymatically. Chemical deglycosylation requires exposure of the antibody to the compound trifluoromethanesulfonic acid, or an equivalent compound. This treatment cleaves most or all sugars except the linking sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the antibody intact. Chemical deglycosylation is described by Sojahr H. et al. (1987) and Edge, A. S. et al. (1981). Enzymatic cleavage of carbohydrate moieties on antibodies can be achieved by the use of a variety of endo- and exoglycosidases as described by Thotakura, N. R. et al. (1987).
[0315] Another type of covalent modification of the antibody involves linking it to any one of a variety of nonproteinaceous polymers, such as polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner described in U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; or 4,179,337.
[0316] In one embodiment, the anti-CEACAM5 antibody is tusamitamab (CAS Registry No. 2349294-95-5).
[0317] Tusamitamab comprises an HCDR1 having the amino acid sequence of SEQ ID NO: 1, an HCDR2 having the amino acid sequence of SEQ ID NO: 2, an HCDR3 having the amino acid sequence of SEQ ID NO: 3, an LCDR1 having the amino acid sequence of SEQ ID NO: 4, an LCDR2 having the amino acid sequence NTR, and an LCDR3 having the amino acid sequence of SEQ ID NO: 5. HCDR1 GFVFSSYD (SEQ ID NO: 1) HCDR2 ISSGGGIT (SEQ ID NO:2) HCDR3 AAHYFGSSGPFAY (SEQ ID NO: 3) LCDR1 ENIFSY (SEQ ID NO: 4) LCDR2 NTR LCDR3 QHHYGTPFT (SEQ ID NO:5)
[0318] Tusamitamab contains a heavy chain variable domain (VH) consisting of SEQ ID NO:6 and a light chain variable domain (VL) consisting of SEQ ID NO:7. [ka]
[0319] Cytotoxic Payloads and Immunoconjugates The present disclosure also includes cytotoxic conjugates, or immunoconjugates, or antibody drug conjugates, or conjugates, all of which have the same meaning and are interchangeable as used herein.
[0320] Thus, the present disclosure relates to an "immunoconjugate" comprising an antibody of the present disclosure (e.g., an anti-CEACAM5 antibody) linked or conjugated to at least one growth inhibitory agent, such as a cytotoxic agent or a radioisotope.
[0321] "Growth inhibitory agents" or "anti-proliferative agents", which may be used interchangeably, refer to compounds or compositions that inhibit the growth of cells, particularly tumor cells, either in vitro or in vivo.
[0322] The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of a cell and / or causes the destruction of a cell. The term "cytotoxic agent" is intended to include chemotherapeutic agents, enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant, or animal origin (including fragments and / or variants thereof), as well as various antitumor or anticancer agents disclosed below. In some embodiments, the cytotoxic agent is a taxoid, a vinca, a maytansinoid or a maytansinoid analog (e.g., DM1 or DM4), a small molecule drug, a tomaymycin or pyrrolobenzodiazepine derivative, a cryptophycin derivative, a leptomycin derivative, an auristatin or dolastatin analog, a prodrug, a topoisomerase II inhibitor, a DNA alkylating agent, an antitubulin agent, CC-1065 or a CC-1065 analog.
[0323] As used herein, "maytansinoids" refers to maytansinoids and maytansinoid analogs. Maytansinoids are drugs that inhibit microtubule formation and are highly toxic to mammalian cells.
[0324] Examples of suitable maytansinoids include maytansinol and maytansinol analogues.
[0325] Examples of suitable maytansinol analogs include those with modified aromatic rings and those with modifications at other positions. Such suitable maytansinoids are described in U.S. Patent Nos. 4,424,219; 4,256,746; 4,294,757; 4,307,016; 4,313,946; 4,315,929; 4,331,598; 4,361,650; and 4,371,651. ,362,663; 4,364,866; 4,450,254; 4,322,348; 4,371,533; 6,333,410; 5,475,092; 5,585,499; and 5,846,545.
[0326] Specific examples of suitable analogues of maytansinol having modified aromatic rings include the following: (1) C-19-dechloro (U.S. Pat. No. 4,256,746) (prepared by LAH reduction of ansamitocin P2); (2) C-20-hydroxy (or C-20-demethyl) + / - C-19-dechloro (U.S. Pat. Nos. 4,361,650 and 4,307,016) (prepared by demethylation using Streptomyces or Actinomyces or by dechlorination using LAH); and (3) C-20-demethoxy, C-20-acyloxy (-OCOR), + / -dechloro (U.S. Pat. No. 4,294,757) (prepared by acylation using acyl chlorides).
[0327] Specific examples of suitable analogs of maytansinol with modifications at other positions include the following: (1) C-9-SH (U.S. Pat. No. 4,424,219) (prepared by reaction of maytansinol with H2S or P2S5); (2) C-14-alkoxymethyl(demethoxy / CH2OR) (U.S. Pat. No. 4,331,598); (3) C-14-hydroxymethyl or acyloxymethyl (CHOH or CHOAc) (U.S. Pat. No. 4,450,254) (prepared from Nocardia); (4) C-15-hydroxy / acyloxy (U.S. Pat. No. 4,364,866) (prepared by conversion of maytansinol by Streptomyces); (5) C-15-methoxy (U.S. Pat. Nos. 4,313,946 and 4,315,929) (isolated from Trewia nudiflora); (6) C-18-N-demethyl (U.S. Pat. Nos. 4,362,663 and 4,322,348) (prepared by demethylation of maytansinol by Streptomyces); and (7) 4,5-deoxy (U.S. Pat. No. 4,371,533) (prepared by titanium trichloride / LAH reduction of maytansinol).
[0328] In certain embodiments of the present disclosure, the cytotoxic conjugates of the present disclosure utilize a thiol-containing maytansinoid, formally known as N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine (DM1), as the cytotoxic agent. DM1 is represented by the following structural formula (I): [ka]
[0329] In another embodiment, the cytotoxic conjugates of the present disclosure utilize the thiol-containing maytansinoid DM4, formally known as N2'-deacetyl-N-2'(4-methyl-4-mercapto-1-oxopentyl)-maytansine, as the cytotoxic agent. DM4 is represented by the following structural formula (II): [ka]
[0330] In further embodiments of the disclosure, other maytansines may be used, including thiol- and disulfide-containing maytansinoids with mono- or di-alkyl substitutions on the carbon atom bearing the sulfur atom, including maytansinoids with acylated amino acid side chains bearing acyl groups bearing hindered sulfhydryl groups at C-3, C-14 hydroxymethyl, C-15 hydroxy, or C-20 desmethyl, where the carbon atom of the acyl group bearing the thiol functionality bears one or two substituents, said substituents being CH3, CH5, linear or branched alkyl or alkenyl with 1-10 groups, and any aggregates that may exist in solution.
[0331] Examples of these cytotoxic agents and methods of conjugation are further provided in WO 2008 / 010101, which is incorporated by reference.
[0332] The term "radioisotope" is intended to include radioisotopes suitable for treating cancer, such as At211, Bi212, Er169, I131, I125, Y90, In111, P32, Re186, Re188, Sm153, Sr89, and radioisotopes of Lu. Such radioisotopes generally emit primarily beta-radiation. In certain embodiments, the radioisotope is an alpha-emitter isotope, more precisely, thorium-227, which emits alpha-radiation.
[0333] Immunoconjugates according to the present disclosure may be prepared as described in WO 2004 / 091668, the entire contents of which are incorporated herein by reference.
[0334] In some embodiments, an antibody of the disclosure is covalently attached to at least one cytotoxic agent or growth inhibitory agent, directly or via a cleavable or non-cleavable linker.
[0335] "Linker," as used herein, means a chemical moiety comprising a covalent bond or chain of atoms that covalently attaches a polypeptide (e.g., an antibody) to a drug (or prodrug) moiety. Suitable linkers are well known in the art and include disulfide groups, thioether groups, acid labile groups, photolabile groups, peptidase labile groups, and esterase labile groups. Exemplary linkers include N-succinimidyl pyridyldithiobutyrate (SPDB), butanoic acid 4-[(5-nitro-2-pyridinyl)dithio]-2,5-dioxo-1-pyrrolidinyl ester (nitro-SPDB), 4-(pyridin-2-yldisulfanyl)-2-sulfobutyric acid (sulfo-SPDB), N-succinimidyl (2-pyridyldithio)propionate (SPDP), succinimidyl (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (azidothiol, ... Examples of crosslinking reagents include, but are not limited to, heterobifunctional crosslinking reagents such as dimethyl polyimidate HCL, active esters (such as subtilisinimidyl diserate), aldehydes (such as glutaraldehyde), bis-azide compounds (such as bis(p-azidobenzoyl)-hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (e.g. toluene 2,6-diisocyanate), and bis-active fluorine compounds (e.g. 1,5-difluoro-2,4-dinitrobenzene). For example, ricin immunotoxins can be prepared as described in Vitetta et al (1987). Carbon-labeled 1-isothiocyanatobenzylmethyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotides to antibodies (WO 94 / 11026).
[0336] The linker may be a "cleavable linker" that facilitates the release of the cytotoxic or growth inhibitory agent in cells. For example, an acid-labile linker, a peptidase-sensitive linker, an esterase-labile linker, a photolabile linker, or a disulfide-containing linker (see, for example, U.S. Pat. No. 5,208,020) may be used. The linker may also be a "non-cleavable linker" (e.g., an SMCC linker), which may provide better resistance in some cases.
[0337] Alternatively, a fusion protein comprising an antibody of the disclosure and a cytotoxic or growth inhibitory polypeptide can be produced by recombinant techniques or peptide synthesis. The length of DNA can include respective regions encoding the two portions of the conjugate, either adjacent to each other or separated by a region encoding a linker peptide that does not destroy the desired properties of the conjugate.
[0338] The antibodies of the present disclosure may also be used in dependent enzyme-mediated prodrug therapy by conjugating the polypeptide to a prodrug-activating enzyme that converts a prodrug (e.g., a peptidyl chemotherapeutic agent, see WO 81 / 01145) into an active anticancer drug (see, e.g., WO 88 / 07378 and U.S. Pat. No. 4,975,278). The enzyme component of the immunoconjugate useful for ADEPT includes any enzyme that can act on a prodrug in such a way as to convert it into its more active, cytotoxic form. Enzymes useful in the methods of the disclosure include alkaline phosphatases, useful for converting phosphate-containing prodrugs to free drugs; arylsulfatases, useful for converting sulfate-containing prodrugs to free drugs; cytosine deaminases, useful for converting the non-toxic fluorocytosin to the anticancer drug, 5-fluorouracil; proteases such as Serratia protease, thermolysin, subtilisin, carboxypeptidase, and cathepsins (such as cathepsins B and L), useful for converting peptide-containing prodrugs to free drugs; carbohydrate cleaving enzymes such as O-galactosidase and neuraminidase, useful for converting glycosylated prodrugs to free drugs; P-lactamases, useful for converting P-lactam derivatized drugs to free drugs; and penicillin amidases, e.g., penicillin V amidase or penicillin G amidase, useful for converting drugs derivatized at an amine nitrogen bearing a phenoxyacetyl or phenylacetyl group, respectively, to free drugs. Enzymes may be covalently attached to the polypeptides of the present disclosure by techniques well known in the art, such as the use of heterobifunctional crosslinking reagents described above.
[0339] According to certain embodiments, in the conjugates of the present disclosure, the growth inhibitory agent is a maytansinoid, in certain embodiments, DM1 or DM4.
[0340] In the conjugate, the antibody is conjugated to at least one of the growth inhibitory agents through a linking group. In some embodiments, the linking group is a cleavable or non-cleavable linker, such as SPDB, sulfo-SPDB, or SMCC.
[0341] The conjugate may be selected from the group consisting of: Antibody-SPDB-DM4 conjugate of formula (III) [ka] Antibody-Sulfo-SPDB-DM4 Conjugate of Formula (IV) [ka] and Antibody-SMCC-DM1 conjugate of formula (V) [ka]
[0342] In certain embodiments, the conjugate is a conjugate of formula (III), (IV) or (V) as defined above, and the antibody is an antibody described herein.
[0343] In formulas (III), (IV) and (V) above, "n" corresponds to the number of molecules of chemotherapeutic agent conjugated per antibody molecule. This corresponds to the "drug-to-antibody ratio" (or "DAR") as defined herein and can range from 1 to 10.
[0344] In certain embodiments, the conjugate is tusamitamaravtansine (CAS Registry Number 2254086-60-5).
[0345] The conjugate, Tusamitamaravtansine, is also referred to in the Examples section as huMAb2-3-SPDB-DM4.
[0346] The conjugates of the present disclosure may be prepared by in vitro methods. In general, the conjugates are (i) contacting an optionally buffered aqueous solution of an antibody according to the present disclosure with a solution of a linker and a cytotoxic compound; and (ii) optionally followed by separating the conjugate formed in (i) from unreacted antibody, linker and cytotoxic compound. The composition can be obtained by a process comprising:
[0347] The aqueous solution of the cell-binding agent may be buffered with a buffer such as, for example, potassium phosphate, acetate, citrate, or N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES buffer). The buffer depends on the nature of the cell-binding agent. The cytotoxic compound is in solution in an organic polar solvent, such as dimethylsulfoxide (DMSO) or dimethylacetamide (DMA).
[0348] The reaction temperature is usually comprised between 20°C and 40°C. The reaction time can vary from 1 hour to 24 hours. The reaction between the cell-binding agent and the cytotoxic agent can be monitored by refractometry and / or size-exclusion chromatography (SEC) using a UV detector. If the yield of the conjugate is too low, the reaction time can be extended.
[0349] To carry out the separation of step (ii), several different chromatographic methods can be used by the skilled artisan: the conjugate can be purified, for example, by SEC, adsorption chromatography (ion exchange chromatography, IEC, etc.), hydrophobic interaction chromatography (HIC), affinity chromatography, mixed support chromatography such as hydroxyapatite chromatography, or high performance liquid chromatography (HPLC). Purification by dialysis or diafiltration can also be used.
[0350] As used herein, the term "aggregate" refers to an association that can be formed between two or more cell-binding agents, the agents being modified or unmodified by conjugation. Aggregates can be formed under the influence of a number of parameters, such as high concentration of cell-binding agents in solution, pH of the solution, high shear force, the number of bound dimers and their hydrophobic properties, temperature (see Wang & Gosh, 2008, J. Membrane Sci., 318:311-316, and references cited therein); it should be noted that the relative influence of some of these parameters has not been clearly established. In the case of proteins and antibodies, the skilled person will refer to Cromwell et al. (2006, AAPS Journal, 8(3):E572-E579). The content in aggregates can be determined by techniques well known to those skilled in the art, such as SEC (Walter et al., 1993, Anal. Biochem., 212(2):469-480).
[0351] After step (i) or (ii), the conjugate-containing solution may be subjected to a further step (iii) of chromatography, ultrafiltration and / or diafiltration.
[0352] The conjugate is recovered at the end of these steps in aqueous solution.
[0353] According to certain embodiments, conjugates according to the present disclosure are characterized by a "drug-to-antibody ratio" (or "DAR") ranging from 1 to 10, such as from 2 to 5, or such as from 3 to 4. This is generally the case for conjugates that include a maytansinoid molecule.
[0354] This DAR number may vary depending on the experimental conditions used for conjugation (such as growth inhibitor / antibody ratio, reaction time, nature of the solvent and nature of the cosolvent, if any) as well as the nature of the antibody and drug (i.e., growth inhibitor). Thus, contact between the antibody and the growth inhibitor results in a mixture containing several conjugates that differ from each other due to different drug-antibody ratios; optionally resulting in naked antibodies; optionally resulting in aggregates. Thus, the determined DAR is an average value.
[0355] Methods that can be used to determine the DAR include: D and measuring the ratio of the absorbance of the solution of the substantially purified conjugate at 280 nm using a spectrophotometer. 280 nm is a wavelength commonly used to measure protein concentrations, such as antibody concentrations. D is selected to be able to distinguish the drug from the antibody, i.e., λ D is the drug has high absorbance and λ D is far enough away from 280 nm to avoid substantial overlap of the drug and antibody absorbance peaks. D may be selected as being 252 nm for maytansinoid molecules. Methods for DAR calculation may be taken from Antony S. Dimitrov (ed), LLC, 2009, Therapeutic Antibodies and Protocols, vol 525, 445, Springer Science.
[0356] λ D (A λD ) and 280 nm (A 280 The absorbance of the conjugate at 100 nm is measured either by size exclusion chromatography (SEC) analysis of the monomer peak (allowing for the calculation of the "DAR(SEC)" parameter) or by using a classical spectrophotometer device (allowing for the calculation of the "DAR(UV)" parameter). The absorbance can be expressed as follows: A λD =(c D xε DλD)+(c A xε AλD ) A 280 =(c D xε D280 )+(c A xε A280 ) During the ceremony, c D and c A are the concentrations of the drug and antibody in solution, respectively, ε DλD and ε D280 are respectively, λ D and the molar extinction coefficient of the drug at 280 nm, ε AλD and ε A280 are respectively, λ D and the molar extinction coefficient of the antibody at 280 nm.
[0357] Resolution of these two equations with two unknowns results in the following equation: c D =[(ε A280 xA λD )-(ε AλD xA 280 )] / [(ε DλD xε A280 )-(ε AλD xε D280 )] c A =[A 280 -(c D xε D280 )] / ε A280
[0358] The average DAR is then calculated from the ratio of drug concentration to antibody: DAR=c D / c A .
[0359] Anti-PD-1 antibody; anti-PD-L1 antibody Anti-PD-1 and anti-PD-L1 antibodies that can disrupt the interaction between PD-1 expressed on the surface of immune cells and PD-L1 expressed on the surface of cancer cells are useful as immune checkpoint inhibitors, thereby blocking a pathway that shields tumor cells from immune system components that are able and ready to fight cancer. When PD-1 and PD-L1 interact, they form a biochemical "shield" that protects tumor cells from being destroyed by the immune system. Thus, blocking either PD-1 or PD-L1, which results in blocking the interaction between PD-1 and PD-L1, prevents or unmasks the biochemical "shield" that protects tumor cells from being destroyed by the immune system.
[0360] Several anti-PD-1 antibodies have been approved for clinical use in the treatment of cancer, including pembrolizumab (KEYTRUDA®), nivolumab (OPDIVO®), cemiplimab (LIBTAYO®), sintilimab (TYVYT®), dostarimab (JEMPERLI®), and tislelizumab.
[0361] Similarly, several anti-PD-L1 antibodies have been approved for clinical use in the treatment of cancer, including atezolizumab (TECENTRIQ®), avelumab (BAVENCIO®), and durvalumab (IMFINZI®).
[0362] Platinum-based chemotherapy Platinum-based antineoplastic agents are coordination compounds of platinum. These drugs are used to treat nearly half of the people undergoing chemotherapy for cancer. In this form of chemotherapy, commonly used drugs include cisplatin, carboplatin, oxaliplatin, and nedaplatin. Their main mechanism of action is thought to be the induction of cancer cell apoptosis as a response to covalent binding to DNA. In recent years, this situation has become more complex based on studies showing that cellular molecules other than DNA can potentially act as targets and that some of the antitumor effects of platinum drugs occur through modulation of the immune system. These immunogenic effects include modulation of STAT signaling; induction of an immunogenic type of cancer cell death through exposure of calreticulin and release of ATP and high mobility group protein box-1 (HMGB-1); and enhancement of effector immune responses through modulation of programmed death receptor 1-ligand (PD-L1) and mannose-6-phosphate receptor expression. Both basic and clinical studies indicate that at least part of the antitumor effects of platinum-based chemotherapy can be attributed to immune-enhancing mechanisms.
[0363] Pemetrexed Pemetrexed (N-[4-[2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid) is a metabolic inhibitor that inhibits at least three enzymes involved in the folate pathway: thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has demonstrated clinical efficacy in non-small cell lung cancer as well as a wide range of other solid tumors, including mesothelioma, breast cancer, colorectal cancer, bladder cancer, cervical cancer, gastric cancer, and pancreatic cancer. In September 2008, the FDA approved pemetrexed as first-line treatment in combination with cisplatin for locally advanced and metastatic NSCLC in patients with a nonsquamous histology diagnosis. Patients should be aware of the risk of developing folate and vitamin B12, even if their levels are normal when on pemetrexed therapy. 12 Taking supplements is recommended.
[0364] Pharmaceutical Compositions The antibodies, immunoconjugates, and compounds of the disclosure may be combined with pharma- ceutically acceptable excipients, and optionally sustained release matrices, such as biodegradable polymers, to form therapeutic compositions.
[0365] Accordingly, another object of the present disclosure relates to a pharmaceutical composition comprising an antibody, immunoconjugate or compound of the present disclosure and a pharma- ceutically acceptable carrier or excipient.
[0366] The present disclosure also relates to an antibody, immunoconjugate or compound according to the present disclosure for use as a medicament.
[0367] The present disclosure also relates to an antibody, immunoconjugate, or compound according to the present disclosure for use in treating cancer.
[0368] "Pharmaceutical" or "pharmaceutical acceptable" refers to molecular entities and compositions that do not produce adverse allergic or other untoward reactions when administered to a mammal, especially a human, as appropriate. A pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
[0369] As used herein, "pharmaceutical acceptable carriers" include any physiologically compatible solvents, dispersion media, coating materials, antibacterial and antifungal agents, etc. Examples of suitable carriers, diluents and / or excipients include water, amino acids, saline, phosphate buffered saline, phosphate buffer, acetates, citrates, succinates; amino acids and derivatives such as histidine, arginine, glycine, proline, glycylglycine; inorganic salts NaCl, calcium chloride; sugars or polyalcohols such as dextrose, glycerol, ethanol, sucrose, trehalose, mannitol; surfactants such as polysorbate 80, polysorbate 20, poloxamer 188, etc., and combinations thereof. In many cases, it is preferable to include an isotonic agent, such as a sugar, polyalcohol or sodium chloride, in the composition, and the formulation may also contain an antioxidant, such as tryptamine, and a stabilizer, such as Tween 20.
[0370] The form of the pharmaceutical composition, the route of administration, the dosage and the regimen will naturally depend on the condition to be treated, the severity of the disease, the age, weight and sex of the patient, etc.
[0371] The pharmaceutical compositions of the present disclosure may be formulated for topical, oral, parenteral, intranasal, intravenous, intramuscular, subcutaneous or intraocular administration, and the like.
[0372] In certain embodiments, the pharmaceutical compositions contain pharma- ceutically acceptable vehicles for injectable preparations, which may be isotonic sterile saline (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride, etc., or mixtures of such salts), or dry compositions, in particular lyophilized compositions, that allow the constitution of an injectable solution upon addition of sterile water or saline, as the case may be.
[0373] The pharmaceutical composition may be administered through a drug combination device.
[0374] The dose used for administration can be adapted depending on various parameters, for example depending on the mode of administration used, the pathology involved or the desired duration of treatment.
[0375] To prepare a pharmaceutical composition, an effective amount of the antibody or immunoconjugate of the disclosure may be dissolved or dispersed in a pharma- ceutically acceptable carrier or aqueous medium.
[0376] Pharmaceutical forms suitable for injection use include sterile aqueous solutions or dispersions; formulations containing sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.In all cases, the form must be sterile and injectable in a suitable device or system for delivery without degradation.It must be stable under the conditions of manufacture and storage and must be protected against the contaminating action of microorganisms such as bacteria and fungi.
[0377] The solution of the active compound as a free base or a pharmacologically acceptable salt can be prepared in water mixed appropriately with a surfactant.Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils.Under normal conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
[0378] The polypeptides, antibodies or immunoconjugates of the present disclosure can be formulated into compositions in neutral or salt form. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of the protein) and are formed with inorganic acids, such as hydrochloric or phosphoric acid, or organic acids such as acetic, oxalic, tartaric, mandelic, etc. Salts formed with the free carboxyl groups can also be derived from inorganic bases, such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, or ferric hydroxide, and organic bases, such as isopropylamine, trimethylamine, glycine, histidine, procaine, etc.
[0379] The carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. Proper fluidity can be maintained, for example, by the use of a coating material such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it is preferable to include an isotonic agent, for example, sugar or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0380] Sterile injection solution is prepared by incorporating the required amount of active compound into a suitable solvent with any of the other ingredients listed above as necessary, followed by filtration sterilization.Generally, dispersion is prepared by incorporating various sterilized active ingredients into a sterile vehicle that contains basic dispersion medium and other necessary ingredients from those listed above.In the case of sterile powder for preparing sterile injection solution, the preferred preparation method is vacuum drying and freeze-drying technology, which obtains powder of active ingredient + any additional desired ingredient from its previously sterile filtered solution.
[0381] The preparation of more concentrated or highly concentrated solutions for direct injection is also contemplated, and the use of DMSO as a solvent is envisioned to result in extremely rapid penetration, delivering high concentrations of active agent to small tumor areas.
[0382] Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as the types of injectable solutions described above, although drug release capsules and the like can also be used.
[0383] In the case of parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary, and the liquid diluent should first be rendered isotonic with sufficient saline or glucose. These aqueous solutions are suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration, among others. In this regard, the sterile aqueous media that can be utilized will be known to those skilled in the art in light of this disclosure. For example, one dosage can be dissolved in 1 ml of isotonic NaCl solution and added to 1000 ml of subcutaneous infusion fluid or injected at the proposed injection site (see, for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
[0384] The antibodies or immunoconjugates of the disclosure may be formulated to contain from about 0.01 to 100 milligrams per dose within the therapeutic mixture.
[0385] In addition to antibodies or immunoconjugates formulated for parenteral administration, e.g., intravenous or intramuscular injection, other pharma- ceutically acceptable forms include, for example, tablets or other solids for oral administration; time-release capsules; and any other form currently in use.
[0386] In certain embodiments, the use of liposomes and / or nanoparticles is contemplated for the introduction of polypeptides into host cells. The formation and use of liposomes and / or nanoparticles are known to those of skill in the art.
[0387] Nanocapsules can generally entrap compounds in a stable and reproducible manner.To avoid side effects due to intracellular polymer overload, such ultrafine particles (size of about 0.1 μm) are generally designed using polymers that can be degraded in vivo.Biodegradable polyalkyl-cyanoacrylate nanoparticles or biodegradable polylactide or polylactide-co-glycolide nanoparticles that meet these requirements are contemplated for use in the present disclosure, and such particles can be easily produced.
[0388] Liposomes are formed from phospholipids that disperse in aqueous media and spontaneously form multilamellar concentric bilayer vesicles, also called multilamellar vesicles (MLVs). MLVs generally have diameters between 25 nm and 4 μm. Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200-500 Å, containing aqueous solution in their core. The physical characteristics of liposomes depend on pH, ionic strength and the presence of divalent cations.
[0389] Methods of treatment: Combination of anti-CEACAM5 ADC and anti-PD1 / PDL1 antibody: One aspect of the disclosure is a method of treating cancer, comprising administering to a subject in need thereof effective amounts of (i) an anti-CEACAM5 ADC and (ii) at least an anti-PD-1 antibody or an anti-PD-L1 antibody.
[0390] As used herein, an "effective amount" or "therapeutically effective amount" is a dose of a therapeutic agent that results in treatment of a CEACAM5-expressing cancer (eg, lung cancer, gastric cancer, gastroesophageal junction cancer, or esophageal cancer).
[0391] As used herein, "treat" refers to causing a detectable improvement in one or more symptoms associated with CEACAM5-expressing cancer or causing a biological effect (e.g., a reduction in the level of a particular biomarker) that correlates with the underlying pathological mechanism causing the condition or symptom. For example, a dose of a therapeutic agent that causes an improvement in any of the following symptoms or conditions associated with CEACAM5-expressing cancer is considered a "therapeutically effective amount."
[0392] In another example, treatment is not effective if a dose of therapeutic agent does not produce a detectable improvement in one or more parameters or symptoms associated with a CEACAM5-expressing cancer (e.g., lung cancer, gastric cancer, esophagogastric junction cancer, or esophageal cancer) or produces a biological effect that correlates with the underlying pathological mechanism causing the cancerous condition or symptom.
[0393] According to some of these embodiments, the anti-CEACAM5 ADC is administered intravenously.
[0394] According to the methods of the present disclosure, the therapeutically effective amount of a therapeutic agent administered to a subject will vary depending on the subject's age and size (e.g., body weight or body surface area), as well as the route of administration and other factors well known to those of skill in the art.
[0395] One aspect of the disclosure is a method of treating cancer, comprising administering to a subject in need thereof effective amounts of (i) an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody and (ii) an anti-PD-1 antibody or an anti-PD-L1 antibody, wherein the cancer expresses CEACAM5, thereby treating the cancer.
[0396] In one embodiment, the anti-CEACAM5 antibody comprises an HCDR1 having the amino acid sequence of SEQ ID NO: 1, an HCDR2 having the amino acid sequence of SEQ ID NO: 2, an HCDR3 having the amino acid sequence of SEQ ID NO: 3, an LCDR1 having the amino acid sequence of SEQ ID NO: 4, an LCDR2 having the amino acid sequence NTR, and an LCDR3 having the amino acid sequence of SEQ ID NO: 5. HCDR1 GFVFSSYD (SEQ ID NO: 1) HCDR2 ISSGGGIT (SEQ ID NO:2) HCDR3 AAHYFGSSGPFAY (SEQ ID NO: 3) LCDR1 ENIFSY (SEQ ID NO: 4) LCDR2 NTR LCDR3 QHHYGTPFT (SEQ ID NO:5)
[0397] In certain embodiments, the anti-CEACAM5 antibody comprises a variable domain (VH) of the heavy chain consisting of SEQ ID NO:6.
[0398] In certain embodiments, the anti-CEACAM5 antibody comprises a variable domain of the light chain (VL) consisting of SEQ ID NO:7.
[0399] In certain embodiments, the anti-CEACAM5 antibody comprises a heavy chain variable domain (VH) consisting of SEQ ID NO:6 and a light chain variable domain (VL) consisting of SEQ ID NO:7. [ka]
[0400] In certain embodiments, the anti-CEACAM5 antibody comprises a heavy chain (HC) consisting of SEQ ID NO:8.
[0401] In certain embodiments, the anti-CEACAM5 antibody comprises a light chain (LC) consisting of SEQ ID NO:9.
[0402] In certain embodiments, the anti-CEACAM5 antibody comprises a heavy chain (HC) consisting of SEQ ID NO:8 and a light chain (LC) consisting of SEQ ID NO:9. [ka]
[0403] In a particular embodiment, the anti-CEACAM5 antibody is tusamitamab.
[0404] In certain embodiments, the cytotoxic agent is selected from the group consisting of a radioisotope, a protein toxin, a small molecule toxin, and any combination thereof.
[0405] In certain embodiments, the small molecule toxin is selected from the group consisting of antimetabolites, DNA alkylating agents, DNA cross-linking agents, DNA intercalating agents, anti-microtubule agents, topoisomerase inhibitors, and any combination thereof.
[0406] In certain embodiments, the anti-microtubule agent is selected from the group consisting of taxanes, vinca alkaloids, maytansinoids, colchicine, podophyllotoxin, griseofulvin, and any combination thereof.
[0407] In certain embodiments, the maytansinoid is selected from the group consisting of N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine (DM1), N2'-deacetyl-N-2'(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4), and any combination thereof.
[0408] In a particular embodiment, the toxin is N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine (DM1).
[0409] In a particular embodiment, the toxin is N2'-deacetyl-N2'-(4-methyl-4-mercapto-1-oxopropyl)-maytansine (DM4).
[0410] In certain embodiments, the anti-CEACAM5 antibody is covalently attached to at least one cytotoxic agent via a cleavable or non-cleavable linker.
[0411] In certain embodiments, the linker is selected from the group consisting of N-succinimidyl pyridyldithiobutyrate (SPDB), butanoic acid 4-[(5-nitro-2-pyridinyl)dithio]-2,5-dioxo-1-pyrrolidinyl ester (nitro-SPDB), 4-(pyridin-2-yldisulfanyl)-2-sulfo-butyric acid (sulfo-SPDB), N-succinimidyl (2-pyridyldithio)propionate (SPDP), succinimidyl (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), and any combination thereof.
[0412] In certain embodiments, the toxin is directly covalently attached to the anti-CEACAM5 antibody.
[0413] In certain embodiments, the toxin is covalently attached to the anti-CEACAM5 antibody by a linker consisting of N-succinimidyl pyridyldithiobutyrate (SPDB).
[0414] In certain embodiments, the toxin is covalently attached to the anti-CEACAM5 antibody by a linker consisting of butanoic acid 4-[(5-nitro-2-pyridinyl)dithio]-2,5-dioxo-1-pyrrolidinyl ester (nitro-SPDB).
[0415] In certain embodiments, the toxin is covalently attached to the anti-CEACAM5 antibody by a linker consisting of 4-(pyridin-2-yldisulfanyl)-2-sulfo-butyric acid (sulfo-SPDB).
[0416] In certain embodiments, the toxin is covalently attached to the anti-CEACAM5 antibody by a linker consisting of N-succinimidyl (2-pyridyldithio)propionate (SPDP).
[0417] In certain embodiments, the toxin is covalently attached to the anti-CEACAM5 antibody by a linker consisting of succinimidyl (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC).
[0418] In certain embodiments, the ADC is characterized by a drug-antibody ratio (DAR) ranging from 1 to 10. In certain embodiments, the ADC has a DAR of 1. In certain embodiments, the ADC has a DAR of 2. In certain embodiments, the ADC has a DAR of 3. In certain embodiments, the ADC has a DAR of 4. In certain embodiments, the ADC has a DAR of 5. In certain embodiments, the ADC has a DAR of 6. In certain embodiments, the ADC has a DAR of 7. In certain embodiments, the ADC has a DAR of 8. In certain embodiments, the ADC has a DAR of 9. In certain embodiments, the ADC has a DAR of 10.
[0419] In certain embodiments, the ADC is characterized by a DAR of 2 to 5. In certain embodiments, the ADC is characterized by a DAR of 3 to 4.
[0420] In certain embodiments, the ADC is tusamitamaravtansine.
[0421] In certain embodiments, the cancer expresses CEACAM5 at moderate or high intensity as defined by immunohistochemistry (IHC).
[0422] In certain embodiments, immunohistochemical analysis may be performed on a contemporaneous sample of the tumor obtained from the subject. In certain embodiments, immunohistochemical analysis may be performed on a suitable historical sample of the tumor obtained from the subject.
[0423] In certain embodiments, the cancer expresses CEACAM5 with moderate intensity (immunohistochemical intensity ≧2+ in ≧1% to <50% of tumor cells). In certain embodiments, the cancer expresses CEACAM5 with high intensity (immunohistochemical intensity ≧2+ in ≧50% of tumor cells).
[0424] In certain embodiments, the cancer is selected from the group consisting of colorectal cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, lung cancer, cervical cancer, pancreatic cancer, ovarian cancer, thyroid cancer, bladder cancer, endometrial cancer, breast cancer, liver cancer, biliary tract cancer (e.g., cholangiocarcinoma), prostate cancer, and skin cancer.
[0425] In certain embodiments, the cancer is selected from the group consisting of gastric cancer, gastroesophageal junction cancer, esophageal cancer, and lung cancer.
[0426] In certain embodiments, the cancer is gastric cancer.
[0427] In certain embodiments, the cancer is gastroesophageal junction cancer.
[0428] In certain embodiments, the cancer is esophageal cancer.
[0429] In certain embodiments, the cancer is lung cancer.
[0430] In certain embodiments, the lung cancer is non-squamous non-small cell lung cancer (NSQ NSCLC).
[0431] In certain embodiments, the subject has advanced or metastatic NSQ NSCLC. In some embodiments, the subject has stage 3A NSQ NSCLC, e.g., the primary tumor has spread to lymph nodes on the same side of the chest where it began. In some embodiments, the subject has stage 3B NSQ NSCLC, e.g., the primary tumor has spread to lymph nodes on the same or opposite side of the chest where it began, above the collarbone, or in the space between the lungs. In some embodiments, the subject has stage 3C NSQ NSCLC, e.g., a large primary tumor has grown and spread to lymph nodes on the opposite side of the chest where it began, above the collarbone, or in the space between the lungs, and has two or more tumors on the same side of the chest. In some embodiments, the subject has stage 4 NSQ NSCLC, e.g., metastases to one or more sites outside the chest. In some embodiments, the subject has widespread metastatic NSQ NSCLC.
[0432] In certain embodiments, the subject has NSQ NSCLC without epidermal growth factor receptor (EGFR) sensitizing mutations or v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations or anaplastic lymphoma kinase / c-ros oncogene 1 (ALK / ROS) alterations. In certain embodiments, the subject has NSQ NSCLC without EGFR sensitizing mutations. In certain embodiments, the subject has NSQ NSCLC without BRAF mutations. In certain embodiments, the subject has NSQ NSCLC without anaplastic lymphoma kinase / c-ros oncogene 1 (ALK / ROS) alterations. In certain embodiments, the subject has NSQ NSCLC without any combination of EGFR sensitizing mutations, BRAF mutations, and ALK / ROS alterations.
[0433] In certain embodiments, the subject has not previously received systemic chemotherapy for the treatment of cancer. In some embodiments, the subject has not previously received platinum-based chemotherapy, e.g., cisplatin or carboplatin. In certain embodiments, the subject has not previously received pemetrexed.
[0434] In certain embodiments, the subject has not previously received immunotherapy for the treatment of cancer. Immunotherapy includes treatment with an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. In certain embodiments, the subject has not previously received treatment with an anti-PD-1 antibody or an anti-PD-L1 antibody. In certain embodiments, the subject has not previously received treatment with an anti-PD-L1 antibody.
[0435] In certain embodiments, the anti-PD-1 antibody is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, sintilimab, dostallimab, and tislelizumab.
[0436] In a particular embodiment, the anti-PD-1 antibody is pembrolizumab.
[0437] In a particular embodiment, the anti-PD-1 antibody is nivolumab.
[0438] In a specific embodiment, the anti-PD-1 antibody is cemiplimab.
[0439] In a specific embodiment, the anti-PD-1 antibody is sintilimab.
[0440] In a particular embodiment, the anti-PD-1 antibody is dostarlimab.
[0441] In a particular embodiment, the anti-PD-1 antibody is tislelizumab.
[0442] In certain embodiments, the anti-PD-1 antibody is not pembrolizumab.
[0443] In certain embodiments, the anti-PD-1 antibody is not nivolumab.
[0444] In certain embodiments, the anti-PD-1 antibody is not cemiplimab.
[0445] In certain embodiments, the anti-PD-1 antibody is not sintilimab.
[0446] In certain embodiments, the anti-PD-1 antibody is not dostarlimab.
[0447] In certain embodiments, the anti-PD-1 antibody is not tislelizumab.
[0448] In certain embodiments, the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, avelumab, and durvalumab.
[0449] In a specific embodiment, the anti-PD-L1 antibody is atezolizumab.
[0450] In a specific embodiment, the anti-PD-L1 antibody is avelumab.
[0451] In a specific embodiment, the anti-PD-L1 antibody is durvalumab.
[0452] In certain embodiments, the anti-PD-L1 antibody is not atezolizumab.
[0453] In certain embodiments, the anti-PD-L1 antibody is not avelumab.
[0454] In certain embodiments, the anti-PD-L1 antibody is not durvalumab.
[0455] In a particular embodiment, the ADC is tusamitamaravtansine and the anti-PD-1 antibody is pembrolizumab.
[0456] Anti-CEACAM5 ADC Administration: In certain embodiments, the dose of the ADC varies depending on the body surface area of the subject.
[0457] In certain embodiments, the dose of an anti-CEACAM5 ADC administered to a subject is about 1 mg / m 2 ~about 500mg / m 2 It is.
[0458] In some embodiments, the dose of ADC administered to a subject is about 5 mg / m 2 ~about 300mg / m 2 It is.
[0459] In various embodiments, the dose of ADC administered to a subject is about 5 mg / m 2 ~about 250mg / m 2 It is.
[0460] In a further embodiment, the dose of ADC administered to a subject is about 60 mg / m 2 ~about 190mg / m 2 It is.
[0461] In various embodiments, the dose is about 5, 10, 20, 30, 40, 60, 80, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, or 210 mg / m based on the subject's body surface area. 2 It is.
[0462] In one embodiment, the dose of the ADC is 120 mg / m 2 It is.
[0463] In one embodiment, the dose of the ADC is 150 mg / m 2 It is.
[0464] In one embodiment, the dose of the ADC is 170 mg / m 2 It is.
[0465] Anti-PD1 / PDL1 Administration: Generally, the anti-PD-1 or anti-PD-L1 antibody may be administered in a fixed dose (e.g., 200-400 mg) or on a body weight basis (e.g., 10 mg / kg) depending on the type of cancer being treated. In certain embodiments, the anti-PD-1 or anti-PD-L1 is administered intravenously. Intravenous administration may be by infusion or injection. Typically, intravenous administration is by infusion.
[0466] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 200 mg to about 400 mg.In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 200 mg to 400 mg.
[0467] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, or about 400 mg.
[0468] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg, or 400 mg.
[0469] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose selected from 200 mg, 350 mg, 360 mg, and 400 mg.
[0470] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to the subject at a dose selected from 200 mg.
[0471] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to the subject at a dose selected from 400 mg.
[0472] In certain exemplary embodiments, the PD1 antibody is pembrolizumab. In other exemplary embodiments, the PD1 antibody is sintilimab.
[0473] Dosing schedule for CEACAM5 ADC and anti-PD1 / PDL1 combination therapy Generally, the combination of a CEACAM5 ADC (e.g., tusamitamaravtansine) and an anti-PD-1 antibody or anti-PD-L1 antibody may be administered simultaneously or contemporaneously in any order. In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered sequentially; i.e., the anti-PD-1 antibody and the ADC are administered sequentially, or the anti-PD-L1 antibody and the ADC are administered sequentially. In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered before the ADC. In certain embodiments, the ADC is administered before the anti-PD-1 antibody or anti-PD-L1 antibody.
[0474] In certain embodiments, there is a delay of at least about 30 minutes between the end of administration of a first agent and the start of administration of a second agent, provided that administration of both agents is completed within a single day or 24 hour period.
[0475] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered simultaneously; i.e., the anti-PD-1 antibody and the ADC are administered simultaneously, or the anti-PD-L1 antibody and the ADC are administered simultaneously.
[0476] In certain embodiments, administration of both agents begins essentially simultaneously, e.g., within minutes of each other. In certain embodiments, administration of both agents ends essentially simultaneously, e.g., within minutes of each other. In certain embodiments, administration of both agents begins essentially simultaneously, e.g., within minutes of each other, and ends essentially simultaneously, e.g., within minutes of each other.
[0477] In certain embodiments, the anti-PD-1 antibody, or the anti-PD-L1 antibody and the ADC are administered to the subject for at least four cycles; i.e., the anti-PD-1 antibody and the ADC are administered to the subject for at least four cycles, or the anti-PD-L1 antibody and the ADC are administered to the subject for at least four cycles.
[0478] In certain embodiments, each cycle is about 2-6 weeks. In certain embodiments, each cycle is about 2-6 weeks.
[0479] In certain embodiments, each cycle is about 2 weeks. In certain embodiments, each cycle is 2 weeks. In certain embodiments, each cycle is 12-17 days. In certain embodiments, a cycle is 12 days. In certain embodiments, a cycle is 13 days. In certain embodiments, a cycle is 14 days. In certain embodiments, a cycle is 15 days. In certain embodiments, a cycle is 16 days. In certain embodiments, a cycle is 17 days. In certain embodiments, at least one cycle is 1 or 2 days shorter or longer than at least one other cycle.
[0480] In certain embodiments, each cycle is about 3 weeks. In certain embodiments, each cycle is 3 weeks. In certain embodiments, each cycle is 18-24 days. In certain embodiments, a cycle is 18 days. In certain embodiments, a cycle is 19 days. In certain embodiments, a cycle is 20 days. In certain embodiments, a cycle is 21 days. In certain embodiments, a cycle is 22 days. In certain embodiments, a cycle is 23 days. In certain embodiments, a cycle is 24 days. In certain embodiments, at least one cycle is 1-3 days shorter or longer than at least one other cycle.
[0481] In certain embodiments, each cycle is about 4 weeks. In certain embodiments, each cycle is 4 weeks. In certain embodiments, each cycle is 25-32 days. In certain embodiments, the cycle is 25 days. In certain embodiments, the cycle is 26 days. In certain embodiments, the cycle is 27 days. In certain embodiments, the cycle is 28 days. In certain embodiments, the cycle is 29 days. In certain embodiments, the cycle is 30 days. In certain embodiments, the cycle is 31 days. In certain embodiments, the cycle is 32 days. In certain embodiments, at least one cycle is 1-4 days shorter or longer than at least one other cycle.
[0482] In certain embodiments, each cycle is about 5 weeks. In certain embodiments, each cycle is 5 weeks. In certain embodiments, each cycle is 33-40 days. In certain embodiments, the cycle is 33 days. In certain embodiments, the cycle is 34 days. In certain embodiments, the cycle is 35 days. In certain embodiments, the cycle is 36 days. In certain embodiments, the cycle is 37 days. In certain embodiments, the cycle is 38 days. In certain embodiments, the cycle is 39 days. In certain embodiments, the cycle is 40 days. In certain embodiments, at least one cycle is 1-4 days shorter or longer than at least one other cycle.
[0483] In certain embodiments, each cycle is about 6 weeks. In certain embodiments, each cycle is 6 weeks. In certain embodiments, each cycle is 36-48 days. In certain embodiments, the cycle is 36 days. In certain embodiments, the cycle is 37 days. In certain embodiments, the cycle is 38 days. In certain embodiments, the cycle is 39 days. In certain embodiments, the cycle is 40 days. In certain embodiments, the cycle is 41 days. In certain embodiments, the cycle is 42 days. In certain embodiments, the cycle is 43 days. In certain embodiments, the cycle is 44 days. In certain embodiments, the cycle is 45 days. In certain embodiments, the cycle is 46 days. In certain embodiments, the cycle is 47 days. In certain embodiments, the cycle is 48 days. In certain embodiments, at least one cycle is 1-6 days shorter or longer than at least one other cycle.
[0484] In certain embodiments, the cycle of each Tusamitamab ravtansine is selected from the group consisting of about 2 weeks, about 3 weeks, about 4 weeks, and about 5 weeks. In certain embodiments, the cycle of each Tusamitamab ravtansine is about 2 weeks. In certain embodiments, the cycle of each Tusamitamab ravtansine is about 3 weeks. In certain embodiments, the cycle of each Tusamitamab ravtansine is about 4 weeks. In certain embodiments, the cycle of each Tusamitamab ravtansine is about 5 weeks.
[0485] In certain embodiments, the cycle of each Tusamitamab ravtansine is selected from the group consisting of 2 weeks, 3 weeks, 4 weeks, and 5 weeks. In certain embodiments, the cycle of each Tusamitamab ravtansine is 2 weeks. In certain embodiments, the cycle of each Tusamitamab ravtansine is 3 weeks. In certain embodiments, the cycle of each Tusamitamab ravtansine is 4 weeks. In certain embodiments, the cycle of each Tusamitamab ravtansine is 5 weeks.
[0486] In certain embodiments, the cycle of each anti-PD-1 antibody or anti-PD-L1 antibody is selected from the group consisting of about 2 weeks, about 3 weeks, and about 6 weeks. In certain embodiments, the cycle of each anti-PD-1 antibody or anti-PD-L1 antibody is about 2 weeks. In certain embodiments, the cycle of each anti-PD-1 antibody or anti-PD-L1 antibody is about 3 weeks. In certain embodiments, the cycle of each anti-PD-1 antibody or anti-PD-L1 antibody is about 4 weeks. In certain embodiments, the cycle of each anti-PD-1 antibody or anti-PD-L1 antibody is about 5 weeks. In certain embodiments, the cycle of each anti-PD-1 antibody or anti-PD-L1 antibody is about 6 weeks.
[0487] In certain embodiments, the cycle for each anti-PD-1 antibody or anti-PD-L1 antibody is two weeks. In certain embodiments, the cycle for each anti-PD-1 antibody or anti-PD-L1 antibody is three weeks. In certain embodiments, the cycle for each anti-PD-1 antibody or anti-PD-L1 antibody is four weeks. In certain embodiments, the cycle for each anti-PD-1 antibody or anti-PD-L1 antibody is five weeks. In certain embodiments, the cycle for each anti-PD-1 antibody or anti-PD-L1 antibody is six weeks.
[0488] In certain embodiments, each tusamitamab ravtansine cycle is 2 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 2 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 2 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 3 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 2 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 6 weeks.
[0489] In certain embodiments, each tusamitamab ravtansine cycle is 3 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 2 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 3 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 3 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 3 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 6 weeks.
[0490] In certain embodiments, each tusamitamab ravtansine cycle is 4 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 2 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 4 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 3 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 4 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 6 weeks.
[0491] In certain embodiments, each tusamitamab ravtansine cycle is 4 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 2 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 4 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 3 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 4 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 6 weeks.
[0492] In certain embodiments, each tusamitamab ravtansine cycle is 6 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 2 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 6 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 3 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 6 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 6 weeks.
[0493] In certain embodiments, tusamitamavutansine is administered at a dose of about 60 mg / m 2 ~about 190mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 60 mg / m 2 ~190mg / m 2 is administered intravenously to the subject at a dose of
[0494] In certain embodiments, tusamitamavutansine is administered at a dose of about 120 mg / m 2~about 170mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 120 mg / m 2 ~170mg / m 2 is administered intravenously to the subject at a dose of
[0495] In certain embodiments, tusamitamavutansine is administered at a dose of about 120 mg / m 2 is administered intravenously to the subject at a dose of
[0496] In certain embodiments, tusamitama ravtansine is administered at a dose of about 130 mg / m 2 is administered intravenously to the subject at a dose of
[0497] In certain embodiments, tusamitamavutansine is administered at a dose of about 140 mg / m 2 is administered intravenously to the subject at a dose of
[0498] In certain embodiments, tusamitamavutansine is administered at a dose of about 150 mg / m 2 is administered intravenously to the subject at a dose of
[0499] In certain embodiments, tusamitamavutansine is administered at a dose of about 160 mg / m 2 is administered intravenously to the subject at a dose of
[0500] In certain embodiments, tusamitamavutansine is administered at a dose of about 170 mg / m 2 is administered intravenously to the subject at a dose of
[0501] In certain embodiments, tusamitamavutansine is administered at 120 mg / m 2 is administered intravenously to the subject at a dose of
[0502] In certain embodiments, tusamitamavutansine is administered at 130 mg / m 2 is administered intravenously to the subject at a dose of
[0503] In certain embodiments, tusamitamavutansine is administered at 140 mg / m 2is administered intravenously to the subject at a dose of
[0504] In certain embodiments, tusamitamavutansine is administered at a dose of 150 mg / m 2 is administered intravenously to the subject at a dose of
[0505] In certain embodiments, tusamitamavutansine is administered at 160 mg / m 2 is administered intravenously to the subject at a dose of
[0506] In certain embodiments, tusamitamavutansine is administered at a dose of 170 mg / m 2 is administered intravenously to the subject at a dose of
[0507] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamab ravtansine are administered about once every three weeks. In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamab ravtansine are administered about once every three weeks.
[0508] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamab ravtansine are administered about once every four weeks. In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamab ravtansine are administered about once every four weeks.
[0509] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamab ravtansine are administered about once every 5 weeks. In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamab ravtansine are administered about once every 5 weeks.
[0510] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamab ravtansine are administered about once every six weeks. In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamab ravtansine are administered about once every six weeks.
[0511] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered about once every three weeks, and the tusamitamaravtansine is administered about once every six weeks.
[0512] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered about once every three weeks, and the tusamitamaravtansine is administered about once every six weeks.
[0513] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered once every three weeks, and the tusamitamaravtansine is administered once every six weeks.
[0514] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered once every three weeks, and the tusamitamaravtansine is administered once every six weeks.
[0515] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered about once every six weeks, and the tusamitamaravtansine is administered about once every three weeks.
[0516] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered once every six weeks, and the tusamitamaravtansine is administered about once every three weeks.
[0517] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered about once every six weeks, and the tusamitamaravtansine is administered about once every three weeks.
[0518] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered once every six weeks, and the tusamitamaravtansine is administered once every three weeks.
[0519] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 200 mg and the tusamitamaravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0520] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 200 mg and the tusamitamaravtansine is administered at a dose of 120 mg / m 2 ~170mg / m 2 is administered intravenously to the subject at a dose of
[0521] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 400 mg and the tusamitamaravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0522] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 400 mg and the tusamitamaravtansine is administered at a dose of 120 mg / m 2 ~170mg / m 2 is administered intravenously to the subject at a dose of
[0523] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 200 mg and the tusamitamaravtansine is administered at a dose of 120 mg / m 2 is administered intravenously to the subject at a dose of
[0524] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 200 mg and the tusamitamaravtansine is administered at a dose of 130 mg / m 2 is administered intravenously to the subject at a dose of
[0525] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 200 mg and the tusamitamaravtansine is administered at a dose of 140 mg / m 2 is administered intravenously to the subject at a dose of
[0526] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 200 mg and the tusamitamaravtansine is administered at a dose of 150 mg / m 2is administered intravenously to the subject at a dose of
[0527] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 200 mg and the tusamitamaravtansine is administered at a dose of 160 mg / m 2 is administered intravenously to the subject at a dose of
[0528] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 200 mg and the tusamitamaravtansine is administered at a dose of 170 mg / m 2 is administered intravenously to the subject at a dose of
[0529] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 400 mg and the tusamitamaravtansine is administered at a dose of 120 mg / m 2 is administered intravenously to the subject at a dose of
[0530] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 400 mg and the tusamitamaravtansine is administered at a dose of 130 mg / m 2 is administered intravenously to the subject at a dose of
[0531] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 400 mg and the tusamitamaravtansine is administered at a dose of 140 mg / m 2 is administered intravenously to the subject at a dose of
[0532] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 400 mg and the tusamitamaravtansine is administered at a dose of 150 mg / m 2 is administered intravenously to the subject at a dose of
[0533] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 400 mg and the tusamitamaravtansine is administered at a dose of 160 mg / m 2 is administered intravenously to the subject at a dose of
[0534] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 400 mg and the tusamitamaravtansine is administered at a dose of 170 mg / m 2 is administered intravenously to the subject at a dose of
[0535] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered to the subject followed by tusamitamab ravtansine, i.e., the anti-PD-1 antibody or anti-PD-L1 antibody first, followed by tusamitamab ravtansine, and the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamab ravtansine are administered to the subject on day 1 of a given cycle.
[0536] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered to the subject followed by tusamitamab ravtansine, i.e., the anti-PD-1 antibody or anti-PD-L1 antibody first, followed by tusamitamab ravtansine, and the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamab ravtansine are administered to the subject on day 1 of each cycle.
[0537] In certain embodiments, tusamitamavutansine is administered at a dose of about 120 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 120 mg / m 2 is administered intravenously to the subject at a dose of
[0538] In certain embodiments, tusamitamavutansine is administered at a dose of about 150 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 150 mg / m 2 is administered intravenously to the subject at a dose of
[0539] In certain embodiments, tusamitamavutansine is administered at a dose of about 170 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 170 mg / m 2 is administered intravenously to the subject at a dose of
[0540] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered once every six weeks, and the tusamitamaravtansine is administered once every three weeks.
[0541] In a particular embodiment, the ADC is tusamitamaravtansine and the anti-PD-1 antibody is pembrolizumab.
[0542] One aspect of the disclosure is a method of treating cancer, comprising administering to a subject in need thereof effective amounts of (i) an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody and (ii) an anti-PD-1 antibody or an anti-PD-L1 antibody, thereby treating the cancer; the cancer expressed CEACAM5 with high intensity (immunohistochemical intensity ≥2+ in ≥50% of tumor cells); In this method, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered to the subject on one day once per cycle (each cycle is approximately 3 weeks).
[0543] One aspect of the disclosure is a method of treating cancer, comprising administering to a subject in need thereof effective amounts of (i) an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody and (ii) an anti-PD-1 antibody or an anti-PD-L1 antibody, thereby treating the cancer; the cancer expressed CEACAM5 with high intensity (immunohistochemical intensity ≥2+ in ≥50% of tumor cells); The ADC is tusamitamab ravtansine; In this method, an anti-PD-1 antibody or an anti-PD-L1 antibody and tusamitamaravtansine are administered to a subject on one day once per cycle (each cycle is approximately 3 weeks).
[0544] One aspect of the disclosure is a method of treating cancer, comprising administering to a subject in need thereof effective amounts of (i) an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody and (ii) an anti-PD-1 antibody or an anti-PD-L1 antibody, thereby treating the cancer; the cancer expressed CEACAM5 with high intensity (immunohistochemical intensity ≥2+ in ≥50% of tumor cells); The ADC is tusamitamab ravtansine; the anti-PD-1 antibody is pembrolizumab; In this method, pembrolizumab and tusamitamab ravtansine are administered to the subject on one day once per cycle (each cycle is approximately 3 weeks).
[0545] One aspect of the present disclosure is a method of treating cancer, comprising administering to a subject in need thereof an effective amount of (i) an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody and (ii) an anti-PD-1 antibody, thereby treating the cancer; the cancer expressed CEACAM5 with high intensity (immunohistochemical intensity ≥2+ in ≥50% of tumor cells); The ADC is tusamitamab ravtansine; the anti-PD-1 antibody is pembrolizumab; Pembrolizumab and tusamitamab ravtansine are administered to the subject on one day once per cycle (each cycle is approximately 3 weeks); Tsusami Tamara ravtansine is approximately 120 mg / m 2 ~about 170mg / m 2 and pembrolizumab is administered at a dose of approximately 200 mg / m 2 This is a method in which the compound is administered at a dose of
[0546] Triple combination therapy of anti-CEACAM5 ADC, anti-PD1 / PDL1 antibody and platinum-based chemotherapy: A further aspect of the present disclosure is a method of treating a CEACAM5-expressing cancer in a subject in need thereof, comprising administering a triple combination therapy comprising a combination of effective amounts of (i) an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody, (ii) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (iii) a platinum-based chemotherapy.
[0547] In certain embodiments, the platinum-based chemotherapy is selected from the group consisting of cisplatin and carboplatin.
[0548] In certain embodiments, the methods include administering cisplatin to the subject.
[0549] In certain embodiments, cisplatin is administered at 38 mg / m 2 ~75mg / m 2 is administered intravenously to the subject at a dose of
[0550] In certain embodiments, cisplatin is administered at about 75 mg / m 2 is administered intravenously to the subject at a dose of
[0551] In certain embodiments, cisplatin is administered at about 75 mg / m following administration of the ADC on Day 1 of each of Cycles 1-4. 2 is administered intravenously to the subject at a dose of
[0552] In certain embodiments, the methods include administering carboplatin to the subject.
[0553] In certain embodiments, carboplatin is administered intravenously to a subject after administration of an ADC on Day 1 of each of Cycles 1-4 at a dose of about (target AUC) x [(140-age) x (weight (kg)) / serum creatinine (mg / dL) x 72 (x 0.85 for women) + 25], where the target AUC is 5 mg*min / mL and the dose of carboplatin per administration does not exceed 750 mg.
[0554] In certain embodiments, carboplatin is administered intravenously to a subject at a dose of about (target AUC) x [(140 - age) x (weight (kg)) / serum creatinine (mg / dL) x 72 (x 0.85 for women) + 25], where the target AUC is between AUC 2.5 and AUC 5.
[0555] In certain embodiments, the target AUC is AUC 5.
[0556] In a particular embodiment, carboplatin is administered intravenously to a subject on Day 1 of each of Cycles 1-4 after administration of pemetrexed at a dose of (target AUC) x [(140-age) x (weight (kg)) / serum creatinine (mg / dL) x 72 (x 0.85 for women) + 25], where the target AUC is 5 mg*min / mL and the dose of carboplatin per administration does not exceed 750 mg.
[0557] In a specific embodiment of the triple combination therapy, the anti-CEACAM5 antibody comprises an HCDR1 having the amino acid sequence of SEQ ID NO: 1, an HCDR2 having the amino acid sequence of SEQ ID NO: 2, an HCDR3 having the amino acid sequence of SEQ ID NO: 3, an LCDR1 having the amino acid sequence of SEQ ID NO: 4, an LCDR2 having the amino acid sequence NTR, and an LCDR3 having the amino acid sequence of SEQ ID NO: 5.
[0558] In certain embodiments, the anti-CEACAM5 antibody comprises a heavy chain variable domain (VH) consisting of SEQ ID NO:6 and a light chain variable domain (VL) consisting of SEQ ID NO:7.
[0559] In a particular embodiment, the anti-CEACAM5 antibody is tusamitamab.
[0560] In certain embodiments, the ADC comprises at least one cytotoxic agent.
[0561] In certain embodiments, the cytotoxic agent is selected from the group consisting of a radioisotope, a protein toxin, a small molecule toxin, and any combination thereof.
[0562] In certain embodiments, the small molecule toxin is selected from the group consisting of antimetabolites, DNA alkylating agents, DNA cross-linking agents, DNA intercalating agents, anti-microtubule agents, topoisomerase inhibitors, and any combination thereof.
[0563] In certain embodiments, the anti-microtubule agent is selected from the group consisting of taxanes, vinca alkaloids, maytansinoids, colchicine, podophyllotoxin, griseofulvin, and any combination thereof.
[0564] In certain embodiments, the maytansinoid is selected from the group consisting of N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine (DM1), N2'-deacetyl-N-2'(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4), and any combination thereof.
[0565] In certain embodiments, the anti-CEACAM5 antibody is covalently attached to at least one cytotoxic agent via a cleavable or non-cleavable linker.
[0566] In certain embodiments, the linker is selected from the group consisting of N-succinimidyl pyridyldithiobutyrate (SPDB), 4-(pyridin-2-yldisulfanyl)-2-sulfo-butyric acid (sulfo-SPDB), and succinimidyl (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC).
[0567] In certain embodiments, the ADC is characterized by a drug-to-antibody ratio (DAR) in the range of 1-10.
[0568] In certain embodiments, the ADC is tusamitamaravtansine.
[0569] In certain embodiments, the cancer expresses CEACAM5 at moderate or high intensity as defined by immunohistochemistry.
[0570] In certain embodiments, the cancer expresses CEACAM5 with moderate intensity (immunohistochemical intensity ≧2+ in ≧1% to <50% of tumor cells).
[0571] In certain embodiments, the cancer expresses CEACAM5 with high intensity (immunohistochemical intensity ≧2+ in ≧50% of tumor cells).
[0572] In certain embodiments, the cancer is selected from the group consisting of colorectal cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, lung cancer, cervical cancer, pancreatic cancer, ovarian cancer, thyroid cancer, bladder cancer, endometrial cancer, breast cancer, liver cancer, biliary tract cancer (e.g., cholangiocarcinoma), prostate cancer, and skin cancer.
[0573] In certain embodiments, the cancer is gastric cancer, gastroesophageal junction cancer, or esophageal cancer.
[0574] In certain embodiments, the cancer is lung cancer.
[0575] In certain embodiments, the lung cancer is non-squamous non-small cell lung cancer (NSQ NSCLC).
[0576] In certain embodiments, the subject has advanced or metastatic NSQ NSCLC.
[0577] In some embodiments, the subject has stage 3A NSQ NSCLC, e.g., the primary tumor has spread to lymph nodes on the same side of the chest where it began. In some embodiments, the subject has stage 3B NSQ NSCLC, e.g., the primary tumor has spread to lymph nodes on the same or opposite side of the chest where it began, above the collarbone, or in the space between the lungs. In some embodiments, the subject has stage 3C NSQ NSCLC, e.g., a large primary tumor has grown and spread to lymph nodes on the opposite side of the chest where it began, above the collarbone, or in the space between the lungs, and has two or more tumors on the same side of the chest. In some embodiments, the subject has stage 4 NSQ NSCLC, e.g., metastases to one or more sites outside the chest. In some embodiments, the subject has widely metastatic NSQ NSCLC.
[0578] In certain embodiments, the subject has NSQ NSCLC without epidermal growth factor receptor (EGFR) sensitizing mutations or v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations or anaplastic lymphoma kinase / c-ros oncogene 1 (ALK / ROS) alterations.
[0579] In certain embodiments, the subject has not received prior systemic chemotherapy for the treatment of cancer, hi certain embodiments, the subject has not received prior systemic treatment with platinum, e.g., cisplatin or carboplatin.
[0580] In certain embodiments, the subject has not previously received immunotherapy for the treatment of cancer. Immunotherapy includes treatment with an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. In certain embodiments, the subject has not previously received treatment with an anti-PD-1 antibody or an anti-PD-L1 antibody. In certain embodiments, the subject has not previously received treatment with an anti-PD-L1 antibody.
[0581] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is an anti-PD-1 antibody.
[0582] In certain embodiments, the anti-PD-1 antibody is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, sintilimab, dostallimab, and tislelizumab.
[0583] In a particular embodiment, the anti-PD-1 antibody is pembrolizumab.
[0584] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is an anti-PD-L1 antibody.
[0585] In certain embodiments, the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, avelumab, and durvalumab.
[0586] In certain embodiments of the triple combination therapy, the anti-PD-1 antibody or anti-PD-L1 antibody is administered before the ADC. In certain embodiments, the ADC is administered before the anti-PD-1 antibody or anti-PD-L1 antibody. In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered before the ADC and platinum-based chemotherapy. In certain embodiments, there is a delay of at least about 30 minutes between the end of administration of the first agent and the start of administration of the second agent, provided that administration of both agents is completed within one day or 24 hours.
[0587] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered simultaneously; i.e., the anti-PD-1 antibody and the ADC are administered simultaneously, or the anti-PD-L1 antibody and the ADC are administered simultaneously. In certain embodiments, administration of both agents begins essentially simultaneously, e.g., within minutes of each other. In certain embodiments, administration of both agents ends essentially simultaneously, e.g., within minutes of each other. In certain embodiments, administration of both agents begins essentially simultaneously, e.g., within minutes of each other, and ends essentially simultaneously, e.g., within minutes of each other.
[0588] In certain embodiments, NSQ NSCLC expresses CEACAM5 with high intensity (immunohistochemical intensity ≧2+ in ≧50% of tumor cells).
[0589] Immunohistochemical analysis can be performed on a contemporaneous sample of the tumor obtained from the subject, or using a suitable historical sample of the tumor obtained from the subject.
[0590] In certain embodiments, the ADC is tusamitamaravtansine.
[0591] In a particular embodiment, the anti-PD-1 antibody is pembrolizumab.
[0592] In a particular embodiment, the ADC is tusamitamaravtansine and the anti-PD-1 antibody is pembrolizumab.
[0593] In certain embodiments of the triple combination therapy, each cycle is about 2-6 weeks. In certain embodiments, each cycle is about 2-6 weeks.
[0594] In certain embodiments, each cycle is about 2 weeks. In certain embodiments, each cycle is about 2 weeks.
[0595] In certain embodiments, each cycle is about 3 weeks. In certain embodiments, each cycle is about 3 weeks.
[0596] In certain embodiments, each cycle is about 6 weeks. In certain embodiments, each cycle is about 6 weeks.
[0597] In certain embodiments, each tusamitamab ravtansine cycle is selected from the group consisting of 2 weeks, 3 weeks, and 4 weeks.
[0598] In certain embodiments, the cycle of each anti-PD-1 antibody or anti-PD-L1 antibody is selected from the group consisting of 2 weeks, 3 weeks, and 6 weeks.
[0599] In certain embodiments, each tusamitamab ravtansine cycle is 2 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 2 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 2 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 3 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 2 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 6 weeks.
[0600] In certain embodiments, each tusamitamab ravtansine cycle is 3 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 2 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 3 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 3 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 3 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 6 weeks.
[0601] In certain embodiments, each tusamitamab ravtansine cycle is 6 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 2 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 6 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 3 weeks. In certain embodiments, each tusamitamab ravtansine cycle is 6 weeks and each anti-PD-1 antibody or anti-PD-L1 antibody cycle is 6 weeks.
[0602] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 200 mg to about 400 mg.In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 200 mg to 400 mg.
[0603] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of about 200 mg to about 400 mg. In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 200 mg to 400 mg. The intravenous administration can be an infusion or injection. Typically, the intravenous administration is an infusion.
[0604] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, or about 400 mg.
[0605] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg, or 400 mg.
[0606] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose selected from 200 mg, 350 mg, 360 mg, and 400 mg.
[0607] In certain embodiments, tusamitamavutansine is administered at a dose of about 60 mg / m 2 ~about 190mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 60 mg / m 2 ~190mg / m 2 is administered intravenously to the subject at a dose of
[0608] In certain embodiments, tusamitamavutansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 120 mg / m 2 ~170mg / m 2 is administered intravenously to the subject at a dose of
[0609] In certain embodiments, tusamitamavutansine is administered at a dose of about 120 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 120 mg / m 2 is administered intravenously to the subject at a dose of
[0610] In certain embodiments, tusamitama ravtansine is administered at a dose of about 130 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 130 mg / m 2 is administered intravenously to the subject at a dose of
[0611] In certain embodiments, tusamitamavutansine is administered at a dose of about 140 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 140 mg / m 2 is administered intravenously to the subject at a dose of
[0612] In certain embodiments, tusamitamavutansine is administered at a dose of about 150 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 150 mg / m 2 is administered intravenously to the subject at a dose of
[0613] In certain embodiments, tusamitamavutansine is administered at a dose of about 160 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 160 mg / m 2 is administered intravenously to the subject at a dose of
[0614] In certain embodiments, tusamitamavutansine is administered at a dose of about 170 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 170 mg / m 2 is administered intravenously to the subject at a dose of
[0615] In a specific embodiment, the anti-PD-1 antibody is administered intravenously to a subject at a dose of about 200 mg and the tusamitamaravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 In a particular embodiment, the anti-PD-1 antibody is administered intravenously to the subject at a dose of 200 mg and the tusamitama ravtansine is administered intravenously to the subject at a dose of 120 mg / m 2 ~170mg / m 2 is administered intravenously to the subject at a dose of
[0616] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of about 200 mg and tusamitamab ravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 200 mg and tusamitamab ravtansine is administered intravenously to a subject at a dose of 120 mg / m 2 ~170mg / m 2 is administered intravenously to the subject at a dose of
[0617] In certain embodiments, the anti-PD-1 antibody and tusamitamab ravtansine are administered about once every three weeks. In certain embodiments, the anti-PD-1 antibody and tusamitamab ravtansine are administered about once every three weeks.
[0618] In certain embodiments, pembrolizumab and tusamitamavutansine are administered about once every three weeks. In certain embodiments, pembrolizumab and tusamitamavutansine are administered about once every three weeks.
[0619] In certain embodiments, pembrolizumab is administered about once every three weeks and tusamitamab ravtansine is administered about once every six weeks. In certain embodiments, pembrolizumab is administered about once every three weeks and tusamitamab ravtansine is administered about once every six weeks. In certain embodiments, pembrolizumab is administered about once every three weeks and tusamitamab ravtansine is administered about once every six weeks. In certain embodiments, pembrolizumab is administered about once every three weeks and tusamitamab ravtansine is administered about once every six weeks.
[0620] In certain embodiments, pembrolizumab is administered about once every 6 weeks and tusamitamab ravtansine is administered about once every 3 weeks. In certain embodiments, pembrolizumab is administered about once every 6 weeks and tusamitamab ravtansine is administered about once every 3 weeks. In certain embodiments, pembrolizumab is administered about once every 6 weeks and tusamitamab ravtansine is administered about once every 3 weeks. In certain embodiments, pembrolizumab is administered about once every 6 weeks and tusamitamab ravtansine is administered about once every 3 weeks. In certain embodiments, pembrolizumab is administered about once every 6 weeks and tusamitamab ravtansine is administered about once every 3 weeks.
[0621] In certain embodiments, pembrolizumab and tusamitamavutansine are administered about once every six weeks. In certain embodiments, pembrolizumab and tusamitamavutansine are administered about once every six weeks.
[0622] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of about 400 mg and tusamitamab ravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0623] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 400 mg and tusamitamab ravtansine is administered at a dose of 120 mg / m 2 ~170mg / m 2 is administered intravenously to the subject at a dose of
[0624] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 400 mg and tusamitamab ravtansine is administered at a dose of 120 mg / m 2 In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 400 mg and tusamitamab ravtansine is administered intravenously to a subject at a dose of 130 mg / m 2 In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 400 mg and tusamitamab ravtansine is administered intravenously to a subject at a dose of 140 mg / m 2 In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 400 mg and tusamitamab ravtansine is administered intravenously to a subject at a dose of 150 mg / m 2 In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 400 mg and tusamitamab ravtansine is administered intravenously to a subject at a dose of 160 mg / m 2 In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 400 mg and tusamitamab ravtansine is administered intravenously to a subject at a dose of 170 mg / m 2 is administered intravenously to the subject at a dose of
[0625] In certain embodiments, pembrolizumab is administered to a subject followed by tusamitamaravudanine, i.e., pembrolizumab first, followed by tusamitamaravudanine, and pembrolizumab and tusamitamaravudanine are administered to the subject on day 1 of a given cycle.
[0626] In certain embodiments, pembrolizumab is administered to a subject followed by tusamitamaravudanine, i.e., pembrolizumab first, followed by tusamitamaravudanine, and pembrolizumab and tusamitamaravudanine are administered to the subject on day 1 of each cycle.
[0627] In certain embodiments, tusamitamavutansine is administered at a dose of about 120 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 120 mg / m 2 is administered intravenously to the subject at a dose of
[0628] In certain embodiments, tusamitamavutansine is administered at a dose of about 150 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 150 mg / m 2 is administered intravenously to the subject at a dose of
[0629] In certain embodiments, tusamitamavutansine is administered at a dose of about 170 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 170 mg / m 2 is administered intravenously to the subject at a dose of
[0630] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of about 200 mg and tusamitamab ravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0631] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 200 mg and tusamitamab ravtansine is administered at a dose of 120 mg / m 2 ~170mg / m 2 is administered intravenously to the subject at a dose of
[0632] Quadruple combination therapy of (i) anti-CEACAM5 ADC, (ii) anti-PD1 / PDL1 antibody, (iii) platinum-based chemotherapy, and (iv) pemetrexed: In yet another aspect, the disclosure provides a method of treating a CEACAM5-expressing cancer in a subject in need thereof, comprising administering an effective amount of a quadruple combination therapy comprising a combination of (i) an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody, (ii) an anti-PD-1 antibody or an anti-PD-L1 antibody, (iii) platinum-based chemotherapy, and (iv) pemetrexed.
[0633] In certain embodiments, pemetrexed is administered at 250 mg / m 2 ~500mg / m 2 It is administered intravenously at a dose of
[0634] In certain embodiments, pemetrexed is administered at a dose of about 250 mg / m 2 In certain embodiments, pemetrexed is administered intravenously at a dose of 250 mg / m 2 It is administered intravenously at a dose of
[0635] In certain embodiments, pemetrexed is administered at about 300 mg / m 2 In certain embodiments, pemetrexed is administered intravenously at a dose of 300 mg / m 2 It is administered intravenously at a dose of
[0636] In certain embodiments, pemetrexed is administered at about 350 mg / m 2 In certain embodiments, pemetrexed is administered intravenously at a dose of 350 mg / m 2 It is administered intravenously at a dose of
[0637] In certain embodiments, pemetrexed is administered at a dose of about 400 mg / m 2 In certain embodiments, pemetrexed is administered intravenously at a dose of 400 mg / m 2 It is administered intravenously at a dose of
[0638] In certain embodiments, pemetrexed is administered at a dose of about 450 mg / m 2 In certain embodiments, pemetrexed is administered intravenously at a dose of 450 mg / m 2 It is administered intravenously at a dose of
[0639] In certain embodiments, pemetrexed is administered at a dose of about 500 mg / m 2 In certain embodiments, pemetrexed is administered intravenously at a dose of 500 mg / m 2 It is administered intravenously at a dose of
[0640] In certain embodiments, pemetrexed is administered intravenously following vitamin supplementation.
[0641] In certain embodiments, pemetrexed is administered at about 500 mg / m following administration of the ADC on day 1 of a given cycle. 2 In certain embodiments, pemetrexed is administered intravenously to a subject at a dose of 500 mg / m following administration of the ADC on day 1 of a given cycle. 2 is administered intravenously to the subject at a dose of
[0642] In certain embodiments, pemetrexed is administered at about 500 mg / m following administration of the ADC on day 1 of each cycle. 2 In certain embodiments, pemetrexed is administered intravenously to a subject at a dose of 500 mg / m following administration of the ADC on day 1 of each cycle. 2 is administered intravenously to the subject at a dose of
[0643] In certain embodiments of the quadruple combination therapy, the anti-CEACAM5 antibody of the ADC comprises an HCDR1 having the amino acid sequence of SEQ ID NO: 1, an HCDR2 having the amino acid sequence of SEQ ID NO: 2, an HCDR3 having the amino acid sequence of SEQ ID NO: 3, an LCDR1 having the amino acid sequence of SEQ ID NO: 4, an LCDR2 having the amino acid sequence NTR, and an LCDR3 having the amino acid sequence of SEQ ID NO: 5.
[0644] In certain embodiments, the anti-CEACAM5 antibody comprises a heavy chain variable domain (VH) consisting of SEQ ID NO:6 and a light chain variable domain (VL) consisting of SEQ ID NO:7.
[0645] In a particular embodiment, the anti-CEACAM5 antibody is tusamitamab.
[0646] In certain embodiments, the ADC comprises at least one cytotoxic agent.
[0647] In certain embodiments, the cytotoxic agent is selected from the group consisting of a radioisotope, a protein toxin, a small molecule toxin, and any combination thereof.
[0648] In certain embodiments, the small molecule toxin is selected from the group consisting of antimetabolites, DNA alkylating agents, DNA cross-linking agents, DNA intercalating agents, anti-microtubule agents, topoisomerase inhibitors, and any combination thereof.
[0649] In certain embodiments, the anti-microtubule agent is selected from the group consisting of taxanes, vinca alkaloids, maytansinoids, colchicine, podophyllotoxin, griseofulvin, and any combination thereof.
[0650] In certain embodiments, the maytansinoid is selected from the group consisting of N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine (DM1), N2'-deacetyl-N-2'(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4), and any combination thereof.
[0651] In a particular embodiment, the toxin is N2'-deacetyl-N2'-(4-methyl-4-mercapto-1-oxopropyl)-maytansine (DM4).
[0652] In certain embodiments, the anti-CEACAM5 antibody is covalently attached to at least one cytotoxic agent via a cleavable or non-cleavable linker.
[0653] In certain embodiments, the linker is selected from the group consisting of N-succinimidyl pyridyldithiobutyrate (SPDB), 4-(pyridin-2-yldisulfanyl)-2-sulfo-butyric acid (sulfo-SPDB), and succinimidyl (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC).
[0654] In certain embodiments, the toxin is covalently attached to the anti-CEACAM5 antibody by an N-succinimidyl pyridyldithiobutyrate (SPDB) linker.
[0655] In a specific embodiment, the toxin is DM4, and the toxin is covalently attached to the anti-CEACAM5 antibody by an SPDB linker.
[0656] In certain embodiments, the ADC is characterized by a drug-to-antibody ratio (DAR) in the range of 1-10.
[0657] In certain embodiments, the ADC is tusamitamaravtansine.
[0658] In certain embodiments, the cancer expresses CEACAM5 at moderate or high intensity as defined by immunohistochemistry.
[0659] In certain embodiments, the cancer expresses CEACAM5 with moderate intensity (immunohistochemical intensity ≧2+ in ≧1% to <50% of tumor cells).
[0660] In certain embodiments, the cancer expresses CEACAM5 with high intensity (immunohistochemical intensity ≧2+ in ≧50% of tumor cells).
[0661] In certain embodiments, the cancer is selected from the group consisting of colorectal cancer, gastric cancer, gastroesophageal junction cancer, esophageal cancer, lung cancer, cervical cancer, pancreatic cancer, ovarian cancer, thyroid cancer, bladder cancer, endometrial cancer, breast cancer, liver cancer, biliary tract cancer (e.g., cholangiocarcinoma), prostate cancer, and skin cancer.
[0662] In certain embodiments, the cancer is gastric cancer, gastroesophageal junction cancer, or esophageal cancer.
[0663] In certain embodiments, the cancer is lung cancer.
[0664] In certain embodiments, the lung cancer is non-squamous non-small cell lung cancer (NSQ NSCLC).
[0665] In certain embodiments, the subject has advanced or metastatic NSQ NSCLC.
[0666] In certain embodiments, the subject has NSQ NSCLC without epidermal growth factor receptor (EGFR) sensitizing mutations or v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations or anaplastic lymphoma kinase / c-ros oncogene 1 (ALK / ROS) alterations.
[0667] In certain embodiments, the subject has not previously received systemic chemotherapy for the treatment of cancer. In certain embodiments, the subject has not previously received systemic chemotherapy for the treatment of NSQ NSCLC.
[0668] In certain embodiments, the subject has not received prior systemic treatment with platinum, eg, cisplatin or carboplatin.
[0669] In certain embodiments, the subject has not been previously systemically treated with pemetrexed.
[0670] In certain embodiments, the subject has not previously received immunotherapy for the treatment of cancer. Immunotherapy includes treatment with an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. In certain embodiments, the subject has not previously received treatment with an anti-PD-1 antibody. In certain embodiments, the subject has not previously received treatment with an anti-PD-L1 antibody.
[0671] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is an anti-PD-1 antibody.
[0672] In certain embodiments, the anti-PD-1 antibody is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, sintilimab, dostallimab, and tislelizumab.
[0673] In a particular embodiment, the anti-PD-1 antibody is pembrolizumab.
[0674] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is an anti-PD-L1 antibody.
[0675] In certain embodiments, the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, avelumab, and durvalumab.
[0676] In certain embodiments, the platinum-based chemotherapy is selected from the group consisting of cisplatin and carboplatin.
[0677] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered sequentially; i.e., the anti-PD-1 antibody and the ADC are administered sequentially, or the anti-PD-L1 antibody and the ADC are administered sequentially. In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered before the ADC. In certain embodiments, the ADC is administered before the anti-PD-1 antibody or anti-PD-L1 antibody. In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered before the ADC, platinum-based chemotherapy, and pemetrexed.
[0678] In certain embodiments, there is a delay of at least about 30 minutes between the end of administration of a first agent and the start of administration of a second agent, provided that administration of both agents is completed within a single day or 24 hour period.
[0679] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and the ADC are administered simultaneously; i.e., the anti-PD-1 antibody and the ADC are administered simultaneously, or the anti-PD-L1 antibody and the ADC are administered simultaneously. In certain embodiments, administration of both agents begins essentially simultaneously, e.g., within minutes of each other. In certain embodiments, administration of both agents ends essentially simultaneously, e.g., within minutes of each other. In certain embodiments, administration of both agents begins essentially simultaneously, e.g., within minutes of each other, and ends essentially simultaneously, e.g., within minutes of each other.
[0680] In certain embodiments, NSQ NSCLC expresses CEACAM5 with at least moderate intensity (immunohistochemical intensity ≧2+ in ≧1% to <50% of tumor cells).
[0681] In certain embodiments, NSQ NSCLC expresses CEACAM5 with high intensity (immunohistochemical intensity ≧2+ in ≧50% of tumor cells).
[0682] Immunohistochemical analysis can be performed on a contemporaneous sample of the tumor obtained from the subject, or using a suitable historical sample of the tumor obtained from the subject.
[0683] In certain embodiments, the subject has advanced or metastatic NSQ NSCLC. In some embodiments, the subject has stage 3A NSQ NSCLC, e.g., the primary tumor has spread to lymph nodes on the same side of the chest where it began. In some embodiments, the subject has stage 3B NSQ NSCLC, e.g., the primary tumor has spread to lymph nodes on the same or opposite side of the chest where it began, above the collarbone, or in the space between the lungs. In some embodiments, the subject has stage 3C NSQ NSCLC, e.g., a large primary tumor has grown and spread to lymph nodes on the opposite side of the chest where it began, above the collarbone, or in the space between the lungs, and has two or more tumors on the same side of the chest. In some embodiments, the subject has stage 4 NSQ NSCLC, e.g., metastases to one or more sites outside the chest. In some embodiments, the subject has widespread metastatic NSQ NSCLC.
[0684] In certain embodiments, the subject has NSQ NSCLC without epidermal growth factor receptor (EGFR) sensitizing mutations or v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations or anaplastic lymphoma kinase / c-ros oncogene 1 (ALK / ROS) alterations.
[0685] In certain embodiments, the subject has NSQ NSCLC without EGFR-sensitive mutations. In certain embodiments, the subject has NSQ NSCLC without BRAF mutations. In certain embodiments, the subject has NSQ NSCLC without anaplastic lymphoma kinase / c-ros oncogene 1 (ALK / ROS) alterations. In certain embodiments, the subject has NSQ NSCLC without any combination of EGFR-sensitive mutations, BRAF mutations, and ALK / ROS alterations.
[0686] In certain embodiments, the ADC is tusamitamaravtansine.
[0687] In a particular embodiment, the anti-PD-1 antibody is pembrolizumab.
[0688] In a particular embodiment, the ADC is tusamitamaravtansine and the anti-PD-1 antibody is pembrolizumab.
[0689] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody, the ADC, and the platinum-based chemotherapy are administered to the subject for at least four cycles.
[0690] In certain embodiments, each cycle is about 2-6 weeks. In certain embodiments, each cycle is about 2-6 weeks.
[0691] In certain embodiments, each cycle is about 2 weeks. In certain embodiments, each cycle is about 2 weeks.
[0692] In certain embodiments, each cycle is about 3 weeks. In certain embodiments, each cycle is about 3 weeks.
[0693] In certain embodiments, each cycle is about 6 weeks. In certain embodiments, each cycle is about 6 weeks.
[0694] In certain embodiments, each tusamitamab ravtansine cycle is selected from the group consisting of 2 weeks, 3 weeks, and 4 weeks.
[0695] In certain embodiments, each anti-PD-1 or anti-PD-L1 cycle is selected from the group consisting of 2 weeks, 3 weeks, and 6 weeks.
[0696] In certain embodiments, the ADC is tusamitamaravtansine.
[0697] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to the subject at a dose of about 200 mg to about 400 mg. In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to the subject at a dose of 200 mg to 400 mg. The intravenous administration can be by infusion or injection. Typically, the intravenous administration is by infusion.
[0698] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of about 200 mg to about 400 mg. In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 200 mg to 400 mg. The intravenous administration can be an infusion or injection. Typically, the intravenous administration is an infusion.
[0699] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, or about 400 mg.
[0700] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg, or 400 mg.
[0701] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose selected from 200 mg, 350 mg, 360 mg, and 400 mg.
[0702] In certain embodiments, tusamitamavutansine is administered at a dose of about 60 mg / m 2 ~about 190mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 60 mg / m 2 ~190mg / m 2 is administered intravenously to the subject at a dose of
[0703] In certain embodiments, tusamitamavutansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 120 mg / m 2 ~170mg / m 2 is administered intravenously to the subject at a dose of
[0704] In certain embodiments, tusamitamavutansine is administered at a dose of about 120 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 120 mg / m 2 is administered intravenously to the subject at a dose of
[0705] In certain embodiments, tusamitama ravtansine is administered at a dose of about 130 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 130 mg / m 2 is administered intravenously to the subject at a dose of
[0706] In certain embodiments, tusamitamavutansine is administered at a dose of about 140 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 140 mg / m 2 is administered intravenously to the subject at a dose of
[0707] In certain embodiments, tusamitamavutansine is administered at a dose of about 150 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 150 mg / m 2 is administered intravenously to the subject at a dose of
[0708] In certain embodiments, tusamitamavutansine is administered at a dose of about 160 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 160 mg / m 2 is administered intravenously to the subject at a dose of
[0709] In certain embodiments, tusamitamavutansine is administered at a dose of about 170 mg / m 2In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 170 mg / m 2 is administered intravenously to the subject at a dose of
[0710] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 200 mg and the tusamitamaravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to the subject at a dose of 200 mg and the tusamitamaravtansine is administered intravenously to the subject at a dose of 120 mg / m 2 ~170mg / m 2 is administered intravenously to the subject at a dose of
[0711] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of about 200 mg and tusamitamab ravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0712] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 200 mg and tusamitamab ravtansine is administered at a dose of 120 mg / m 2 ~170mg / m 2 is administered intravenously to the subject at a dose of
[0713] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamab ravtansine are administered about once every three weeks. In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamab ravtansine are administered about once every three weeks.
[0714] In certain embodiments, pembrolizumab and tusamitamavutansine are administered about once every three weeks. In certain embodiments, pembrolizumab and tusamitamavutansine are administered about once every three weeks.
[0715] In certain embodiments, pembrolizumab is administered about once every three weeks and tusamitamab ravtansine is administered about once every six weeks. In certain embodiments, pembrolizumab is administered about once every three weeks and tusamitamab ravtansine is administered about once every six weeks. In certain embodiments, pembrolizumab is administered about once every three weeks and tusamitamab ravtansine is administered about once every six weeks. In certain embodiments, pembrolizumab is administered about once every three weeks and tusamitamab ravtansine is administered about once every six weeks.
[0716] In certain embodiments, pembrolizumab is administered about once every 6 weeks and tusamitamab ravtansine is administered about once every 3 weeks. In certain embodiments, pembrolizumab is administered about once every 6 weeks and tusamitamab ravtansine is administered about once every 3 weeks. In certain embodiments, pembrolizumab is administered about once every 6 weeks and tusamitamab ravtansine is administered about once every 3 weeks. In certain embodiments, pembrolizumab is administered about once every 6 weeks and tusamitamab ravtansine is administered about once every 3 weeks. In certain embodiments, pembrolizumab is administered about once every 6 weeks and tusamitamab ravtansine is administered about once every 3 weeks.
[0717] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of about 400 mg and the tusamitamaravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0718] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered intravenously to a subject at a dose of 400 mg and the tusamitamaravtansine is administered at a dose of 120 mg / m 2 ~170mg / m 2 is administered intravenously to the subject at a dose of
[0719] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of about 400 mg and tusamitamab ravtansine is administered at a dose of about 120 mg / m 2 ~about 170mg / m 2 is administered intravenously to the subject at a dose of
[0720] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 400 mg and tusamitamab ravtansine is administered at a dose of 120 mg / m 2 ~170mg / m 2 is administered intravenously to the subject at a dose of
[0721] In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 400 mg and tusamitamab ravtansine is administered at a dose of 120 mg / m 2 In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 400 mg and tusamitamab ravtansine is administered intravenously to a subject at a dose of 130 mg / m 2 In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 400 mg and tusamitamab ravtansine is administered intravenously to a subject at a dose of 140 mg / m 2 In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 400 mg and tusamitamab ravtansine is administered intravenously to a subject at a dose of 150 mg / m 2 In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 400 mg and tusamitamab ravtansine is administered intravenously to a subject at a dose of 160 mg / m 2 In certain embodiments, pembrolizumab is administered intravenously to a subject at a dose of 400 mg and tusamitamab ravtansine is administered intravenously to a subject at a dose of 170 mg / m 2 is administered intravenously to the subject at a dose of
[0722] In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamab ravtansine are administered about once every six weeks. In certain embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody and tusamitamab ravtansine are administered about once every six weeks.
[0723] In certain embodiments, pembrolizumab and tusamitamavutansine are administered about once every six weeks. In certain embodiments, pembrolizumab and tusamitamavutansine are administered about once every six weeks.
[0724] In a specific embodiment, the anti-PD-1 antibody or anti-PD-L1 antibody is administered once every six weeks, and the tusamitamaravtansine is administered once every three weeks.
[0725] In certain embodiments, pembrolizumab is administered to a subject followed by tusamitamaravudanine, i.e., pembrolizumab first, followed by tusamitamaravudanine, and pembrolizumab and tusamitamaravudanine are administered to the subject on day 1 of a given cycle.
[0726] In certain embodiments, pembrolizumab is administered to a subject followed by tusamitamaravudanine, i.e., pembrolizumab first, followed by tusamitamaravudanine, and pembrolizumab and tusamitamaravudanine are administered to the subject on day 1 of each cycle.
[0727] In certain embodiments, tusamitamavutansine is administered at a dose of about 120 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 120 mg / m 2 is administered intravenously to the subject at a dose of
[0728] In certain embodiments, tusamitamavutansine is administered at a dose of about 150 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 150 mg / m 2 is administered intravenously to the subject at a dose of
[0729] In certain embodiments, tusamitamavutansine is administered at a dose of about 170 mg / m 2 In certain embodiments, tusamitama ravtansine is administered intravenously to a subject at a dose of 170 mg / m 2 is administered intravenously to the subject at a dose of
[0730] In certain embodiments, the methods include administering cisplatin to the subject.
[0731] In certain embodiments, cisplatin is administered at 38 mg / m 2 ~75mg / m 2 is administered intravenously to the subject at a dose of
[0732] In certain embodiments, cisplatin is administered at about 75 mg / m following administration of pemetrexed on Day 1 of each of Cycles 1-4. 2 In certain embodiments, cisplatin is administered intravenously to the subject at a dose of 75 mg / m following administration of pemetrexed on Day 1 of each of Cycles 1-4. 2 is administered intravenously to the subject at a dose of
[0733] In certain embodiments, the methods include administering carboplatin to the subject.
[0734] In certain embodiments, carboplatin is administered intravenously to a subject at a dose of about (target AUC) x [(140 - age) x (weight (kg)) / serum creatinine (mg / dL) x 72 (x 0.85 for women) + 25], where the target AUC is between AUC 2.5 and AUC 5.
[0735] In certain embodiments, the target AUC is AUC 5.
[0736] In certain embodiments, carboplatin is administered intravenously to a subject on Day 1 of each of Cycles 1-4 after administration of pemetrexed at a dose of about (target AUC)×[(140−age)×(weight (kg)) / serum creatinine (mg / dL)×72 (×0.85 for women)+25], where the target AUC is 5 mg*min / mL and the dose of carboplatin per administration does not exceed 750 mg.
[0737] In a particular embodiment, carboplatin is administered intravenously to a subject on Day 1 of each of Cycles 1-4 after administration of pemetrexed at a dose of (target AUC) x [(140-age) x (weight (kg)) / serum creatinine (mg / dL) x 72 (x 0.85 for women) + 25], where the target AUC is 5 mg*min / mL and the dose of carboplatin per administration does not exceed 750 mg.
[0738] In a particular embodiment, the ADC is tusamitamab and the anti-PD-1 antibody is pembrolizumab. EXAMPLES
[0739] Example 1. A Phase 2, Open-Label, Multicenter Study of Combination Treatment in Patients with CEACAM5-Positively Expressing Advanced / Metastatic NSQ NSCLC The efficacy, safety, and pharmacokinetics (PK) of tusamitamaravtansine, an ADC consisting of anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) conjugated to the cytotoxic agent DM4, will be evaluated in human subjects with CEACAM5-positive advanced / metastatic non-squamous non-small cell lung cancer.
[0740] In a previous Phase 1 study (NCT02187848), 92 NSQ NSCLC patients treated with tusamitama ravtansine demonstrated antitumor activity in 64 heavily pretreated patients with NSQ NSCLC with ≥50% tumor CEACAM5 expression. This antitumor activity was associated with an overall response rate of 20.3% (95% CI: 12.27% to 31.71%) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, justifying further development of tusamitama ravtansine to treat this patient population. In 28 heavily pretreated patients with NSQ NSCLC with ≥1% and <50% tumor CEACAM5 expression, the overall response rate was 7.1% according to RECIST 1.1 (95% CI: 1.98% to 22.65%).
[0741] Pembrolizumab is the first approved and most used immune checkpoint inhibitor (ICI) in first-line NSCLC in combination with standard of care (SOC) and as monotherapy (see, e.g., Gandhi, L., et al., N. Engl. J. Med. 2018, 378(22):2078-926; and Tony, SKM, et al., Lancet 2019, 393(10183):1819-30, which are incorporated by reference in their entirety). The combination of an ICI with tusamitamab ravtansine should result in improved prognosis compared to the combination with non-targeted, toxic systemic chemotherapy.
[0742] the purpose Main purpose The primary objective of this study is to evaluate the tolerability and determine the recommended dose of tusamitamab ravtansine in combination with pembrolizumab and tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy with or without pemetrexed in the NSQ NSCLC population.Evaluation measures consist of the incidence of drug-related dose-limiting toxicities (DLTs) in cycle 1 (C1D1-C1D21), including but not limited to corneal toxicity.
[0743] Secondary Objectives Secondary objectives of this study are to: (i) To evaluate the safety and tolerability of tusamitamazavvtansine in combination with pembrolizumab (T2), and tusamitamazavvvtansine in combination with pembrolizumab and platinum-based chemotherapy (T3) with or without pemetrexed (T4).Evaluation outcomes consisted of the incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and laboratory abnormalities according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V5.0. (ii) To evaluate the antitumor activity of tusamitamab ravtansine in combination with pembrolizumab, and tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy, both with and without pemetrexed, in the NSQ NSCLC population. Endpoints consist of response rate, defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) according to RECIST 1.1. (iii) To evaluate the pharmacokinetics (PK) of tusamitamab lavtansine, pembrolizumab, pemetrexed, cisplatin, and carboplatin when given in double (tusamitamab lavtansine + pembrolizumab-T2), triple (tusamitamab lavtansine + pembrolizumab + platinum-based chemotherapy-T3), or quadruple (tusamitamab lavtansine + pembrolizumab + platinum-based chemotherapy + pemetrexed-T4) combinations, respectively. Endpoints consist of pharmacokinetic concentrations of tusamitamab lavtansine, pembrolizumab, pemetrexed, cisplatin, and carboplatin. (iv) To evaluate the immunogenicity of tusamitamab in combination with pembrolizumab, and tusamitamab in combination with pembrolizumab and platinum-based chemotherapy, both with and without pemetrexed. The outcome measures consisted of the incidence of anti-therapeutic antibody (ATA) against tusamitamab.
[0744] Test Design The study is a three-part, phase 2, open-label, multicenter study: Part A is to evaluate the safety, efficacy (antitumor activity), and PK of tusamitamab ravtansine (T2) in combination with pembrolizumab in NSQ NSCLC participants with CEACAM5-high expressing tumors (defined as CEACAM5 immunohistochemistry [IHC] intensity ≥ 2+ in ≥ 50% of tumor cells). The intensity of CEACAM5 staining is scored on a scale of 0 to 3, with 0 being negative, 1+ being weakly positive, 2+ being moderately positive, and 3+ being strongly positive. A general description of the IHC process, including scoring, is given by So-Woon Kim et al., J Pathol Transl Med, 2016, 50(6):411-418, doi:10.4132 / jptm.2016.08.08, which is hereby incorporated by reference in its entirety. Part B is to evaluate the safety, efficacy (antitumor activity), and PK of tusamitamab ravtansine (T3) in combination with pembrolizumab and platinum-based chemotherapy in NSQ NSCLC participants with CEACAM5-high expressing tumors; Part C is to evaluate the safety, efficacy (antitumor activity), and PK of tusamitamab ravtansine (T4) in combination with pembrolizumab, platinum-based chemotherapy, and pemetrexed in NSQ NSCLC participants with CEACAM5 high or intermediate expression (defined as intensity ≥2+ in ≥1% and <50% of tumor cells).
[0745] During the pre-screening phase, patient tumor samples are collected to assess CEACAM5 status (central evaluation by IHC). Central evaluation by immunohistochemistry (IHC) is based on the evaluation of the intensity of staining for CEACAM5 to assess antigen expression.
[0746] During the Screening Phase, only participants with NSQ NSCLC whose tumors are determined to have high CEACAM5 expression (≥ 50%) will undergo protocol screening procedures and be enrolled in Part A, Part B, or Part C, according to the investigator's choice. Participants with intermediate CEACAM5 expression (≥ 1% and < 50%) tumors will undergo protocol screening procedures and be enrolled in Part C.
[0747] Part A The tolerability of the combination of tusamitamab ravtansine and pembrolizumab (T2) will be evaluated.
[0748] The first three participants received pembrolizumab infusions of 200 mg once every three weeks (Q3W), followed by 150 mg / m 2 receive a tusamitamavera ravtansine infusion at a starting dose of
[0749] The DLT observation period is the first cycle (21 days). Depending on the observed DLT, up to three dose levels (DL) of tusamitamab ravtansine will be tested: 150 mg / m 2 , 170 mg / m 2 , and 120 mg / m 2 .
[0750] For each DL in the combination arm (starting dose, DL plus one [DL+1], if applicable, and DL minus one [DL-1]), a minimum of 1 week is mandatory between the first dose of the first participant treated with this DL and the first dose of the next participant treated with the same DL. Once three participants are treated with this DL and are DLT-evaluable, the tolerability of the combination will be evaluated according to the algorithm shown in Figure 1.
[0751] Part B The tolerability and safety of the combination of pembrolizumab, tusamitamab ravtansine, and platinum-based chemotherapy (T3) will be evaluated. Participants may be assigned to either cisplatin or carboplatin according to the investigator's choice.
[0752] Cisplatin combination arm: Participants received Q3W pembrolizumab 200 mg + tusamitamab ravtansine (150 mg / m 2 , 170 mg / m 2 , or 120 mg / m 2 ) + Cisplatin 75mg / m 2 followed by Q3W pembrolizumab 200 mg + tusamitamab ravtansine (150 mg / m 2 , 170 mg / m 2 , or 120 mg / m 2 ) is accepted.
[0753] Carboplatin combination arm: Participants received Q3W pembrolizumab 200 mg + tusamitamab ravtansine (150 mg / m 2 , 170 mg / m 2 , or 120 mg / m 2 ) + carboplatin AUC 5, followed by Q3W pembrolizumab 200mg + tusamitamab ravtansine (150mg / m 2 , 170 mg / m 2 , or 120 mg / m 2 Accepts Q3W).
[0754] The DLT observation period is the first cycle (21 days). Depending on the DLT observed, up to three dose levels (DL) of tusamitama ravtansine may be tested during this safety confirmation part: 150 mg / m 2 , 170 mg / m 2 , and 120 mg / m 2 .
[0755] For each DL in the cisplatin and carboplatin combination arms, a minimum of 1 week is mandatory between the first dose of the first participant treated with this DL and the first dose of the next participant treated with the same DL. Once three participants assigned to a combination arm have been treated with a DL and become DLT-evaluable, the tolerability of this combination will be evaluated according to the decision algorithm as shown in Figure 1. The tolerability of each triple combination will be evaluated in at least six participants.
[0756] Approximately 12 to 36 treated participants (6 to 18 in each arm) in the cisplatin and carboplatin combination arms in Part B are expected to be evaluable for tolerability and safety.
[0757] Part C The tolerability and safety of the combination of tusamitamab lavtansine, pembrolizumab, platinum-based chemotherapy and pemetrexed (T4) will be evaluated. Participants may be assigned to either cisplatin or carboplatin according to the investigator's choice.
[0758] Cisplatin combination arm: Participants received Q3W pembrolizumab 200 mg + tusamitamab ravtansine (150 mg / m 2 , 170 mg / m 2 , or 120 mg / m 2 ) + pemetrexed 500mg / m 2 (with vitamin supplementation) + cisplatin 75mg / m 2 followed by Q3W pembrolizumab 200 mg + tusamitamab ravtansine (150 mg / m 2 , 170 mg / m 2 , or 120 mg / m 2 ) + pemetrexed 500mg / m 2 Acceptance (with vitamin supplementation).
[0759] Carboplatin combination arm: Participants received Q3W pembrolizumab 200 mg + tusamitamab ravtansine (150 mg / m 2 , 170 mg / m 2 , or 120 mg / m 2 ) + pembrolizumab 500mg / m 2 (with vitamin supplementation) + carboplatin AUC 5, followed by Q3W pembrolizumab 200mg + tusamitamab ravtansine (150mg / m 2 , 170 mg / m 2 , or 120 mg / m 2 Q3W) + pemetrexed 500mg / m 2 Acceptance (with vitamin supplementation).
[0760] The DLT observation period is the first cycle (21 days). Depending on the DLT observed, up to three dose levels (DL) of tusamitama ravtansine may be tested during this safety confirmation part: 150 mg / m 2 , 170 mg / m 2 , and 120 mg / m 2 .
[0761] For each DL in the cisplatin and carboplatin combination arm, a minimum of 1 week is mandatory between the first dose of the first participant treated with this DL and the first dose of the next participant treated with the same DL. Once three participants assigned to the combination arm have been treated with a DL and are DLT-evaluable, the tolerability of this combination will be evaluated according to the decision algorithm shown in Figure 1. The tolerability of each quadruple combination will be evaluated in at least six participants.
[0762] Approximately 12 to 36 treated participants (6 to 18 in each arm) in the cisplatin and carboplatin combination arms in Part C are expected to be evaluable for tolerability and safety.
[0763] patient Inclusion criteria Participants were eligible for inclusion in the study if they met the following criteria: Histologically or cytologically confirmed diagnosis of advanced or metastatic NSQ NSCLC without epidermal growth factor receptor (EGFR) sensitizing mutations or v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations or anaplastic lymphoma kinase (ALK) / c-ros oncogene (ROS) alterations. Participants had not received previous systemic chemotherapy for the treatment of progressive or metastatic disease (treatment involving chemotherapy and / or radiotherapy as part of neoadjuvant / adjuvant therapy is acceptable if completed at least 6 months prior to the diagnosis of progressive or metastatic disease). Expression of CEACAM5 as prospectively demonstrated by centrally reviewed IHC assay of ≥ 2+ intensity involving at least 50% (for Parts A and B) and at least 1% (for Part C) of the tumor cell population in archival tumor samples (or, if not available, a fresh biopsy sample will be taken if deemed an acceptable risk by the treating physician). At least 5 slides of formalin-fixed paraffin-embedded (FFPE) tumor tissue sectioned at 4 μm thickness are required. Even if less material is available, patients may be considered eligible after discussion with the sponsor, who may assess and confirm that the available material is sufficient for pivotal evaluation.
[0764] Measurable disease per RECIST 1.1. Exclusion criteria Participants will be excluded from the study if any of the following criteria apply:
[0765] 1. Medical Conditions Medical conditions requiring the concomitant administration of drugs that are metabolized by cytochrome P450 (CYP450) and have a narrow therapeutic window where dose reduction is not considered. Medical conditions requiring concomitant use of strong cytochrome P450 family 3 subfamily A (CYP3A) inhibitors, unless such use can be discontinued beginning at least 2 weeks prior to the first dose of the study intervention and continuing for the entire duration of study treatment. History of uncontrolled brain metastases and leptomeningeal disease. Significant concurrent illness, including any serious medical condition that, in the opinion of the investigator or sponsor, would interfere with the patient's participation in the study or interpretation of the results. History of invasive malignancies other than those being treated on this study within the past 3 years, with the exception of excised / amputated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix, or other localized tumors considered cured by local treatment. Known acquired immune deficiency syndrome (AIDS) related disease or known HIV disease requiring antiretroviral treatment, or a personal history of active hepatitis A, hepatitis B (defined as either a positive hepatitis B surface antigen (HBsAg) or a positive hepatitis B virus DNA test above the lower limit of detection of the assay), or hepatitis C (defined as a known positive hepatitis C antibody result and a known quantitative hepatitis C virus (HCV) RNA result above the lower limit of detection of the assay). HIV serology will be tested at screening only for participants enrolled at German facilities or in countries where it is mandatory according to local requirements. History of active autoimmune disease requiring systemic treatment within the past 2 years. History of allogeneic tissue / solid organ transplant. Active infection requiring IV systemic therapy within 2 weeks prior to the first study intervention dose or active tuberculosis. History of interstitial lung disease or pneumonitis requiring oral or IV steroids. Non-recovery of any prior treatment-related toxicity to < Grade 2 per NCI CTCAE V5.0, except for alopecia, vitiligo, or active thyroiditis controlled with hormone replacement therapy. Unresolved corneal damage or any previous corneal damage considered by an ophthalmologist to predict a higher risk of drug-induced keratopathy. The use of contact lenses is not permitted. Patients who wear contact lenses and are not willing to discontinue wearing them during the study intervention will be excluded. Symptomatic herpes zoster within 3 months prior to screening. Severe allergy to humanized monoclonal antibodies. Clinically significant multiple or severe drug allergy, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, severe erythema multiforme, linear immunoglobulin A [IgA] dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
[0766] 2. Previous / concomitant therapy Concurrent treatment with any other anti-cancer therapy. Have received previous chemotherapy treatment for advanced / metastatic NSCLC. Patients are candidates for curative treatment by either surgical resection and / or chemoradiotherapy. For any investigational drug treatment, a washout period prior to the first dose of the study intervention that is less than 3 weeks or less than 5 half-lives, whichever is shorter. Any prior therapy targeting CEACAM5. Any prior treatment with any other anti-programmed cell death protein 1 (PD-1), or programmed death-ligand 1 (PD-L1) or programmed death-ligand 2 (PD-L2), anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibodies (including ipilimumab or any other antibody or drug that specifically targets T cell costimulatory or checkpoint pathways). Any prior maytansinoid treatment (maytansinoid emtansine (DM1) or ravtansine (DM4) ADC). Receiving systemic steroid therapy or any other form of immunosuppressive medication ≦3 days prior to the first dose of study therapy. Daily steroid replacement therapy or optional corticosteroid premedication, if applicable, is permitted. Any radiotherapy to the lungs >30 Gy within 6 months of the first study intervention administration. Have received or are scheduled to receive a live vaccine within 30 days prior to the first study intervention dose. Any major surgery within 3 weeks immediately preceding the first administration of study intervention. Current participation in any other clinical trials, including investigational treatments or any other type of medical research. Decreased organ function as defined by any one of the following: Serum creatinine >1.5 × upper limit of normal (ULN) or estimated glomerular filtration rate (eGFR) <60 mL / min / 1.73 m as estimated using the Modification of Diet in Renal Disease (MDRD) method 2 1.0 to 1.5 × ULN with Total bilirubin >1.0 × ULN. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 2.5 x ULN or AST, ALT > 1.5 x ULN in combination with ALP > 2.5 x ULN. For patients with bone metastases, ALP > 5 x ULN, with normal ALT / AST. <1.5×10 9 / L neutrophils or <100 × 10 9 / L platelet count or <9g / dL hemoglobulin (no transfusions within 2 weeks prior to screening) Thyroid Stimulating Hormone (TSH) outside the normal range. If TSH is not within the normal range at baseline, the subject may still be eligible if T3 and free T4 are within the normal range. An international normalized ratio (INR) of >1.5, unless the participant is on anticoagulant therapy or is within the therapeutic range if on anticoagulant therapy that affects the INR
[0767] Number of targets In Part A, approximately 38–150 participants will be prescreened (prescreen failure is estimated to be approximately 80%, resulting in a study screen failure rate of approximately 20%) to reach 6–24 DLT-evaluable participants (including 12 participants treated at a DL other than the RP2D, plus 12 DLT-evaluable participants at the recommended Phase 2 dose (RP2D)).
[0768] In Part B, approximately 75–225 participants will be prescreened (prescreening failure is estimated to be approximately 80%, resulting in a study screening failure rate of approximately 20%) to reach 12–36 DLT-evaluable participants (6–18 DLT-evaluable participants in each triple combination arm).
[0769] In Part C, approximately 28–82 participants will be prescreened (prescreening failure is estimated to be 45%, resulting in a study screening failure rate of 20%) to reach 12–36 DLT-evaluable participants (6–18 DLT-evaluable participants in each quadruple combination arm).
[0770] "Enrolled" means that the participant or his / her legally permitted representative agrees to participate in the clinical trial after completing the informed consent process. Potential participants who are screened for purposes of determining eligibility for the trial but do not participate in the trial are not considered enrolled unless otherwise specified by the clinical trial protocol.
[0771] Clinical and laboratory follow-up statistical analysis Efficacy analyses (overall response rate (ORR) according to RECIST 1.1) will be performed for each combination arm, for all treated populations by dose level and overall. Response rates will be derived using local radiologist / investigator assessment.
[0772] The study cutoff for the primary safety endpoint analysis (DLT) is at the end of the first cycle of the last participant treated to determine the RP2D in Part A, Part B, or Part C. The study cutoff for the ORR (secondary efficacy endpoint analysis) corresponds to the date when all treated participants have had at least two post-baseline tumor assessments, experienced a confirmed objective response, or discontinued the study for any reason. This study cutoff occurs approximately 4.5 months after the last participant's first investigational drug (IMP) administration date: 3 months for two tumor assessments and 1.5 months if confirmation of response is required. All analyses will be updated at that time.
[0773] All safety analyses will be performed for all treatment populations, by treatment arm, DL (as appropriate), and overall. For each safety parameter, the baseline value will be defined as the most recent value or measurement obtained up until the first dose of IMP.
[0774] Pharmacokinetics (PK) Blood samples will be collected for measurement of tusamitamab, pembrolizumab, cisplatin or carboplatin, and pemetrexed concentrations. The actual date and time of each sample will be recorded.
[0775] The concentrations of tusamitamab ravtansine, pemetrexed and cisplatin or carboplatin are used for population PK analysis by nonlinear mixed-effects modeling. max ), trough concentration (C trough Empirical Bayes estimates of individual exposure parameters such as the mean mean sigma-dominis ratio (MGR) and area under the curve (AUC) are derived.
[0776] Pembrolizumab C for Parts A, B, and C trough The value is reported.
[0777] Efficacy evaluation 1. Tumor measurability at baseline At baseline, tumor lesions / lymph nodes are classified as measurable or nonmeasurable as follows:
[0778] Measurable lesions must be accurately measured in at least one dimension (the longest diameter of the measurement surface to be recorded) with the following minimum sizes: 10 mm by CT scan (CT scan slice thickness not to exceed 5 mm). Clinical examination with 10 mm caliper measurement (lesions that cannot be accurately measured with a caliper should be recorded as non-measurable). Chest x-ray showed 20mm.
[0779] Malignant lymph nodes: To be considered pathologically enlarged and measurable, lymph nodes must be ≥15 mm in the short axis when assessed by computed tomography scan (CT scan) (CT scan slice thickness of ≤5 mm is recommended). Only the short axis will be measured and tracked at baseline and follow-up.
[0780] Non-measurable lesions are all other lesions including small lesions (pathologic lymph nodes with a longest diameter of <10 mm or a short axis of ≥10 to <15 mm) as well as true non-measurable lesions. Lesions considered non-measurable include leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, cutaneous or pulmonary lymphatic complications, abdominal masses / organomegaly identified by physical exam that are not measurable by reproducible imaging techniques.
[0781] Special considerations regarding lesion measurability are given below. (1) Bone lesions: Bone scans, positron emission tomography scans, or plain films are not considered sufficient imaging techniques to measure bone lesions, however, these techniques may be used to confirm the presence or absence of bone lesions. Lytic bone lesions or mixed lytic-blastic lesions with a discernible soft tissue component that can be assessed by cross-sectional imaging techniques such as CT scan or magnetic resonance imaging scan (MRI scan) can be considered measurable lesions if the soft tissue component meets the definition of measurability above. Blastoblastic bone lesions are not measurable. (2) Cystic lesions: Lesions that meet the criteria for radiographically defined simple cysts should not be considered malignant lesions (neither measurable nor nonmeasurable) because they are by definition simple cysts. "Cystic lesions" believed to represent cystic metastases may be considered measurable lesions if they meet the definition of measurability above. However, when noncystic lesions are present in the same patient, these are preferred for selection as target lesions. (3) Lesions from previous local treatment: Tumor lesions located in areas that have previously been irradiated or have received other locoregional therapy are usually not considered measurable unless the lesion has progressed.
[0782] 2. Evaluation Method Measurements, when clinically assessed, will be recorded in metric notation using calipers. Baseline assessments will be performed as close as possible to the start of treatment, but no earlier than 4 weeks prior to the start of treatment.
[0783] The same assessment methods and the same techniques will be used to characterize each lesion identified and reported at baseline and during follow-up. Assessments will be based on imaging rather than clinical examination, except when the lesion being followed is not imageable but can be assessed by clinical examination.
[0784] Clinical Lesions: Clinical lesions are considered measurable only if they are superficial and of a diameter of ≧10 mm when assessed using calipers.
[0785] Chest X-ray: Chest CT is preferred over chest x-ray, especially when progression is the key endpoint, because CT is more sensitive than x-ray, especially in identifying new lesions. However, chest radiographic lesions may be considered measurable if they are well defined and surrounded by aerated lung.
[0786] CT, MRI: CT is the best currently available and reproducible method for measuring lesions selected for response assessment. Measurability of lesions on CT scan is based on the assumption that the CT slice thickness is 5 mm or less. If the CT scan slice thickness is greater than 5 mm, the minimum size of a measurable lesion is twice the slice thickness.
[0787] Tumor markers: Tumor markers alone cannot be used to assess objective tumor response.
[0788] Cytology, histology: Using these techniques, it was possible to distinguish between partial responses (PR) and complete responses (CR) in rare cases, if required by the clinical trial protocol.
[0789] 3. Baseline documentation of "target" and "non-target" lesions If two or more measurable lesions are present at baseline, all lesions up to a total of up to five lesions (and a maximum of two lesions per organ) representing all involved organs will be identified as target lesions, recorded and measured at baseline.
[0790] Target lesions are selected based on their size (lesions with the longest diameter), representative of all organs involved, and amenable to reproducible repeated measurements.
[0791] Lymph nodes are normal anatomy and can be visualized by imaging even when not involved in the tumor. Pathological nodes that can be defined as measurable and identified as target lesions must meet the criterion of a short axis of ≥15 mm by CT scan. Only the short axis of these nodes contributed to the baseline sum. All other pathological nodes (those that are ≥10 mm but have a short axis <15 mm) are not considered non-target lesions. Nodes with a short axis <10 mm are considered non-pathological and are not recorded or tracked.
[0792] The sum of the diameters of all target lesions (longest for non-nodal lesions, short axis for nodal lesions) is calculated and reported as the baseline sum diameter, which is used as a reference to further characterize any objective tumor regression in the measurable dimension of disease.
[0793] All other lesions (or sites of disease), including pathological lymph nodes, were identified as non-target lesions and were also recorded at baseline. No measurements were required and these lesions were tracked as "present," "absent," or "definite progression." In addition, multiple non-target lesions involving the same organ could be recorded as a single item on the case (e.g., "multiple enlarged pelvic lymph nodes" or "multiple liver metastases").
[0794] 4. Criteria for Efficacy Assessment The efficacy criteria are listed in Table 1.
[0795] [Table 1]
[0796] 5. Special Notes for Evaluation of Target Lesions Lymph nodes identified as target lesions have their actual short axis measurements recorded and are measured in the same anatomical plane as the baseline exam, even if the node has regressed to less than 10 mm at the time of exam. This means that when a lymph node is included as a target lesion, the "sum" of the lesion is not zero even if the CR criteria are met, because normal lymph nodes are defined as having a short axis of <10 mm. For PR, SD, and PD, the actual short axis measurement of the node is included in the sum of the target lesion.
[0797] Target Lesions "Too Small to Measure": All lesions (nodular and nonnodular) recorded at baseline will have their actual measurements recorded at each subsequent assessment, even if they are very small (e.g., 2 mm). However, a lesion or lymph node recorded as a target lesion at baseline may be so faint on the CT scan that the radiologist is reluctant to assign an accurate measurement and reports it as "too small to measure." In these cases, it is important to record the value on the Case Report Form (CRF). If the radiologist determines that the lesion may have disappeared, the measurement will be recorded as 0 mm. If a lesion is believed to be present and appears faint but is too small to measure, a default value of 5 mm will be assigned.
[0798] When non-nodular lesions are "fragments," the longest diameters of the fragmented portions are added together to calculate the total target lesion. Similarly, if lesions coalesce, a plane between them is maintained, which serves to obtain the maximum diameter measurement of each individual lesion. If lesions truly coalesce such that they are no longer separable, the vector of the longest diameters in this case is the maximum diameter of the "combined lesion."
[0799] 6. Evaluation of Non-Target Lesions Although some non-target lesions are in fact measurable, they do not need to be measured and instead will be assessed only qualitatively at time points specified in the clinical trial protocol. CR: Disappearance of all non-target lesions and normalization of tumor marker levels. All lymph nodes must be non-pathological in size (<10 mm short axis). Non-CR / Non-PD: persistence of one or more non-target lesions and / or maintenance of tumor marker levels above the normal range. Progressive Disease (PD): Definite progression of pre-existing non-target lesions. (Note: the appearance of one or more new lesions is also considered progression).
[0800] The concept of non-target disease progression is as follows: If the participant also has measurable disease; in this situation, achieving "definite progression" based on non-target disease requires an overall level of substantial worsening in non-target disease such that the overall tumor burden has increased sufficiently to merit ceasing therapy, even if there is SD or PR in the target disease. A gradual "increase" in the size of one or more non-target lesions is usually not sufficient to qualify as definite progression. If a participant has only non-measurable disease; to achieve "definite progression" based on non-target disease, an overall level of substantial worsening is required such that the overall tumor burden has increased sufficiently to merit stopping therapy. A gradual "increase" in the size of one or more non-target lesions is usually not sufficient to qualify a definite progression state. Because worsening of non-target disease is not easily quantifiable (by definition: if all lesions are truly non-measurable), a useful test that can be applied when evaluating patients for definite progression is to consider whether the increase in overall disease burden based on non-measurable disease change is of comparable magnitude to the increase required to declare PD of measurable disease: i.e., an increase in tumor burden representing an additional 73% increase in "volume" (corresponding to a 20% increase in diameter in measurable lesions). Examples include an increase in pleural effusion from "trace" to "massive," an increase in lymphatic disease from focal to widespread, or may be noted in the protocol as "sufficient to require a change in therapy." If "definite progression" is seen, the patient is considered to have overall PD at that point.
[0801] 7. New lesions The appearance of new malignant lesions signifies disease progression. Findings of new lesions are unambiguous: i.e., not due to differences in scanning technique, changes in imaging modality, or findings thought to represent something other than tumor (e.g., some "new" bone lesions may simply be healing or relapse of existing lesions). This is particularly important when a participant's baseline lesions show PR or CR. For example, necrosis of a liver lesion would be reported as a "new" cystic lesion on the CT scan report, but this is not the case.
[0802] Lesions identified on follow-up examinations in anatomical locations not scanned at baseline are considered new lesions and indicate disease progression. An example of this would be a patient with visceral disease at baseline who has an ordered CT or MRI brain showing metastases during the study. A participant's brain metastases would be considered to qualify as PD even if they did not undergo brain imaging at baseline.
[0803] If a new lesion is equivocal, for example because of its small size, therapy is continued and follow-up evaluations are performed to determine whether it represents new disease. If a repeat scan identifies a new lesion, progression is declared using the date of the first scan.
[0804] Fluorodeoxyglucose-positron emission tomography (FDG-PET) response assessment requires additional testing, but it may be reasonable to incorporate the use of FDG-PET scans to complement CT scans in the assessment of progression, especially in cases of potentially "new" disease. New lesions based on FDG-PET imaging may be identified according to the following algorithm: Negative FDG-PET at baseline with positive FDG-PET at follow-up was indicative of PD based on new lesions. No FDG-PET at baseline, positive FDG-PET at follow-up: If a positive FDG-PET at follow-up corresponds to a new site of disease confirmed by CT, this is PD; If a positive FDG-PET at follow-up is not confirmed as a new site of disease on CT, an additional follow-up CT scan is necessary to determine whether true progression has occurred at that site (if so, the date of PD is the date of the first abnormal FDG-PET scan). If a positive FDG-PET at follow-up corresponds to a pre-existing site of disease on CT that had not progressed based on anatomic imaging, this is not PD.
[0805] 8. Evaluation of best overall response Time Point Efficacy: Response assessments will be performed at each protocol-specified time point. Table 2 provides an overview of the calculation of global response status at each time point for patients with measurable disease at baseline.
[0806] [Table 2]
[0807] If the patient has only non-measurable (and therefore non-target) disease, Table 3 will be used.
[0808] [Table 3]
[0809] Missing Assessment and Non-Evaluable Designation: If no imaging / measurements are performed at a particular time point, the patient is not evaluable (NE) at that time point.
[0810] If only a subset of lesion measurements are made at the time of evaluation, the case is usually considered both at that time point and as NE, unless a compelling argument can be made that the contribution of individual missing lesions does not change the assigned time point effect, which is most likely to occur in the case of PD.
[0811] 9. Special notes on effectiveness assessment Nodal disease is included in the target lesion totals, and when nodes shrink to a "normal" size (<10mm), they may still have a reported measurement on the scan. This measurement is recorded so as not to overstate progression based on an increase in node size, even if the nodes are normal. As mentioned earlier, this means that patients who have a CR may not have a total of "zero" on the CRF.
[0812] In trials where confirmation of response is required, repeat "NE" time point assessments may have complex best response adjudications. The analysis plan for this trial will address how missing data / assessments in adjudication of response and progression will be addressed. For example, in most trials, it is reasonable to consider patients with a PR-NE-PR time point response as confirmed responders.
[0813] Patients whose overall health is deteriorating and who need to discontinue treatment without objective evidence of disease progression at that time will be reported as "symptomatic deterioration." Every effort will be made to document objective progression even after cessation of treatment. Symptomatic deterioration is not a descriptor of objective response; it is a reason to discontinue study therapy.
[0814] Objective response status in such patients will be determined by evaluation of target and non-target disease. For equivocal findings of progression (e.g., very small equivocal new lesions; cystic changes or necrosis of existing lesions), treatment may continue until the next scheduled evaluation. If progression is confirmed at the next scheduled evaluation, the progression date will be the earlier date when progression was suspected.
[0815] 10.Duration of response Duration of overall response will be measured from the time the measurement criteria for CR / PR were first met (whichever was first recorded) to the first date of objective documentation of recurrence or PD (taking the smallest measurement recorded on the study as the criterion for PD).
[0816] Duration of overall CR is measured from the time that metrics for CR are first met to the first date of objective documentation of recurrent disease.
[0817] 11. Duration of stable disease Stable disease is measured from the start of treatment until progression criteria are met, taking the minimum sum on study as the criterion (if the baseline sum is the minimum, this is the criterion for calculation of PD).
[0818] Efficacy measurements will be performed based on best practices such as those described by Eisenhauer, EA et al., "New response evaluation criteria in solid tumours: revised RECIST guidelines (version 1.1)," Eur. J. Cancer, 2009, 45:228-47, which is incorporated herein by reference in its entirety.
[0819] result Table 4 below provides an overview of best overall response and response rate according to RECIST 1.1, as confirmed by the investigator.
[0820] [Table 4]
[0821] CI: confidence interval, CR: complete response, PR: partial response, SD: stable disease Confirmed response (CR / PR) is required: Subsequent tumor assessments used for confirmation must be assessed at least 4 weeks (≥28 days) after the first CR / PR assessment. Responses may be confirmed if a single non-evaluable tumor assessment is performed between two tumor assessments showing response a Includes participants with unconfirmed CR or PR. b Patients without evaluable tumor assessments after baseline but with early clinical progression are included. cIt is estimated by the Clopper-Pearson interval.
[0822] Table 5 below provides an overview of best overall response and response rate according to RECIST 1.1 by investigator confirmed response by PD-L1 expression in the T2 part-active population.
[0823] [Table 5]
[0824] CI: confidence interval, CR: complete response, PR: partial response, SD: stable disease, NE: not evaluable, NC: not calculated Confirmed response (CR / PR) is required: Subsequent tumor assessments used for confirmation must be assessed at least 4 weeks (≥28 days) after the first CR / PR assessment. Responses may be confirmed if a single non-evaluable tumor assessment is performed between two tumor assessments showing response a Includes participants with unconfirmed CR or PR. b Patients without evaluable tumor assessments after baseline but with early clinical progression are included. c It is estimated by the Clopper-Pearson interval.
[0825] Table 6 below provides an overview of best overall response and response rate according to RECIST 1.1 by investigator confirmed response by PD-L1 expression in the T3 part-active population.
[0826] [Table 6]
[0827] CI: confidence interval, CR: complete response, PR: partial response, SD: stable disease, NE: not evaluable, NC: not calculated Confirmed response (CR / PR) is required: Subsequent tumor assessments used for confirmation must be assessed at least 4 weeks (≥28 days) after the first CR / PR assessment. Responses may be confirmed if a single non-evaluable tumor assessment is performed between two tumor assessments showing response a Includes participants with unconfirmed CR or PR. b Patients without evaluable tumor assessments after baseline but with early clinical progression are included. c It is estimated by the Clopper-Pearson interval.
[0828] Table 7 below provides an overview of best overall response and response rate according to RECIST 1.1 by investigator confirmed response by PD-L1 and CEACAM5 expression in the T4 part-active population.
[0829] [Table 7]
[0830] [Table 8]
[0831] CI: confidence interval, CR: complete response, PR: partial response, SD: stable disease, NE: not evaluable, NC: not calculated Confirmed response (CR / PR) is required: Subsequent tumor assessments used for confirmation must be assessed at least 4 weeks (≥28 days) after the first CR / PR assessment. Responses may be confirmed if a single non-evaluable tumor assessment is performed between two tumor assessments showing response a Includes participants with unconfirmed CR or PR. b Patients without evaluable tumor assessments after baseline but with early clinical progression are included. cIt is estimated by the Clopper-Pearson interval.
[0832] Table 8 below provides an overview of response duration for responder participants according to RECIST 1.1-Responders in the Active Population.
[0833] [Table 9]
[0834] CI: confidence interval, CR: complete response, PR: partial response, SD: stable disease, NE: not evaluable, NC: not calculated Confirmed response (CR / PR) is required: Subsequent tumor assessments used for confirmation must be assessed at least 4 weeks (≥28 days) after the first CR / PR assessment. Responses may be confirmed if a single non-evaluable tumor assessment is performed between two tumor assessments showing response a Includes participants with unconfirmed CR or PR. b Patients without evaluable tumor assessments after baseline but with early clinical progression are included. c It is estimated by the Clopper-Pearson interval.
[0835] Table 9 below provides an overview of progression free survival according to RECIST 1.1 - all treatment population.
[0836] [Table 10]
[0837] PFS: progression-free survival, CI: confidence interval, NC: not calculated a It is estimated using a log-log transformation of the survival function and the method of Brookmeyer and Crowley. bKaplan-Meier estimates. CIs are calculated using a log-log transformation based on the survival function and a normalization test according to Greenwood's rule. If no progression or death is observed before the analysis cutoff date and before the initiation of further anticancer therapy, PFS will be censored at the date of the last evaluable tumor assessment performed before the analysis cutoff date or the date of initiation of further anticancer therapy, whichever occurs first.
[0838] If progression or death is observed after one or more non-evaluable tumor assessments, PFS is not censored and the event is the date of progression, or date of death, whichever occurs first.
[0839] Tsusami Tamara ravtansine 150 mg / m 2 All regimens with T2, T3 and T4 have been well tolerated, with manageable toxicity and encouraging response data.
[0840] No increased safety profile is observed from standard of care pembrolizumab + platinum-based chemotherapy + pemetrexed.
[0841] Tsusami Tamara ravtansine 170 mg / m 2 The regimens T2 and T3 are well tolerated and have manageable toxicity.
[0842] Example 2. Activity of immunoconjugate huMAb2-3-SPDB-DM4 and anti-muPD-1 antibody as single agents or in combination against a subcutaneous colon MC38 syngeneic tumor model in C57BL / 6 mice. Preclinical testing of PD-1 and PD-L1 blockade has relied heavily on mouse syngeneic tumor models with intact immune systems that facilitate dismantling immune suppressive mechanisms in the tumor microenvironment. Commercially developed monoclonal antibodies (mAbs) targeting human PD-L1 and PD-1 do not exhibit cross-reactive binding to their mouse orthologues, and surrogate anti-mouse antibodies are often used instead to inhibit these immune checkpoints (Schofield et al,Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer,mAbs,2021;13:1). They are functionally equivalent to therapeutic human antibodies, although they are not strictly equivalent (IgG isotype, level of affinity, biological activity, effector function, ...). For preclinical investigation of the PD-1 blocker, anti-muPD-1 surrogate mAb, clone RMP1-14 (rat IgG1 anti-muPD-1) was used.
[0843] In addition, CEACAM5 protein is not expressed in rodents and human CEACAM5 engineered mouse tumors do not grow in immunocompetent mice because these experiments are performed with huMAb2-3-SPDB-DM4 ADC at a dose high enough to deliver the payload in a non-specific manner. It will be administered at a high dose to take advantage of the enhanced penetration and retention effect observed for solid tumors implanted subcutaneously in mice, resulting in selective delivery of macromolecular drugs to the tumor site. The dose was adjusted to obtain different levels of antitumor activity (inactive, active and / or highly active).
[0844] Experimental procedure The activity of huMAb2-3-SPDB-DM4 and anti-muPD-1 antibodies was evaluated as single agents or in combination in subcutaneously implanted colon MC38 syngeneic tumors in female C57BL / 6 mice. Control groups were left untreated. Doses of compounds used are given in mg / kg.
[0845] Mice had a median tumor volume of approximately 135 mm 3 When the tumor volume reached 10 mg / kg, subjects were randomized into six groups (n=6) on day 10 after tumor implantation. huMAb2-3-SPDB-DM4 was administered at 15 and 25 mg / kg after a single IV dose on day 10, and anti-muPD-1 antibody (clone RMP1-14) was administered at 10 mg / kg after IV doses on days 10, 14, 17, and 21.
[0846] For evaluation of antitumor activity, animals were weighed and tumors were measured by caliper twice weekly. Doses causing 20% weight loss in the nadir (mean of group) or 10% or more drug deaths were considered excessively toxic doses. Animal body weights included tumor weights. Tumor volumes were calculated using the formula mass (mm 3 ) = [length (mm) x width (mm) x width (mm)] / 2. The primary efficacy outcomes were ΔT / ΔC, percent median regression, partial regression, and complete regression (PR and CR).
[0847] The change in tumor volume for each treatment (T) and control (C) is calculated for each tumor by subtracting the tumor volume on the first treatment date (date of progression diagnosis) from the tumor volume on the designated observation date. The median ΔT is calculated for the treatment group and the median ΔC is calculated for the control group. The ratio ΔT / ΔC is then calculated and expressed as a percentage: ΔT / ΔC=(delta T / delta C)×100.
[0848] A dose is considered therapeutically active if ΔT / ΔC is less than 40% and highly active if ΔT / ΔC is less than 10%. If ΔT / ΔC is less than 0, the dose is considered highly active and the percentage of regression is dated (Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L and Alley MC. Human tumor xenograft models in NCI drug development. In:Feibig HH BA, editor.Basel:Karger.;1999 p101-125): % Tumor regression is defined as the % reduction in tumor volume in a treatment group on a particular observation day compared to the volume on day 1 of the first treatment.
[0849] For each animal and specific time point, the % regression is calculated. Then, for that group, the median % regression is calculated: %Involution(at t)=
number
[0850] result The results of efficacy evaluation of the immunoconjugate huMAb2-3-SPDB-DM4 and anti-muPD-1 antibody as single agents or in combination against the subcutaneous colon MC38 syngeneic tumor model in C57BL / 6 mice are presented in FIG. 5 and Table 10.
[0851] HuMAb2-3-SPDB-DM4 and anti-muPD-1 mAb were administered at doses lower than the maximum tolerated dose (MTD) and treatment was well tolerated and did not induce toxicity.
[0852] huMAb2-3-SPDB-DM4 as a single agent was highly active at 25 mg / kg with ΔT / ΔC below 0% (p<0.0001 vs. control), 43% tumor regressions, 4 / 6 PR and 1 / 6 CR, and inactive at 15 mg / kg with ΔT / ΔC equal to 46% (non-significant vs. control).
[0853] Anti-muPD-1 as a single agent was inactive with ΔT / ΔC equal to 42% (non-significant vs. control).
[0854] The combination between 25 mg / kg huMAb2-3-SPDB-DM4 and anti-muPD-1 mAb was highly active with ΔT / ΔC below 0% (p<0.0001 vs. control), 100% tumor regression, 5 / 6 PR and 5 / 6 CR.
[0855] The combination between 15 mg / kg huMAb2-3-SPDB-DM4 and anti-muPD-1 mAb was active with ΔT / ΔC equal to 12% (p<0.0030 vs. control), 2 / 6 PR and 1 / 6 CR.
[0856] In conclusion to experiments in colon MC38 syngeneic tumors, huMAb2-3-SPDB-DM4, when active as a single agent, synergized with anti-muPD-1 mAb to produce complete tumor regression despite the lack of activity of the anti-muPD-1 mAb; the combination produced robust activity when both huMAb2-3-SPDB-DM4 and anti-muPD-1 mAb were inactive as single agents.
[0857] [Table 11]
[0858] [Table 12]
[0859] aStatistical analysis: p values were obtained using contrast analysis to compare each treatment group against control using a Bonferroni-Holm adjustment for multiplicity following a two-way anova with repeated measures for tumor volume change from baseline. A probability of less than 5% (p<0.05) was considered significant. ΔT / ΔC = ratio of median tumor volume change from baseline between treatment and control groups; PR = partial regression; CR = complete regression.
[0860] Example 3: Activity of immunoconjugate huMAb2-3-SPDB-DM4 and anti-mu / huPD-L1 antibodies as single agents or in combination against a subcutaneous colon MC38 syngeneic tumor model in C57BL / 6 mice. For these preclinical trials in combination with PD-L1 blockers, an anti-huPD-L1 mAb, atezolizumab (Magiera-Mularz et al, Human and mouse PD-L1: similar molecular structure, but different druggability profiles. iScience 2021;24), which can bind to and block mouse PD-L1, was used.
[0861] Experimental procedure The activity of huMAb2-3-SPDB-DM4 and anti-mu / huPD-L1 antibodies was evaluated as single agents or in combination in subcutaneously implanted colon MC38 syngeneic tumors in female C57BL / 6 mice. Control groups were left untreated. Doses of compounds used are given in mg / kg.
[0862] Mice were randomized into six groups (n=6) on day 10 after tumor implantation, when the median tumor volume reached approximately 135 mm3. huMAb2-3-SPDB-DM4 was administered at 15 and 25 mg / kg after a single IV dose on day 10, and anti-mu / huPD-L1 antibody was administered at 10 mg / kg after IV doses on days 10, 14, 17, and 21.
[0863] For the conditions for evaluating antitumor activity and toxicity, see above (Example 2).
[0864] result The results of the efficacy evaluation of the immunoconjugate huMAb2-3-SPDB-DM4 and anti-mu / huPD-L1 antibodies as single agents or in combination against the subcutaneous colon MC38 syngeneic tumor model in C57BL / 6 mice are presented in Figure 6 and Table 11.
[0865] HuMAb2-3-SPDB-DM4 and anti-mu / huPD-L1 mAb were administered at doses lower than the maximum tolerated dose (MTD) and treatment was well tolerated and did not induce toxicity.
[0866] huMAb2-3-SPDB-DM4 as a single agent was highly active at 25 mg / kg with ΔT / ΔC below 0% (p<0.0001 vs. control), 43% tumor regressions, 4 / 6 PR and 1 / 6 CR, and inactive at 15 mg / kg with ΔT / ΔC equal to 46% (non-significant vs. control).
[0867] Anti-mu / PD-L1 mAb as a single agent was modestly active with ΔT / ΔC equal to 35% (non-significant vs. control), 1 / 6 PR and 1 / 6 CR.
[0868] The combination between 25 mg / kg huMAb2-3-SPDB-DM4 and anti-mu / huPD-L1 mAb was highly active with ΔT / ΔC below 0% (p<0.0001 vs. control), 100% tumor regression, 5 / 6 PR and 5 / 6 CR.
[0869] The combination between 15 mg / kg huMAb2-3-SPDB-DM4 and anti-mu / huPD-L1 mAb was highly active with ΔT / ΔC equal to 8% (p<0.0004 vs. control) and 1 / 6 PR.
[0870] In conclusion to experiments in colon MC38 syngeneic tumors, huMAb2-3-SPDB-DM4, when active, synergized with anti-mu / huPD-L1 mAb to produce complete tumor regression despite the minimal activity of anti-mu / huPD-L11 mAb as a single agent; the combination produced robust activity when both huMAb2-3-SPDB-DM4 and anti-mu / huPD-L1 mAb were inactive or minimally active as single agents.
[0871] [Table 13]
[0872] [Table 14]
[0873] a Statistical analysis: p values were obtained using contrast analysis to compare each treatment group against control using a Bonferroni-Holm adjustment for multiplicity following a two-way anova with repeated measures for tumor volume change from baseline. A probability of less than 5% (p<0.05) was considered significant. ΔT / ΔC = ratio of median tumor volume change from baseline between treatment and control groups; PR = partial regression; CR = complete regression.
Claims
1. 1. A combination of (i) an antibody drug conjugate (ADC) comprising an anti-CEACAM5 antibody and (ii) an anti-PD-1 antibody or an anti-PD-L1 antibody in effective amounts, for use in treating cancer in a subject in need thereof, wherein the cancer expresses CEACAM5.
2. The combination for use according to claim 1, wherein the anti-CEACAM5 antibody comprises an HCDR1 having the amino acid sequence of SEQ ID NO:1, an HCDR2 having the amino acid sequence of SEQ ID NO:2, an HCDR3 having the amino acid sequence of SEQ ID NO:3, an LCDR1 having the amino acid sequence of SEQ ID NO:4, an LCDR2 having the amino acid sequence NTR, and an LCDR3 having the amino acid sequence of SEQ ID NO:
5.
3. The combination for use according to claim 1 or 2, wherein the anti-CEACAM5 antibody comprises a heavy chain variable domain (VH) consisting of SEQ ID NO:6 and a light chain variable domain (VL) consisting of SEQ ID NO:
7.
4. The combination for use according to any one of claims 1 to 3, wherein said anti-CEACAM5 antibody is tusamitamab.
5. The combination for use according to any one of claims 1 to 4, wherein the ADC comprises at least one cytotoxic agent.
6. The combination for use according to claim 5, wherein the cytotoxic agent is selected from the group consisting of a radioisotope, a protein toxin, a small molecule toxin, and any combination thereof.
7. 7. The combination for use according to claim 6, wherein the small molecule toxin is selected from the group consisting of antimetabolites, DNA alkylating agents, DNA cross-linking agents, DNA intercalating agents, anti-microtubule agents, topoisomerase inhibitors, and any combination thereof.
8. 8. The combination for use according to claim 7, wherein the anti-microtubule agent is selected from the group consisting of taxanes, vinca alkaloids, maytansinoids, colchicine, podophyllotoxin, griseofulvin, and any combination thereof.
9. 9. The combination for use according to any one of claims 5 to 8, wherein the cytotoxic agent is a maytansinoid selected from the group consisting of N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine (DM1), N2'-deacetyl-N2'(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4), and any combination thereof.
10. The combination for use according to any one of claims 5 to 9, wherein said anti-CEACAM5 antibody is covalently linked to at least one said cytotoxic agent via a cleavable or non-cleavable linker.
11. 11. The combination for use according to claim 10, wherein the linker is selected from the group consisting of N-succinimidyl pyridyldithiobutyrate (SPDB), 4-(pyridin-2-yldisulfanyl)-2-sulfo-butyric acid (sulfo-SPDB), and succinimidyl (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC).
12. The combination for use according to any one of claims 1 to 11, wherein said ADC is characterized by a drug-to-antibody ratio (DAR) ranging from 1 to 10.
13. The combination for use according to any one of claims 1 to 12, wherein the ADC is tusamitamaravtansine.
14. The combination for use according to any one of claims 1 to 13, wherein said cancer expresses CEACAM5 at moderate or high intensity as defined by immunohistochemistry.
15. The combination for use according to any one of claims 1 to 14, wherein said cancer expresses CEACAM5 with moderate intensity (immunohistochemical intensity ≧2+ in ≧1% to <50% of the tumor cells).
16. The combination for use according to any one of claims 1 to 14, wherein said cancer expresses CEACAM5 with high intensity (immunohistochemical intensity ≧2+ in ≧50% of the tumor cells).
17. 17. The combination for use according to any one of claims 1 to 16, wherein the cancer is selected from the group consisting of colorectal cancer, gastric cancer, cancer of the esophagogastric junction, cancer of the esophagus, lung cancer, cervical cancer, pancreatic cancer, ovarian cancer, thyroid cancer, bladder cancer, endometrial cancer, breast cancer, liver cancer, biliary tract cancer (e.g. cholangiocarcinoma), prostate cancer, and skin cancer.
18. 18. The combination for use according to claim 17, wherein the cancer is gastric cancer, gastroesophageal junction cancer, or esophageal cancer.
19. 18. The combination for use according to claim 17, wherein the cancer is lung cancer.
20. 20. The combination for use according to claim 19, wherein the lung cancer is non-squamous non-small cell lung cancer (NSQ NSCLC).
21. 21. The combination for use according to claim 20, wherein the subject has advanced or metastatic NSQ NSCLC.
22. 21. The combination for use according to claim 20, wherein the subject has NSQ NSCLC without epidermal growth factor receptor (EGFR) sensitizing mutations or v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations or anaplastic lymphoma kinase / c-ros oncogene 1 (ALK / ROS) alterations.
23. The combination for use according to any one of claims 1 to 22, wherein said subject has not previously received systemic chemotherapy for the treatment of said cancer.
24. The combination for use according to any one of claims 1 to 23, wherein the anti-PD-1 antibody is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, sintilimab, dostallimab, and tislelizumab.
25. The combination for use according to any one of claims 1 to 24, wherein the anti-PD-1 antibody is pembrolizumab.
26. The combination for use according to any one of claims 1 to 23, wherein the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, avelumab, and durvalumab.
27. The combination for use according to any one of claims 1 to 26, wherein the anti-PD-1 antibody or the anti-PD-L1 antibody and the ADC are administered sequentially.
28. The combination for use according to any one of claims 1 to 27, wherein the anti-PD-1 antibody or the anti-PD-L1 antibody is administered prior to the ADC.
29. The combination for use according to any one of claims 1 to 26, wherein the anti-PD-1 antibody or the anti-PD-L1 antibody and the ADC are administered simultaneously.
30. The combination for use according to any one of claims 1 to 29, wherein the anti-PD-1 antibody or the anti-PD-L1 antibody is administered intravenously to the subject at a dose of about 200 mg to about 400 mg.
31. 31. The combination for use of claim 30, wherein the anti-PD-1 antibody or the anti-PD-L1 antibody is administered intravenously to the subject at a dose selected from 200 mg, 350 mg, 360 mg, and 400 mg.
32. The tusamitamab ravtansine is about 60 mg / m 2 ~Approx. 190mg / m 2 The combination for use according to any one of claims 13 to 31, wherein the combination is administered intravenously to the subject at a dose of
33. The tusamitamab ravtansine is about 120 mg / m 2 ~Approx. 170mg / m 2 The combination for use according to claim 32, wherein the combination is administered intravenously to the subject at a dose of
34. The anti-PD-1 antibody or the anti-PD-L1 antibody is administered intravenously to the subject at a dose of about 200 mg, and the tusamitama ravtansine is administered at a dose of about 120 mg / m 2 ~Approx. 170mg / m 2 The combination for use according to any one of claims 30 to 33, wherein the combination is administered intravenously to the subject at a dose of
35. The combination for use according to claim 34, wherein the anti-PD-1 antibody or the anti-PD-L1 antibody and the tusamitamaravtansine are administered once every three weeks.
36. The anti-PD-1 antibody or the anti-PD-L1 antibody is administered intravenously to the subject at a dose of about 400 mg, and the tusamitama ravtansine is administered at a dose of about 120 mg / m 2 ~Approx. 170mg / m 2 The combination for use according to any one of claims 30 to 35, wherein the combination is administered intravenously to the subject at a dose of
37. 37. The combination for use according to claim 36, wherein the anti-PD-1 antibody or the anti-PD-L1 antibody is administered once every 6 weeks and the tusamitama ravtansine is administered once every 3 weeks.
38. The combination for use according to any one of claims 1 to 37, wherein the ADC is tusamitamaravtansine and the anti-PD-1 antibody is pembrolizumab.
39. The anti-PD-1 antibody or the anti-PD-L1 antibody and the ADC are administered about once every three weeks, and the ADC is tusamitamaravtansine and is administered at about 120 mg / m 2 The combination for use according to any one of claims 1 to 36, wherein the combination is administered intravenously to the subject at a dose of
40. The anti-PD-1 antibody or the anti-PD-L1 antibody and the ADC are administered about once every three weeks, and the ADC is tusamitamaravtansine and is administered at a dose of about 150 mg / m 2 The combination for use according to any one of claims 1 to 36, wherein the combination is administered intravenously to the subject at a dose of
41. The combination for use according to claim 39 or 40, wherein the anti-PD-1 antibody is pembrolizumab.
42. The combination for use according to any one of claims 39 to 41, wherein the anti-PD-1 antibody is administered intravenously to the subject at a dose of about 200 mg.
43. The combination for use according to any one of claims 1 to 38, further comprising (iii) administering to said subject a platinum-based chemotherapy.
44. The combination for use according to any one of claims 1 to 38 and 41, wherein said platinum-based chemotherapy is selected from the group consisting of cisplatin and carboplatin.
45. The combination for use according to any one of claims 1 to 38, 41 and 42, wherein said anti-PD-1 antibody or said anti-PD-L1 antibody is administered prior to said ADC and said platinum-based chemotherapy.
46. The combination for use according to any one of claims 1 to 38 and 41 to 43, wherein the anti-PD-1 antibody or the anti-PD-L1 antibody, the ADC, and the platinum-based chemotherapy are administered to the subject for at least 4 cycles.
47. The combination for use according to any one of claims 1 to 38 and 41 to 44, wherein said use comprises administering cisplatin to said subject.
48. The cisplatin is 38 mg / m 2 ~75mg / m 2 46. The combination for use according to claim 45, wherein the combination is administered intravenously to the subject at a dose of
49. The cisplatin is about 75 mg / m 2 46. The combination for use according to claim 45, wherein the combination is administered intravenously to the subject at a dose of
50. The combination for use according to any one of claims 1 to 38 and 41 to 44, wherein said use comprises administering carboplatin to said subject.
51. 49. The combination for use of claim 48, wherein said carboplatin is administered intravenously to said subject at a dose of about (target AUC) x [(140 - age) x (weight (kg)) / serum creatinine (mg / dL) x 72 (x 0.85 for women) + 25], and said target AUC is between AUC 2.5 and AUC 5.
52. 50. The combination for use according to claim 49, wherein the target AUC is AUC 5.
53. The combination of any one of claims 1 to 52, further comprising administering pemetrexed to the subject.
54. The pemetrexed is administered at a dose of 250 mg / m 2 ~500mg / m 2 52. The combination for use according to claim 51, wherein the combination is administered intravenously at a dose of
55. The pemetrexed is administered at a dose of about 500 mg / m 2 53. The combination for use according to claim 52, wherein the combination is administered intravenously at a dose of
56. The combination for use according to any one of claims 51 to 53, wherein said pemetrexed is administered intravenously after vitamin supplementation.
57. The anti-PD-1 antibody or the anti-PD-L1 antibody and the ADC are administered about once every three weeks, and the ADC is tusamitamaravtansine and is administered at about 120 mg / m 2 The combination for use according to any one of claims 51 to 54, wherein the combination is administered intravenously to the subject at a dose of
58. The anti-PD-1 antibody or the anti-PD-L1 antibody and the ADC are administered about once every three weeks, and the ADC is tusamitamaravtansine and is administered at a dose of about 150 mg / m 2 The combination for use according to any one of claims 51 to 54, wherein the combination is administered intravenously to the subject at a dose of
59. 59. The combination for use according to claim 57 or 58, wherein the anti-PD-1 antibody is pembrolizumab.
60. The combination for use according to any one of claims 57 to 59, wherein the anti-PD-1 antibody is administered intravenously to the subject at a dose of about 200 mg.
